"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"AOU_FERRARA",2000,29,6.89655172413793,1.82758620689655,0.551724137931034,0.241379310344828,0.551724137931034,1.12765957446809,1.14285714285714,0.875,1.14285714285714,0.137931034482759,1,5,5,7,11,0.17,0.17,0.24,0.38,25.21,0.556063378174239,NA,0.0344827586206897,0.586206896551724,0.402,0.237,0.159,0.237,"P. PAZZI;CARLO SALVARANI;SUSANNA STEA;L. SAVARINO;VINCENZO DE SANCTIS;A. PIZZOFERRATO;LEONARDO TASSINARI;LIA PULSATELLI;E MORSIANI;LUIGI BOIARDI;FABRIZIO CANTINI;S PUTINATI;R. SCAGLIARINI;IGNAZIO OLIVIERI;ANDREA CORRIAS;ELISA CALZOLARI;GIOVANNI BATTISTA POZZAN;A POTENA;M. CERVELLATI;SILVANO BERTELLONI","4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","P. PAZZI;E MORSIANI;R. SCAGLIARINI;VINCENZO DE SANCTIS;CARLO SALVARANI;E RAVAIOLI;FABRIZIO CANTINI;IGNAZIO OLIVIERI;SUSANNA STEA;L. SAVARINO;A. PIZZOFERRATO;S PUTINATI;A POTENA;VITALIANA DE SANCTIS;MONICA SPROCATI;S. GAMBERINI;ELISA CALZOLARI;LEONARDO TASSINARI;M. CERVELLATI;G. CIAPETTI","1.15;1.07;0.83;0.82;0.56;0.5;0.43;0.43;0.41;0.41;0.41;0.4;0.4;0.39;0.38;0.33;0.32;0.29;0.29;0.29","P. PAZZI;VINCENZO DE SANCTIS;E MORSIANI;LUIGI BOIARDI;FABRIZIO CANTINI;S PUTINATI;R. SCAGLIARINI;IGNAZIO OLIVIERI;ANDREA CORRIAS;GIOVANNI BATTISTA POZZAN;A POTENA;SILVANO BERTELLONI;MONICA SPROCATI;VITALIANA DE SANCTIS;VINCENZO DE SANCTIS;F. GALLUZZI;V. RIZZO;MARIA I. LUNA-CARBONEL;TANIA SILVESTRI;IVA MAESTRI","4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1","P. PAZZI;E MORSIANI;R. SCAGLIARINI;VINCENZO DE SANCTIS;FABRIZIO CANTINI;IGNAZIO OLIVIERI;S PUTINATI;A POTENA;VITALIANA DE SANCTIS;MONICA SPROCATI;ÂNGELO PAULO FERRARI;G. CASTELLINO;FRANCESCO TROTTA;VINCENZO DE SANCTIS;LUIGI BOIARDI;G.L PANELLA;MARCO PIATTELLA;F ONGARO;LICIA BALLERIN;G ATTI","1.15;1.07;0.83;0.82;0.43;0.43;0.4;0.4;0.39;0.38;0.25;0.25;0.25;0.24;0.22;0.2;0.2;0.2;0.2;0.2","COHEN;DIPALMA;GALANELLO;PIGA;TRICTA;VULLO;VINCENZO DE SANCTIS;ANDREA CORRIAS;F. GALLUZZI;GIOVANNI BATTISTA POZZAN;M. CISTERNINO;SILVANO BERTELLONI;V. RIZZO;ALBA PILOTTA;ANNA MARIA PASQUINO;F. DE LUCA;GIUSEPPE TONINI;L GARGANTINI;LOREDANA URSO;M SPOSITO","200;200;200;200;200;200;180;133;133;133;133;133;133;109;109;109;109;109;109;109","DIPALMA;VULLO;VINCENZO DE SANCTIS;RENATO LA CORTE;IVA MAESTRI;LUIGI BOIARDI;LUIGIP MACCHIONI;A POTENA;G ATTI;G.L PANELLA;LICIA BALLERIN;MARCO PIATTELLA;S PUTINATI;MONICA SPROCATI;R. GOVONI;A.M. PASQUINO;ANDREA CORRIAS;F. GALLUZZI;GIOVANNI BATTISTA POZZAN;MONICA FORTINI","200;200;170;93;59;56;44;29;29;29;29;29;29;25;25;24;24;24;24;24","VINCENZO DE SANCTIS;E MORSIANI;LUIGI BOIARDI;P. PAZZI;VITALIANA DE SANCTIS;A FRANCHELLA;A MANGIAGLI;A POTENA;A.M. PASQUINO;ANDREA CORRIAS;ANDREA RANZI;DIPALMA;F ONGARO;F. GALLUZZI;FABRIZIO CANTINI;FRANCESCO S. DI GIOVINE;FRANCESCO TROTTA;G ATTI;G. CASTELLINO;G.L PANELLA","5;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;CHEMISTRY;BIOLOGY;PHILOSOPHY;PHYSICS;COMPUTER SCIENCE;ECONOMICS;ENGINEERING","28;5;4;2;2;1;1;1","INTERNAL MEDICINE;PATHOLOGY;SURGERY;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;RADIOLOGY;ANATOMY;GASTROENTEROLOGY;IMMUNOLOGY;ANESTHESIA;BIOMEDICAL ENGINEERING;GENETICS;ORGANIC CHEMISTRY;PEDIATRICS;CHROMATOGRAPHY;ENDOCRINOLOGY;OPTICS;PHARMACOLOGY;CELL BIOLOGY;CLINICAL PSYCHOLOGY;COMPUTATIONAL BIOLOGY;DERMATOLOGY;EPISTEMOLOGY;EVOLUTIONARY BIOLOGY;FAMILY MEDICINE;LINGUISTICS;MECHANICAL ENGINEERING;MEDICAL EMERGENCY;MICROECONOMICS;NUCLEAR MEDICINE;PROGRAMMING LANGUAGE","18;11;10;5;5;5;4;4;4;3;3;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","BIOPSY;DISEASE;TRANSPLANTATION;GENE;IN VITRO;LESION;ALTERNATIVE MEDICINE;ANTIBODY;BIOCOMPATIBLE MATERIAL;BONE PATHOLOGY;DEFEROXAMINE;DISCONTINUATION;ETIOLOGY;HEMODIALYSIS;HORMONE;INCIDENCE (GEOMETRY);LIVER FAILURE;RADIOLOGICAL WEAPON;RECEPTOR;STAINING;THALASSEMIA;THROMBOSIS","5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","VASCULITIS;HEPATOCYTE;LIVER TRANSPLANTATION;ALLELE;ARTIFICIAL LIVER;DEFERIPRONE;HEMOPERFUSION;PRECOCIOUS PUBERTY;ACTIVATED CHARCOAL;ACUTE RESPIRATORY FAILURE;AGONIST;ANTIPHOSPHOLIPID SYNDROME;BASAL (MEDICINE);BIOEQUIVALENCE;BONE BIOPSY;BREAST CANCER;CARBOXYMETHYL CELLULOSE;CENTRAL VENOUS CATHETER;CHEMOKINE;CHRONIC LIVER DISEASE;CYTOKERATIN;DEFERASIROX;DRUG HOLIDAY;ENDOTRACHEAL INTUBATION;ENTERIC COATING;GASTRIC LYMPHOMA;GASTRITIS;GENOTYPE;H&E STAIN;HEART RATE;HEPATIC ENCEPHALOPATHY;HEPATITIS C VIRUS;HUMAN FACTORS AND ERGONOMICS;INJURY PREVENTION;LOCUS (GENETICS);LUTEINIZING HORMONE;MENDELIAN INHERITANCE;METHYLPREDNISOLONE ACETATE;MUTATION;NEUTROPENIA;OVERWEIGHT;PEDIGREE CHART;PHENOTYPE;PLACEBO;POSITIVE PRESSURE VENTILATION;PROVOCATION TEST;PULMONARY HEMORRHAGE;RANDOMIZATION;SKIN BIOPSY;SPONTANEOUS BACTERIAL PERITONITIS;SUBCLAVIAN VEIN;SUICIDE PREVENTION;SYNOVITIS;VENOUS ACCESS;VENOUS THROMBOSIS;VIRAL DISEASE;VIRAL LOAD","4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BIOARTIFICIAL LIVER DEVICE;GIANT CELL ARTERITIS;CENTRAL PRECOCIOUS PUBERTY;ALCOHOL INTOXICATION;ALCOHOLIC INTOXICATION;ANTIRETROVIRAL THERAPY;AUTOIMMUNE GASTRITIS;AUTONOMIC NERVOUS SYSTEM;BUSERELIN;CHEMOKINE RECEPTOR;CHRONIC GASTRITIS;GONADOTROPIN-RELEASING HORMONE;HYPOTHALAMIC HAMARTOMA;ORTHOTOPIC LIVER TRANSPLANTATION;PROBAND;SENTINEL LYMPH NODE;SENTINEL NODE;SIDA;UNDERWEIGHT","3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;POLYMYALGIA RHEUMATICA;PUBERTY, PRECOCIOUS;DEFEROXAMINE;THALASSEMIA;ADOLESCENT;AGED;BONE DISEASES;BRAIN DISEASES;CHILD;HIV INFECTIONS;ADULT;BETA-THALASSEMIA;CHELATING AGENTS;IRON CHELATING AGENTS;TIBIA;ALCOHOLIC INTOXICATION;ANTI-INFLAMMATORY AGENTS","25;14;13;8;8;7;7;6;6;6;6;6;6;5;5;5;5;5;4;4","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;MECHANISMS AND TREATMENT OF LIVER FIBROSIS;REGULATION OF PUBERTY AND REPRODUCTION;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;DIAGNOSIS AND MANAGEMENT OF GESTATIONAL TROPHOBLASTIC DISEASE;DRUG DELIVERY SYSTEMS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;FEMOROACETABULAR IMPINGEMENT SYNDROME AND HIP PATHOLOGY;HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS;HEREDITARY ANGIOEDEMA: MOLECULAR MECHANISMS AND CLINICAL MANAGEMENT;MANAGEMENT OF DIFFICULT AIRWAY IN ANESTHESIA PRACTICE;MANAGEMENT OF VASCULAR ACCESS IN HEALTHCARE;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MECHANISMS OF DRUG-INDUCED HEPATOTOXICITY;MOLECULAR BIOLOGY OF STEROIDOGENESIS AND DISORDERS;MOLECULAR RESEARCH ON BREAST CANCER;PATHOPHYSIOLOGY AND MANAGEMENT OF CEREBRAL ANEURYSMS;POLYPHARMACY AND INAPPROPRIATE MEDICATION USE IN ELDERLY;PREVALENCE AND TREATMENT OF HYPERHIDROSIS","5;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BIOARTIFICIAL LIVER DEVICE;POLYMYALGIA RHEUMATICA;ARTIFICIAL LIVER;BIOCOMPATIBLE MATERIAL;BONE PATHOLOGY;CENTRAL PRECOCIOUS PUBERTY;DEFERIPRONE;DISCONTINUATION;ETIOLOGY;HEMOPERFUSION;LIVER REGENERATION;LIVING DONOR LIVER TRANSPLANTATION;NONINVASIVE VENTILATION;ACTIVATED CHARCOAL;ACUTE RESPIRATORY FAILURE;ALCOHOL INTOXICATION;ALCOHOLIC INTOXICATION;AMMONIUM CHLORIDE;ANTIPHOSPHOLIPID SYNDROME;ANTIRETROVIRAL THERAPY","3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","BONE LESIONS;POLYMYALGIA RHEUMATICA;THALASSEMIC PATIENTS;CENTRAL PRECOCIOUS;LIVER SUPPORT;MICROSTRUCTURAL ANALYSIS;PATIENTS TREATED;PRECOCIOUS PUBERTY;SEVERE BONE;ACCESS REPORT;ACID BIOAVAILABILITY;ACUTE ALCOHOL;ACUTE LIVER;ACUTE RESPIRATORY;ADDITIONAL EXTRAHEPATIC;ADOLESCENCE EXPERIENCE;ADOLESCENT ADOLESCENCE;ADOLESCENT MALE;ALCOHOL INTOXICATION;ANTIPHOSPHOLIPID SYNDROME;ANTIRETROVIRAL THERAPY;ARTIFICIAL LIVER;AUTOIMMUNE DISEASE;BIOARTIFICIAL SYSTEMS;BREAST CANCER;CANDIDATE REGION;CARBOXYMETHYL CELLULOSE;CC CHEMOKINE;CHELATED THALASSEMIC;CHELATOR DEFERIPRONE","3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","URSODEOXYCHOLIC ACID;APACHE II;II SCORE;ACUTE RESPIRATORY;ALT LEVELS;CARBOXYMETHYL CELLULOSE;DRUGPOLYMER SYSTEM;FERRITIN LEVELS;LOW ALBUMIN;MILDER FORMS;PLASMA CONCENTRATION;RESPIRATORY FAILURE;SODIUM CARBOXYMETHYL;ABNORMALITIES OCCURRED;ACID CAPSULE;ACID CAPSULES;ACIDCROSS-LINKED SODIUM;ACIDPOLYMER SYSTEM;ACTIVE IRON;ACUTE PHYSIOLOGY;ADDITIONAL ADVANTAGES;ADDITIONAL FAMILY;AGE SEX;AGRANULOCYTOSIS MILDER;AGRANULOCYTOSIS NEUTROPHILS;ALANINE TRANSAMINASE;ALBUMIN LEVEL;ALBUMIN SERUM;ANALYSED SUCCESS;ANALYSIS DEMONSTRATED","5;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",2,0.07,3,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,35.25,35.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_FERRARA",2001,27,6.62962962962963,3.33333333333333,0.592592592592593,0.481481481481481,0.592592592592593,1.18421052631579,1,0.928571428571429,1,0.111111111111111,1,7,6,3,11,0.26,0.22,0.11,0.41,18.33,0.401233502479662,NA,0.111111111111111,0.62962962962963,0.344,0.193,0.144,0.193,"LUIGI BOIARDI;CARLO SALVARANI;FRANCESCO TROTTA;VITALIANA DE SANCTIS;R. AUDOGLIO;ANDREA GIOMBI;FABRIZIO CANTINI;SERGIO SARTORI;FABRIZIO SALVI;MARCELLO GOVONI;GIOVANNI CIANCÌO;DAVIDE FILIPPINI;ANTONIOLI GE;IGNAZIO OLIVIERI;RENATO MALATESTA;TIZIANO TOSELLI;L MALAGUTTI;SIMONE SALA;P. PAZZI;ROBERTO GALEOTTI","3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","VITALIANA DE SANCTIS;F. ROILA;L MALAGUTTI;DE ROSA E;VINCENZO DE SANCTIS;R. AUDOGLIO;ANTONIOLI GE;TIZIANO TOSELLI;ANDREA GIOMBI;SIMONE SALA;ROBERTO GALEOTTI;L URSO;PATRIZIA BANIN;L MALAGUTI;LUIGI BOIARDI;CARLO SALVARANI;FRANCESCO TROTTA;F RAVENNA;EMILIA MANZATO;RENATA STRUMÌA","1.17;1;0.83;0.5;0.5;0.4;0.4;0.4;0.37;0.37;0.37;0.33;0.33;0.33;0.3;0.3;0.28;0.25;0.25;0.25","LUIGI BOIARDI;FRANCESCO TROTTA;VITALIANA DE SANCTIS;ANDREA GIOMBI;FABRIZIO CANTINI;SERGIO SARTORI;MARCELLO GOVONI;GIOVANNI CIANCÌO;DAVIDE FILIPPINI;ANTONIOLI GE;IGNAZIO OLIVIERI;RENATO MALATESTA;TIZIANO TOSELLI;SIMONE SALA;P. PAZZI;ROBERTO GALEOTTI;L. SERRA;EZIO PAOLINO;A. VANINI;F RAVENNA","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","VITALIANA DE SANCTIS;F. ROILA;VINCENZO DE SANCTIS;ANTONIOLI GE;TIZIANO TOSELLI;ANDREA GIOMBI;SIMONE SALA;ROBERTO GALEOTTI;PATRIZIA BANIN;LUIGI BOIARDI;FRANCESCO TROTTA;F RAVENNA;EMILIA MANZATO;MARIA LETIZIA GUALANDI;P. PAZZI;SERGIO SARTORI;L. SERRA;GIOVANNI LO SCOCCO;GABRIELE GUARDIGLI;G. BISIGHINI","1.17;1;0.5;0.4;0.4;0.37;0.37;0.37;0.33;0.3;0.28;0.25;0.25;0.25;0.24;0.21;0.2;0.2;0.2;0.2","ELISA VAROTTI;EMILIA MANZATO;MARIA LETIZIA GUALANDI;RENATA STRUMÌA;CARLO SALVARANI;LUIGI BOIARDI;FRANCESCO TROTTA;DAVIDE FILIPPINI;FABRIZIO CANTINI;FABRIZIO SALVI;GIOVANNI CIANCÌO;IGNAZIO OLIVIERI;MARCELLO GOVONI;RENATO MALATESTA;ANDREA GIOMBI;SIMONE SALA;A FRANCHELLA;FEDERICA D’AGOSTINO;GLÓRIA PELIZZO;MARIA LEMBO","137;137;137;137;128;128;121;94;94;94;94;94;94;94;59;59;58;58;58;58","EMILIA MANZATO;MARIA LETIZIA GUALANDI;FRANCESCO TROTTA;DAVIDE FILIPPINI;FABRIZIO CANTINI;GIOVANNI CIANCÌO;IGNAZIO OLIVIERI;MARCELLO GOVONI;RENATO MALATESTA;SIMONE SALA;A FRANCHELLA;GLÓRIA PELIZZO;MARIA LEMBO;GIOVANNI PAOLAZZI;LUIGI MACCHIONI;MICHELE ZINI;CARLA MOLINOTTI;GIUSEPPE PAOLAZZI;LUIGI BOIARDI;MARIAGABRIELLA VIGGIANI","137;137;121;94;94;94;94;94;94;59;58;58;58;56;56;53;38;38;38;38","FRANCESCO TROTTA;ANTONIOLI GE;DAVIDE FILIPPINI;FABRIZIO CANTINI;GIOVANNI CIANCÌO;IGNAZIO OLIVIERI;MARCELLO GOVONI;P. PAZZI;RENATO MALATESTA;SERGIO SARTORI;SIMONE SALA;TIZIANO TOSELLI;A BEDETTI;A CARIANI;A FRANCHELLA;A. VANINI;ANDREA GIOMBI;ANTONIO CUNEO;CARLA MOLINOTTI;EMILIA MANZATO","3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;ART;CHEMISTRY;ECONOMICS;GEOLOGY;MATERIALS SCIENCE;MATHEMATICS;PHYSICS;SOCIOLOGY","27;8;1;1;1;1;1;1;1;1","INTERNAL MEDICINE;GASTROENTEROLOGY;SURGERY;GENETICS;IMMUNOLOGY;PATHOLOGY;RADIOLOGY;ONCOLOGY;CARDIOLOGY;ANESTHESIA;BIOCHEMISTRY;CANCER RESEARCH;DERMATOLOGY;ENDOCRINOLOGY;GENERAL SURGERY;GYNECOLOGY;PHARMACOLOGY;ACOUSTICS;ANATOMY;ANDROLOGY;DEMOGRAPHY;ECONOMIC GROWTH;ENVIRONMENTAL HEALTH;FAMILY MEDICINE;FISHERY;GEOMORPHOLOGY;INTENSIVE CARE MEDICINE;LITERATURE;METALLURGY;NURSING;PALEONTOLOGY;PEDIATRICS;PHYSIOLOGY;UROLOGY;VIROLOGY","17;7;7;6;5;5;5;4;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GENE;CANCER;ANTIGEN;ASYMPTOMATIC;CHEMOTHERAPY;DISEASE;HEPATOLOGY;HERNIA;HUMAN IMMUNODEFICIENCY VIRUS (HIV);ABDOMEN;ABDOMINAL SURGERY;ACCIDENTAL;ACNE;ADVERSE EFFECT;ALTERNATIVE MEDICINE;ANTIBODY;ATRIAL FIBRILLATION;BASAL CELL;BOLUS (DIGESTION);BONE AGE;BRONCHOSCOPY;CALCIFICATION;CARCINOMA;CARDIAC SURGERY;CATHETER;CELL ADHESION MOLECULE;CHONDROBLASTOMA;CONCOMITANT;CONFIDENCE INTERVAL;CYTOKINE;DEVELOPING COUNTRY;DISSECTION (MEDICAL);DUAL (GRAMMATICAL NUMBER);ENDOSCOPY;ENZYME;EOSINOPHILIA;ERYTHEMA;ETIOLOGY;FISH <ACTINOPTERYGII>;FORCEPS;FOREIGN BODY;HEAD AND NECK;HEMATOLOGY;HORMONE;HYPERPIGMENTATION;HYPERTRICHOSIS;IMMUNE SYSTEM;IMMUNOPATHOLOGY;IN VITRO;INFLAMMATION;INTERPHASE;INTRACELLULAR;INTRATHECAL;KIDNEY;LEAD (GEOLOGY);LEUKEMIA;LUNG;LYSOZYME;MELASMA;MICROSURGERY;MYELOID LEUKEMIA;MYOCARDIAL INFARCTION;NODULE (GEOLOGY);ORTHOPEDIC SURGERY;OVERALL SURVIVAL;PERCUTANEOUS;PILL;PNEUMONIA;POPULATION;PREGNANCY;PROSPECTIVE COHORT STUDY;PSORIASIS;PULMONARY EMBOLISM;PUNCHING;RADIATION THERAPY;RADIOLOGICAL WEAPON;RECEPTOR;REGIMEN;RHEUMATOLOGY;SEBORRHEIC DERMATITIS;SINGLE CHAMBER;SPERM;SPLEEN;STOMACH;SURGICAL ONCOLOGY;SURVIVAL RATE;TACHYCARDIA;THALASSEMIA;THROMBOSIS;THROMBUS;THYROID;TOXICITY;TUMOR NECROSIS FACTOR ALPHA;ULTRASONOGRAPHY;ULTRASOUND;UROKINASE;VOLVULUS","6;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ALLELE;CHROMOSOME;COLORECTAL CANCER;AGONIST;ANGIOLYMPHOID HYPERPLASIA WITH EOSINOPHILIA;BEHCET'S DISEASE;CARCINOGENESIS;CHEMORADIOTHERAPY;CHEMOTAXIS;CISPLATIN;CYTARABINE;DEEP VEIN;DEVELOPED COUNTRY;DIAPHRAGMATIC BREATHING;DIAPHRAGMATIC HERNIA;EPIDIDYMIS;EXON;FETUS;GASTRIC VOLVULUS;GEMCITABINE;GENETIC PREDISPOSITION;GENOTYPE;GROWTH HORMONE;HEAD AND NECK CANCER;HERNIA REPAIR;HUMAN LEUKOCYTE ANTIGEN;HUMORAL IMMUNITY;ICAM-1;INGUINAL HERNIA;INTERCELLULAR ADHESION MOLECULE-1;INTERLEUKIN;INTERLEUKIN 6;KIMURA'S DISEASE;LOCUS (GENETICS);MAXIMUM TOLERATED DOSE;MECHANISM OF ACTION;MITOXANTRONE;NECK DISSECTION;NEUTROPHILE;PERFORATION;PULMONARY ANGIOGRAPHY;RELATIVE RISK;RESEARCH METHODOLOGY;RESPIRATORY DISEASE;RETINOIC ACID;ROSACEA;SEXUALLY ACTIVE;SPLENECTOMY;SUPEROXIDE;SUPRAVENTRICULAR ARRHYTHMIA;SUPRAVENTRICULAR TACHYCARDIA;SYPHILIS;THROMBOLYSIS;THYROID CARCINOMA;VASCULAR SURGERY;VASCULITIS;VIRAL DISEASE;WESTERN BLOT","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FLUORESCENCE IN SITU HYBRIDIZATION;ACUTE PROMYELOCYTIC LEUKEMIA;ALLELE FREQUENCY;BRONCHUS;CARBOPLATIN;COLONOSCOPY;CONDOM;CONGENITAL DIAPHRAGMATIC HERNIA;CYTOGENETICS;FAMILY PLANNING;GENE POLYMORPHISM;GIANT CELL ARTERITIS;HAPLOTYPE;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HIV ANTIGENS;HLA-C;IDARUBICIN;KARYOTYPE;N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE;WANDERING SPLEEN","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;ADULT;MIDDLE AGED;ADOLESCENT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;AGED;CARCINOMA, SQUAMOUS CELL;HEAD AND NECK NEOPLASMS;BEHCET SYNDROME;BRONCHIAL DISEASES;CALCULI;TIME FACTORS;;AGE FACTORS;CHONDROBLASTOMA;COLONIC NEOPLASMS;FEMORAL NEOPLASMS;HIV ANTIBODIES","23;18;14;12;9;7;7;6;6;6;5;5;5;5;4;4;4;4;4;4","PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;ADOLESCENT SEXUAL HEALTH AND BEHAVIOR PATTERNS;ANALYSIS OF ELECTROCARDIOGRAM SIGNALS;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;CALCINEURIN-NFAT SIGNALING IN TRANSCRIPTIONAL REGULATION;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;DIAGNOSIS AND MANAGEMENT OF CONGENITAL DIAPHRAGMATIC HERNIA;EATING DISORDERS AND BODY IMAGE CONCERNS;EPIDEMIOLOGY AND MANAGEMENT OF OCULAR INFLAMMATORY DISEASES;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;HEREDITARY ANGIOEDEMA: MOLECULAR MECHANISMS AND CLINICAL MANAGEMENT;HERNIA REPAIR TECHNIQUES AND MATERIALS;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;IMPACT OF CHRONIC STRESS ON CANCER PROGRESSION;INFECTION CONTROL IN HEALTHCARE SETTINGS;INSULIN-LIKE GROWTH FACTORS IN HEALTH AND DISEASE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","COLONOSCOPY;TREATMENT;ABDOMINAL WALL DEFECTS;ACCIDENTAL;ACUTE MYELOID LEUKEMIA;ACUTE PROMYELOCYTIC LEUKEMIA;ADOLESCENTS;AIDS;ANESTHETIC TECHNIQUE;ANTIBODIES;ANTIEMETIC THERAPY;ARRHYTHMIA DETECTION;ARRHYTHMIAS;BOLUS (DIGESTION);BONE GROWTH;CARBOPLATIN;CARDIAC HEALTH DIAGNOSIS;CHEMORADIOTHERAPY;CHONDROBLASTOMA;CLINICAL FEATURES","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BEHÇETS DISEASE;GENE POLYMORPHISMS;A-V LEAD;ACUTE PROMYELOCYTIC;ADDITIONAL CHROMOSOME;ADHESION MOLECULE-;ADOLESCENCE SPERMOGRAM;ADOLESCENT AFFECTED;AIDS-RELATED NEUROLOGICAL;ANGIOLINFOIDE CON;ANOREXIA NERVOSA;ANTERIOR APPROACH;ASYMPTOMATIC INCREASED-RISK;ATRIAL IEGMS;BARRIER EFFICIENCY;CAVAL THROMBUS;CHAMBER PACING;CHEMORADIOTHERAPY IMPROVE;CHROMOSOME ABNORMALITIES;COLORECTAL CANCER;COMBINATION CHEMOTHERAPY;CON EOSINOFILIA;CONGENITAL DIAPHRAGMATIC;CT FINDINGS;DESCRIZIONE DI;DIAPHRAGMATIC HERNIA;DISCRIMINATE SUPRAVENTRICULAR;DISSECTION COMBINED;DOMAIN ANALYSIS;DUAL CHAMBER","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANION PRODUCTION;CHEMOTAXIS SUPEROXIDE;CLINICALLY EVIDENT;JOINT DAMAGE;LYSOZYME RELEASE;NEUTROPHIL FUNCTIONS;PAPILLARY THYROID;SUPEROXIDE ANION;ADENOMAS SURROUNDING;AGONISTSTIMULATED NEUTROPHIL;ANDOR MODULATE;ANTIINFLAMMATORY DRUG;ARTHRITIS RA;ASSAYS CHEMOTAXIS;BINDING EXPERIMENTS;CA CONCENTRATION;CAI METHODS;CALCIUM MEASUREMENTS;CARCINOMAS PTCS;CELLS RESPONSIBLE;COMMON INVOLVING;COMMON THYROID;CONCENTRATION CAI;CONSIDERABLE POTENTIAL;CSA ACTION;CSA APPEARED;CSA APPEARS;DAMAGE PROGRESSION;EFFECTIVE AGENT;EVIDENT PAPILLARY","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",1,0.04,21,6,0,0,0,2,0,0,1,6,0,0,0,0,3,0,0,0,0,0,0,88,88,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,10,105,1.35,0,0,27,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","1;1","CANCER;CHILDHOOD LEUKEMIA;CLINICAL RESEARCH;HEMATOLOGY;ORPHAN DRUG;PEDIATRIC;PEDIATRIC CANCER;PEDIATRIC RESEARCH INITIATIVE;RARE DISEASES;STEM CELL RESEARCH","1;1;1;1;1;1;1;1;1;1","CANCER","1","5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","1;1","BLOOD CANCER;LEUKEMIA / LEUKAEMIA","1;1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_FERRARA",2002,29,6.31034482758621,2.55172413793103,0.655172413793103,0.206896551724138,0.689655172413793,1.08823529411765,1.05555555555556,0.857142857142857,1.05263157894737,0.172413793103448,2,8,2,3,15,0.28,0.07,0.1,0.52,27.62,0.500658605150707,NA,0.0344827586206897,0.551724137931034,0.411,0.124,0.167,0.119,"S BIGHI;ANDREA GIOMBI;FABRIZIO CANTINI;CARLO SALVARANI;MARCELLO GOVONI;IGNAZIO OLIVIERI;GIOVANNI SCANELLI;MASSIMO TILLI;STEFANO CERUTI;SIMONE SALA;ROBERTO FERRARI;ROBERTO GALEOTTI;LUCIANO FEGGI;MARIA CRISTINA MARZOLA;GIOACCHINO LEANDRO;L. SPISANI;VINCENZO BETTOLI;MELISSA DABUSTI;EZIO PAOLINO;EMANUELA RIZZIOLI","2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","GIOVANNI SCANELLI;DANIELE SANTILLI;F GHINELLI;MARCO LIBANORE;S BIGHI;ANDREA GIOMBI;MASSIMO TILLI;SIMONE SALA;ROBERTO GALEOTTI;FABRIZIO CANTINI;CARLO SALVARANI;IGNAZIO OLIVIERI;ROBERTO FERRARI;STEFANO CERUTI;VINCENZO BETTOLI;MELISSA DABUSTI;GIULIO TOSTI;MARCO STACCHINI;FRANCESCO CAVAZZINI;ANNAROSA VIRGILI","1.33;1;0.5;0.5;0.4;0.4;0.4;0.4;0.4;0.4;0.4;0.4;0.38;0.35;0.33;0.33;0.33;0.33;0.33;0.33","S BIGHI;ANDREA GIOMBI;FABRIZIO CANTINI;MARCELLO GOVONI;IGNAZIO OLIVIERI;GIOVANNI SCANELLI;MASSIMO TILLI;STEFANO CERUTI;SIMONE SALA;ROBERTO GALEOTTI;LUCIANO FEGGI;MARIA CRISTINA MARZOLA;VINCENZO BETTOLI;MELISSA DABUSTI;EZIO PAOLINO;MARIA RITA GAMBERINI;DANIELE SANTILLI;DANIELA RESCA;DONATO MELE;MASSIMILIANO CASTELLAZZI","2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","GIOVANNI SCANELLI;DANIELE SANTILLI;F GHINELLI;S BIGHI;ANDREA GIOMBI;MASSIMO TILLI;SIMONE SALA;ROBERTO GALEOTTI;FABRIZIO CANTINI;IGNAZIO OLIVIERI;STEFANO CERUTI;VINCENZO BETTOLI;MELISSA DABUSTI;FRANCESCO CAVAZZINI;MARCELLO GOVONI;LUCIANO FEGGI;DANIELA RESCA;DONATO MELE;G LODI;ROBERTO REVERBERI","1.33;1;0.5;0.4;0.4;0.4;0.4;0.4;0.4;0.4;0.35;0.33;0.33;0.33;0.32;0.31;0.25;0.25;0.25;0.25","ADRIANA CECI;ANTONIO PIGA;AURELIO MAGGIO;FERNANDO TRICTA;FRANCESCO SCHETTINI;GIUSEPPE MASERA;IPPAZIO STEFÀNO;MARIA DOMENICA CAPPELLINI;MARIAGRAZIA FELISI;PAOLA BAIARDI;RENZO GALANELLO;V. CARNELLI;VINCENZO DE SANCTIS;A. TONON;ALESSANDRA FAEDO;C. MARZOLINO;E. BOTTONA;G VERDIANELLI;GIANCARLO PARISI;GIOACCHINO LEANDRO","215;215;215;215;215;215;215;215;215;215;215;215;215;102;102;102;102;102;102;102","VINCENZO DE SANCTIS;G VERDIANELLI;GIUSEPPE BATTAGLIA;STEFANO CERUTI;FABRIZIO CANTINI;IGNAZIO OLIVIERI;GUIDO GUALANDI;MICHELE MARINÒ;C. STINCKENS;DAVIDE FILIPPINI;FRANCESCO TROTTA;GIOVANNI CIANCÌO;GIUSEPPE PAOLAZZI;LUIGI BOIARDI;MARCELLO GOVONI;PIERLUIGI MACCHIONI;RENATO MALATESTA;DANIELE SANTILLI;MARIA RITA GAMBERINI;MONICA FORTINI","215;102;102;90;85;85;76;76;73;62;62;62;62;62;62;62;62;51;41;41","FABRIZIO CANTINI;GIOVANNI SCANELLI;IGNAZIO OLIVIERI;LUCIANO FEGGI;STEFANO CERUTI;ANGELO MARGUTTI;C. STINCKENS;DANIELE SANTILLI;DAVIDE FILIPPINI;ENRICO FAINARDI;ENRICO GRANIERI;ETTORE C. DEGLI UBERTI;EZIO PAOLINO;F GHINELLI;F MASCOLI;FRANCESCO TROTTA;G VERDIANELLI;GIOVANNI CIANCÌO;GIUSEPPE BATTAGLIA;GIUSEPPE PAOLAZZI","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;ENGINEERING;MATHEMATICS;PHILOSOPHY;CHEMISTRY;POLITICAL SCIENCE;SOCIOLOGY","27;7;3;3;2;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;RADIOLOGY;NUCLEAR MEDICINE;ARTIFICIAL INTELLIGENCE;DERMATOLOGY;ENDOCRINOLOGY;IMMUNOLOGY;PSYCHIATRY;BIOCHEMISTRY;CARDIOLOGY;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;OPTICS;PALEONTOLOGY;PEDIATRICS;PHYSICAL THERAPY;VIROLOGY;AESTHETICS;ANATOMY;ANESTHESIA;ASTRONOMY;BIOMEDICAL ENGINEERING;CLINICAL PSYCHOLOGY;COMPUTER VISION;DENTISTRY;ELECTRICAL ENGINEERING;EMERGENCY MEDICINE;ENVIRONMENTAL HEALTH;FAMILY MEDICINE;GENERAL SURGERY;GENETICS;GEOMETRY;LAW;LIBRARY SCIENCE;MEDICAL PHYSICS;MICROBIOLOGY;MOLECULAR BIOLOGY;NEUROSCIENCE;ONCOLOGY;OPERATING SYSTEM;ORGANIC CHEMISTRY;PHARMACOLOGY;PHYSICAL MEDICINE AND REHABILITATION;PHYSIOLOGY;RISK ANALYSIS (ENGINEERING);STATISTICS;STRUCTURAL ENGINEERING;THEOLOGY;UROLOGY","21;9;8;6;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DISEASE;CANCER;HORMONE;ADVERSE EFFECT;ANTIGEN;ARTHRITIS;GENE;HEART FAILURE;IMMUNE SYSTEM;INCIDENCE (GEOMETRY);MAGNETIC RESONANCE IMAGING;ABDOMINAL PAIN;ACNE;ALTERNATIVE MEDICINE;ANEURYSM;ANKLE;ANKYLOSING SPONDYLITIS;ANTIBIOTICS;ANTIBODY;ARTERITIS;ASYMPTOMATIC;ATRIAL FIBRILLATION;BIOPSY;BLOOD PRESSURE;BODY MASS INDEX;CARCINOMA;CEREBROSPINAL FLUID;CHEMOTHERAPY;CHRISTIAN MINISTRY;CHRONIC FATIGUE SYNDROME;CIRRHOSIS;CLINICAL EFFICACY;CLINICAL PRACTICE;COCHLEA;CONSTIPATION;DEFECATION;DENGUE FEVER;DIARRHEA;DISCONTINUATION;DISSECTION (MEDICAL);DISTAL INTERPHALANGEAL JOINT;DOPPLER EFFECT;ENDOSCOPY;EPIDEMIOLOGY;EXTRAVASATION;FINGER JOINT;GLASGOW COMA SCALE;GUAR GUM;HELMINTHS;HEMODYNAMICS;HEMOSTASIS;HEPATOLOGY;HYPOPLASIA;IMPLANT;IN VITRO;INNER EAR;INTENSIVE CARE UNIT;INTERFERON;INTERPHALANGEAL JOINT;INTERVENTIONAL RADIOLOGY;IRRITABLE BOWEL SYNDROME;LINE (GEOMETRY);LITHIUM (MEDICATION);LIVER DISEASE;LIVER PARENCHYMA;LOTION;LUMBAR;LYME DISEASE;LYMPH;LYMPH NODE;MALARIA;MESOTHELIOMA;METHOTREXATE;MODE (COMPUTER INTERFACE);MODULATION (MUSIC);MULTIPLE MYELOMA;MULTIPLE SCLEROSIS;NEUROLOGY;NITRIC OXIDE;NODE (PHYSICS);ORAL CAVITY;PARENCHYMA;PEPTIC ULCER;PERCEPTION;PHARYNX;PNEUMONIA;POPULATION;PREDNISOLONE;PREDNISONE;PREFERRED WALKING SPEED;PRESENTATION (OBSTETRICS);PSORIASIS;PUBLICATION;PUBLISHING;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;RAW MATERIAL;REHABILITATION;RENAL FUNCTION;RENDERING (COMPUTER GRAPHICS);REPEATABILITY;REST (MUSIC);RHEUMATOID ARTHRITIS;RISK MODEL;SENSATION;SOMATOSTATIN;STAGE (STRATIGRAPHY);TEMPORAL BONE;TEST (BIOLOGY);THALASSEMIA;THYROID;TRANSMISSION (TELECOMMUNICATIONS);TRAUMATIC BRAIN INJURY;ULTRASONOGRAPHY;ULTRASOUND;URINARY INCONTINENCE;URINARY SYSTEM;VARIETY (CYBERNETICS);VASCULAR DISEASE;VIRUS","5;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;ALLELE;AMIODARONE;ANTIRHEUMATIC AGENTS;ARTERIAL DISEASE;BEHCET'S DISEASE;BORRELIA BURGDORFERI;BRACHYTHERAPY;BRAN;CARDIAC FUNCTION CURVE;CARDIAC OUTPUT;CD8;CHRONIC FATIGUE;COMMUNITY-ACQUIRED PNEUMONIA;CYTOTOXIC T CELL;DEFERIPRONE;DEMYELINATING DISEASE;DEMYELINATING DISORDER;DIASTOLE;EJECTION FRACTION;ENDOCRINE SYSTEM;EPITOPE;ERYTHROMYCIN;EXON;FILARIASIS;GENOTYPE;GOITER;GROWTH HORMONE;HEPATITIS C VIRUS;HUMAN LEUKOCYTE ANTIGEN;INFECTIOUS DISEASE (MEDICAL SPECIALTY);INFLIXIMAB;INTENTION-TO-TREAT ANALYSIS;INTRON;LEFLUNOMIDE;LIVEDO RETICULARIS;MASS INDEX;MEMBRANOUS LABYRINTH;METASTASIS;NECK DISSECTION;NEURORADIOLOGY;NEUTROPENIA;NITRIC OXIDE SYNTHASE;OSTEOARTHRITIS;PEPTIC;PROSTATE;PSEUDOANEURYSM;PSORIATIC ARTHRITIS;RECOMBINANT DNA;THYROIDITIS;TOLERABILITY;ULCERATIVE COLITIS;UPPER GASTROINTESTINAL BLEEDING;VESTIBULAR AQUEDUCT;VOLUME RENDERING","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","SENTINEL NODE;ALLELE FREQUENCY;ANTIRHEUMATIC DRUGS;ARTHROPATHY;BORRELIA;CARDIAC INDEX;CLAUDICATION;CTL*;DIASTOLIC FUNCTION;ENDOCRINE DISEASE;ENOS;GROWTH HORMONE DEFICIENCY;GROWTH HORMONE–RELEASING HORMONE;INTERMITTENT CLAUDICATION;LYMPHATIC FILARIASIS;MICROMETASTASIS;NS3;POLYMORPHISM (COMPUTER SCIENCE);SENTINEL LYMPH NODE;STROKE VOLUME;SULFASALAZINE;TRANSRECTAL ULTRASONOGRAPHY;VECTOR (MOLECULAR BIOLOGY)","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;AGED;BETA-THALASSEMIA;LYMPH NODES;OROPHARYNGEAL NEOPLASMS;BREAST NEOPLASMS;;ADOLESCENT;COMMUNITY-ACQUIRED INFECTIONS;MENINGOENCEPHALITIS;PNEUMONIA;ACUTE KIDNEY INJURY;BUNYAVIRIDAE INFECTIONS;CARCINOMA, SQUAMOUS CELL;CENTRAL NERVOUS SYSTEM;DENGUE","24;16;16;13;10;9;7;7;7;6;5;5;5;5;5;4;4;4;4;4","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;AORTIC ATHEROSCLEROTIC DISEASE AND EMBOLIC EVENTS;BRANCHIAL ANOMALIES AND THYROID ABNORMALITIES;CLASSIFICATION AND TREATMENT OF HISTIOCYTIC DISORDERS;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;DIAGNOSIS AND MANAGEMENT OF FIBROMYALGIA SYNDROME;DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL BLEEDING;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF HEART FAILURE;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND IMPLICATIONS OF MULTIMORBIDITY IN HEALTHCARE;EPIDEMIOLOGY AND MANAGEMENT OF OCULAR INFLAMMATORY DISEASES;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;FUNCTIONAL BOWEL DISORDERS AND GASTROINTESTINAL HEALTH;GLOBAL IMPACT OF ARBOVIRAL DISEASES;GLYCOGEN METABOLISM AND MYOCLONIC DISORDERS;HEPATITIS C INFECTION AND TREATMENT;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MANAGEMENT AND PATHOPHYSIOLOGY OF ACNE AND ROSACEA","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TREATMENT;RADIATION THERAPY;ANEURYSM RUPTURE;ANEURYSM SCREENING;ANKLE-BRACHIAL INDEX;ANTIBODY ENGINEERING;ANTIRHEUMATIC DRUGS;AORTIC ANEURYSMS;AORTIC DISSECTION;ARTERITIS;ARTHROPATHY;ATHEROEMBOLIC RENAL DISEASE;B LYMPHOCYTE DEPLETION;BRANCHIAL ANOMALIES;BRANCHIO-OTO-RENAL SYNDROME;BREAST CANCER;BREAST CANCER DIAGNOSIS;CARDIAC IMAGING;CARDIAC INDEX;CHOLESTEROL EMBOLIZATION SYNDROME","4;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTI-CE RH;ANTIRHEUMATIC DRUG;AORTIC PSEUDOANEURYSM;ATHEROEMBOLIC DISEASE;BEHÇETS DISEASE;BLEEDING PEPTIC;BODY CAUSED;BONE ANOMALIES;BOWEL SYNDROME;BRAN DIET;BRANCHIO-OTO-RENAL SYNDROME;BREAST CANCER;CEREBROSPINAL FLUID;CHRONIC HEART;CLINICAL APPLICATIONS;CLINICAL PRESENTATION;COMMUNITY-ACQUIRED PNEUMONIA;COMPARATIVA SPLIT-FACE;COMPUTED TOMOGRAPHIC;CORTICOSTEROID THERAPY;CT FINDINGS;DETAILED COMPUTED;DIAGNOSIS TREATMENT;DIASTOLIC FUNCTION;DIET SUPPLEMENTATION;DISEASE ACTIVITY;DISEASE EVALUATION;DISEASE-MODIFYING ANTIRHEUMATIC;DISEASES RECENT;DISTAL INTERPHALANGEAL","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FERRITIN LEVELS;INCREMENTAL WALKING;MONTH REHABILITATION;WALKING TEST;ABI DETERMINATION;ABI ROSE;ADVERSE EVENTS;ALANINE TRANSAMINASE;ANKLE BRACHIAL;ARTHRITIDESNAMELY OSTEOARTHRITIS;ARTHRITIS PSORIATIC;ARTHRITIS TOPHACEOUS;AVERAGE INCREMENTS;BACKGROUND MULTICENTRIC;BOOKS CONFERENCE;BRACHIAL INDEX;BREAST CANCER;CAREFUL CLINICAL;CELL INFILTRATE;CHARACTERISTIC HISTIOCYTIC;CLAUDICATION OCCURS;CLINICAL TRIALS;COLLECT DATA;COMMON DISTAL;COMMONLY REPORTED;CONFERENCE PROCEEDINGS;CONTROLLED DISTRIBUTION;CORRELATION COEFFICIENT;DEFERIPRONETREATED PATIENTS;DIALYSIS RELATED","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",3,0.1,8.5,3.5,0,0,0,1,1,0,0,3.5,0,0,1,0,3,0,0,1,0,0,0,75,75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,6.5,3687.5,3.12,0,0,176,0,0,0,0,2,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Italy","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","2;1;1","CARDIOVASCULAR;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEART DISEASE;NUTRITION","1;1;1;1;1","CANCER;CARDIOVASCULAR","1;1","6.1 PHARMACEUTICALS","1","PANCREATIC CANCER","1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_FERRARA",2003,27,6.37037037037037,2.40740740740741,0.62962962962963,0.296296296296296,0.62962962962963,1.18181818181818,1.0625,0.888888888888889,1.0625,0.296296296296296,2,11,1,2,8,0.41,0.04,0.07,0.3,16.81,0.317692828743127,NA,0.111111111111111,0.592592592592593,0.378,0.238,0.167,0.238,"ENRICO FAINARDI;T. SCALISE;CLAUDIO PRATOLA;DONATO MELE;MASSIMO BORRELLI;MASSIMILIANO CASTELLAZZI;GIOVANNI CASADIO;A FRANCHELLA;LUCA VAGHI;F. CALZOLARI;ENRICO GRANIERI;G. GASPARINI;TIZIANO TOSELLI;R TAMAROZZI;ROBERTO FERRARI;ILARIA CASETTA;BRUNO ANDREI;STEFANO VOLPATO;VINCENZO BETTOLI;SARA LAPPI","4;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","DONATO MELE;P. GILLI;GIOVANNI CASADIO;A FRANCHELLA;ENRICO FAINARDI;R. QUATRALE;T. SCALISE;CLAUDIO PRATOLA;D CHENDI;F. CALZOLARI;MICHELINI ME;G. GASPARINI;ROBERTO ELEOPRA;TIZIANO TOSELLI;TUGNOLI;MASSIMO BORRELLI;R TAMAROZZI;ROBERTO FERRARI;G ZANDI;P. MAZZA","1.11;1;0.67;0.67;0.47;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.28;0.28;0.28;0.25;0.25","ENRICO FAINARDI;CLAUDIO PRATOLA;DONATO MELE;MASSIMO BORRELLI;MASSIMILIANO CASTELLAZZI;GIOVANNI CASADIO;A FRANCHELLA;LUCA VAGHI;F. CALZOLARI;ENRICO GRANIERI;TIZIANO TOSELLI;R TAMAROZZI;ROBERTO FERRARI;ILARIA CASETTA;STEFANO VOLPATO;VINCENZO BETTOLI;EZIO PAOLINO;GLORIA GIOVANNINI;VITTORIA CATAPANO;G ZANDI","4;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","DONATO MELE;P. GILLI;GIOVANNI CASADIO;A FRANCHELLA;ENRICO FAINARDI;CLAUDIO PRATOLA;D CHENDI;F. CALZOLARI;MICHELINI ME;ROBERTO ELEOPRA;TIZIANO TOSELLI;MASSIMO BORRELLI;R TAMAROZZI;ROBERTO FERRARI;G ZANDI;GIOVANNI SCANELLI;VINCENZO DE SANCTIS;MASSIMILIANO CASTELLAZZI;LUCA VAGHI;ENRICO GRANIERI","1.11;1;0.67;0.67;0.47;0.33;0.33;0.33;0.33;0.33;0.33;0.28;0.28;0.28;0.25;0.25;0.25;0.23;0.23;0.23","ENRICO FAINARDI;ENRICO GRANIERI;LUCA VAGHI;MASSIMILIANO CASTELLAZZI;ANDREA MARZOLA;EZIO PAOLINO;LOREDANA MELCHIORRI;MARIA ROSARIA TOLA;OLAVIO R. BARICORDI;ROBERTA RIZZO;VITTORIO GOVONI;DONATO MELE;BRUNO CASALI;CARLO SALVARANI;DAVIDE NICOLI;ENRICO FARNETTI;LIA PULSATELLI;LUIGI BOIARDI;MARIA GRAZIA CATANOSO;PIERLUIGI MACCHIONI","111;107;107;107;84;84;84;84;84;84;84;75;64;64;64;64;64;64;64;64","ENRICO FAINARDI;ENRICO GRANIERI;LUCA VAGHI;MASSIMILIANO CASTELLAZZI;EZIO PAOLINO;MARIA ROSARIA TOLA;OLAVIO R. BARICORDI;VITTORIO GOVONI;DONATO MELE;MARIA GRAZIA CATANOSO;PIERLUIGI MACCHIONI;GIOVANNI GUERRA;ROSANNA CARROCCIA;FRANCESCA NESTA;INCORONATA D’AIELLO;ROBERTO FERRARI;F. PANSINI;ANGELINA PASSARO;ANNA SOLINI;EDOARDO DALLA NORA","111;107;107;107;84;84;84;84;75;64;64;47;47;37;37;37;31;27;27;27","ENRICO FAINARDI;DONATO MELE;ENRICO GRANIERI;F. CALZOLARI;LUCA VAGHI;MASSIMILIANO CASTELLAZZI;ROBERTO FERRARI;A FRANCHELLA;ANGELINA PASSARO;ANNA SOLINI;D CHENDI;EDOARDO DALLA NORA;ELISABETTA SARTI;EZIO PAOLINO;F. CALZONI;F. CARTEI;F. PANSINI;FRANCESCA NESTA;FRANCESCO FIORICA;G ZANDI","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;MATHEMATICS;PHYSICS;ECONOMICS;POLITICAL SCIENCE","26;5;3;3;1;1","INTERNAL MEDICINE;SURGERY;RADIOLOGY;CARDIOLOGY;PATHOLOGY;PSYCHIATRY;IMMUNOLOGY;ENDOCRINOLOGY;NUCLEAR MEDICINE;OPTICS;ANESTHESIA;BIOCHEMISTRY;GASTROENTEROLOGY;GENERAL SURGERY;GENETICS;ONCOLOGY;STATISTICS;ANATOMY;CANCER RESEARCH;DERMATOLOGY;ENVIRONMENTAL HEALTH;GEOMETRY;LAW;MANAGEMENT;MEDICAL EDUCATION;MICROBIOLOGY;MOLECULAR BIOLOGY;NURSING;PEDIATRICS;PHARMACOLOGY;PHYSICAL MEDICINE AND REHABILITATION;PUBLIC RELATIONS;UROLOGY","17;10;9;5;5;5;4;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CEREBRAL BLOOD FLOW;GENE;HORMONE;MAGNETIC RESONANCE IMAGING;CARDIAC PACING;CEREBROSPINAL FLUID;HEART FAILURE;LASER;MULTIPLE SCLEROSIS;NEUROLOGY;NEUROSURGERY;RADIATION THERAPY;REPRODUCIBILITY;VENTRICLE;ACCREDITATION;ACNE;ADJUVANT;ALTERNATIVE MEDICINE;ANTIBIOTICS;ANTIBODY;ANTIGEN;ARTERITIS;ASYMPTOMATIC;ATRESIA;ATRIAL FIBRILLATION;AURICLE;BETA-2 MICROGLOBULIN;BLOOD FLOW;BONE MARROW;BONE REMODELING;BOTULINUM TOXIN;CHEMOTHERAPY;CHLAMYDIA;CHOLECYSTECTOMY;COMPETENCE (HUMAN RESOURCES);COMPLICATION;CONCOMITANT;CONFIDENCE INTERVAL;CRANIOFACIAL;CREATININE;CYST;DIABETES MELLITUS;DIFFERENTIAL DIAGNOSIS;DISEASE;DYSPLASIA;EAR CANAL;EMBOLISM;EMBOLIZATION;EMERGENCY DEPARTMENT;EMERGENCY SURGERY;ENZYME;EPILEPSY;FACIAL NERVE;FOREIGN BODIES;HEALTH CARE;HERNIA;HISTOLOGY;HISTOPATHOLOGICAL EXAMINATION;HOMOCYSTEINE;HYOID BONE;IMMUNE SYSTEM;IN VITRO;INCIDENCE (GEOMETRY);INGESTION;INNER EAR;INSUFFLATION;INTERVENTIONAL RADIOLOGY;INTRATHECAL;LAPAROSCOPY;LARYNX;LEGISLATURE;LESION;MENOPAUSE;METHOTREXATE;MIDDLE EAR;MITOMYCIN C;MULTIPLE MYELOMA;NECK MASS;NEUROLOGICAL EXAMINATION;ODDS RATIO;OSTEOPOROSIS;PALLIATIVE CARE;PALLIATIVE TREATMENT;PATHOLOGICAL;PEDIATRIC SURGERY;PERFUSION;PLASMINOGEN ACTIVATOR;POPULATION;PRESENTATION (OBSTETRICS);PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;REDUCTION (MATHEMATICS);RENAL FUNCTION;RISK FACTOR;SKULL;SPASTICITY;SURGICAL EMERGENCY;TEMPORAL BONE;TESTICULAR TORSION;THYROID;TRANSDERMAL;TRANSPLANTATION;VEGF RECEPTORS;VITAMIN B12","3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EJECTION FRACTION;LEFT VENTRICLES;NEURORADIOLOGY;SECOND-HARMONIC GENERATION;AIR EMBOLISM;ALLELE;ANTIBIOTIC RESISTANCE;BLOOD UREA NITROGEN;BONE DENSITY;BONE MINERAL;BREAST CANCER;CACHEXIA;CATHETER ABLATION;CHLAMYDIACEAE;CYCLOPHOSPHAMIDE;EMERGENCY PHYSICIAN;FLUID-ATTENUATED INVERSION RECOVERY;FLUOROURACIL;FOREIGN BODY INGESTION;GANGLIOGLIOMA;GENOTYPE;GROWTH HORMONE;HERNIA REPAIR;HUMAN LEUKOCYTE ANTIGEN;INGUINAL HERNIA;LAPAROSCOPIC SURGERY;METABOLIC CONTROL ANALYSIS;MITOCHONDRIAL DNA;MITOXANTRONE;PERFUSION SCANNING;PERIPHERAL BLOOD MONONUCLEAR CELL;PHASES OF CLINICAL RESEARCH;PLACEBO;PLASMA CELL;PLASMIN;PNEUMOPERITONEUM;POLYMERASE CHAIN REACTION;PROSTATE CANCER;RECOMBINANT DNA;RESEARCH METHODOLOGY;TEMPORAL LOBE;THYROGLOSSAL DUCT;THYROID CANCER;THYROID FUNCTION;THYROID-STIMULATING HORMONE;THYROIDECTOMY;TYPE 2 DIABETES;UROKINASE RECEPTOR;VASCULAR ENDOTHELIAL GROWTH FACTOR;VASCULITIS","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","SECOND-HARMONIC IMAGING MICROSCOPY;ATRIAL TACHYCARDIA;BREAST CARCINOMA;CANCER CACHEXIA;EPIRUBICIN;FEMORAL HERNIA;GIANT CELL ARTERITIS;GROWTH HORMONE DEFICIENCY;HLA-G;HUMAN GROWTH HORMONE;KEARNS–SAYRE SYNDROME;METHYLENETETRAHYDROFOLATE REDUCTASE;NORETHISTERONE;SUPAR;THYROGLOSSAL CYST;VERESS NEEDLE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;BRAIN;ADULT;MAGNETIC RESONANCE IMAGING;CHLAMYDIA INFECTIONS;GIANT CELL ARTERITIS;GROWTH DISORDERS;INFLAMMATION;ISCHEMIA;MULTIPLE SCLEROSIS;MULTIPLE SCLEROSIS, RELAPSING-REMITTING;NERVOUS SYSTEM DISEASES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BRAIN HEMORRHAGE, TRAUMATIC;BREAST NEOPLASMS","18;11;11;9;9;8;8;6;5;4;4;4;4;4;4;4;4;3;3;3","CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;GLIOMAS;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;ABDOMINAL COMPARTMENT SYNDROME AND INTRA-ABDOMINAL HYPERTENSION;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;BRANCHIAL ANOMALIES AND THYROID ABNORMALITIES;CHARGE SYNDROME AND RELATED GENETIC DISORDERS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;HEREDITARY ANGIOEDEMA: MOLECULAR MECHANISMS AND CLINICAL MANAGEMENT;HERNIA REPAIR TECHNIQUES AND MATERIALS;IMMUNOLOGICAL MECHANISMS IN PREGNANCY AND FETAL-MATERNAL INTERFACE;MANAGEMENT AND PATHOPHYSIOLOGY OF ACNE AND ROSACEA;MANAGEMENT AND PATHOPHYSIOLOGY OF INTRACEREBRAL HEMORRHAGE;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;MANAGEMENT OF INGESTED FOREIGN BODIES AND FOOD IMPACTIONS;MANAGEMENT OF SPINAL METASTATIC TUMORS;MARKET-DRIVEN MANAGEMENT AND GLOBAL COMPETITION;METABOLIC DISORDERS AND BIOCHEMICAL GENETICS","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ARRHYTHMIAS;CARDIAC IMAGING;CARDIAC PACING;CARDIAC ULTRASOUND;CEREBRAL BLOOD FLOW;COMPUTED TOMOGRAPHY ANGIOGRAPHY;ECHOCARDIOGRAPHY;LEFT VENTRICLES;LEFT VENTRICULAR FUNCTION;NEURORADIOLOGY;SECOND-HARMONIC IMAGING MICROSCOPY;;AIR EMBOLISM;ANTIBIOTIC RESISTANCE;ANTICOAGULANT THERAPY;ARTERITIS;ATRIAL FIBRILLATION;ATRIAL FLUTTER;ATRIAL TACHYCARDIA;AURICLE","2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","ATRIAL PACING;ATRIAL TACHYARRHYTHMIAS;AUTOMATED ECHOCARDIOGRAPHIC;BLOOD FLOW;CEREBRAL BLOOD;DISTORTED LEFT;ECHOCARDIOGRAPHIC ASSESSMENT;EJECTION FRACTION;FRACTIONATED RADIOTHERAPY;HARMONIC IMAGING;LEFT VENTRICLES;LEFT VENTRICULAR;MULTIPLE SCLEROSIS;PACING MODALITIES;PAROXYSMAL ATRIAL;TISSUE HARMONIC;VENTRICLES IMPROVEMENT;VENTRICULAR EJECTION;VISUAL MANUAL;ACCREDITATION PROCESS;ACTIVATOR RECEPTOR;ACUTE SPONTANEOUS;ADVANCED HORMONE-RESISTANT;ANOMALIE CONGENITE;BONE LOSS;BONE METASTASES;BOTULINUM TOXIN;BRAIN CONTUSIONS;BREAST CARCINOMA;CANCER CACHEXIA","2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","HARMONIC IMAGING;TISSUE HARMONIC;CONVENTIONAL ECHOCARDIOGRAPHY;DISTORTED LEFT;EJECTION FRACTION;LEFT VENTRICLES;LEFT VENTRICULAR;VENTRICULAR EJECTION;AUTOMATED QUANTITATION;AUTOMATED TRACING;ECHOCARDIOGRAPHY ECHO;IMAGE QUALITY;MANUAL TRACING;MEGESTROL ACETATE;TRACING SE;ADVANCED HORMONE-RESISTANT;EXTRABM INVOLVEMENT;HORMONE-RESISTANT PROSTATE;PLASMA CELLS;PROSTATE CANCER;ANTIBIOTIC RESISTANCE;APICAL VIEWS;ATRIAL OVERPACING;ATRIAL TACHYARRHYTHMIAS;BONE METASTASES;CANCER CACHEXIA;CLINICALLY REASONABLE;DDD-CLS DDDO;DDDO MODE;DECREASED INTER-OBSERVER","10;10;8;6;6;6;6;6;4;4;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2",1,0.04,3,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,17,53,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_FERRARA",2004,24,8.125,2.625,0.541666666666667,0.208333333333333,0.541666666666667,1.18867924528302,1,0.833333333333333,1,0,1,6,8,5,4,0.25,0.33,0.21,0.17,33.17,0.704869711681362,NA,0.25,0.666666666666667,0.385,0.25,0.28,0.25,"ENRICO FAINARDI;ENRICO GRANIERI;MASSIMILIANO CASTELLAZZI;ARTURO CHIEREGATO;C RAMPULLA;LICIA BALLERIN;A POTENA;LUISA CANIATTI;LUCIO TREVISANI;CARLO BUNIOLO;FRANCO SERVADEI;ROBERTO FERRARI;VINCENZO DE SANCTIS;MASSIMO FILIPPI;ROBERT A. LEVINE;MAURO ZAFFARONI;ANGELO GHEZZI;MARILENA COCO;EZIO PAOLINO;DOMENICO CUCINOTTA","4;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","R SCOLOZZI;LUCIO TREVISANI;ENRICO FAINARDI;PIERGIORGIO GAUDENZI;VITALIANA DE SANCTIS;C. PINTOR;ROBERTO FERRARI;ENRICO GRANIERI;ARTURO CHIEREGATO;FRANCO SERVADEI;VINCENZO DE SANCTIS;CRISTINA MALAVENTURA;VINCENZO DE SANCTIS;ANDROULLA ELEFTHERIOU;MASSIMILIANO CASTELLAZZI;S BIGHI;BEATRICE GAMBI;RAJAT SETHI;L TAMISARI;PAOLO MANNELLA","1;0.62;0.61;0.5;0.5;0.5;0.39;0.36;0.34;0.34;0.34;0.33;0.33;0.33;0.27;0.25;0.25;0.25;0.25;0.25","ENRICO FAINARDI;ENRICO GRANIERI;MASSIMILIANO CASTELLAZZI;C RAMPULLA;LICIA BALLERIN;A POTENA;LUISA CANIATTI;LUCIO TREVISANI;CARLO BUNIOLO;ROBERTO FERRARI;VINCENZO DE SANCTIS;EZIO PAOLINO;S BIGHI;ADRIANO PIATTELLI;FRANCO H. FALCONE;RICARDO H. RODA;MARIACHIARA SENSI;R. QUATRALE;CORRADO CITTANTI;GIOVANNI PASANISI","4;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","R SCOLOZZI;LUCIO TREVISANI;ENRICO FAINARDI;VITALIANA DE SANCTIS;ROBERTO FERRARI;ENRICO GRANIERI;VINCENZO DE SANCTIS;VINCENZO DE SANCTIS;MASSIMILIANO CASTELLAZZI;S BIGHI;PAOLO MANNELLA;F. CALZOLARI;RITA BARALDI;SIMONE SALA;LUISA CANIATTI;C RAMPULLA;LICIA BALLERIN;A POTENA;CARLO BUNIOLO;CORRADO CITTANTI","1;0.62;0.61;0.5;0.39;0.36;0.34;0.33;0.27;0.25;0.25;0.25;0.25;0.25;0.22;0.2;0.2;0.2;0.2;0.14","ANGELO GHEZZI;E. MERELLI;GIANCARLO COMI;L. MANCARDI;M. R. TOLA;MARIA TROJANO;MASSIMO FILIPPI;MAURO ZAFFARONI;PAOLO GALLO;ROBERTO BERGAMASCHI;VITTORIO MARTINELLI;VINCENZO DE SANCTIS;ENRICO FAINARDI;ENRICO GRANIERI;ANDROULLA ELEFTHERIOU;CRISTINA MALAVENTURA;MARIA ROSARIA TOLA;ARTURO CHIEREGATO;FRANCO SERVADEI;ELISABETTA SETTE","266;266;266;266;266;266;266;266;266;266;266;155;145;142;120;120;108;88;88;85","M. R. TOLA;VINCENZO DE SANCTIS;ENRICO FAINARDI;ENRICO GRANIERI;MARIA ROSARIA TOLA;ELISABETTA SETTE;J.G. CAPONE;MARIACHIARA SENSI;MICHELE ALESSANDRO CAVALLO;PAOLA MILANI;R. QUATRALE;ROBERTO ELEOPRA;V. TUGNOLI;MASSIMILIANO CASTELLAZZI;LUISA CANIATTI;ROBERTO FERRARI;ADRIANO PIATTELLI;FURIO PEZZETTI;LUCA SCAPOLI;F GHINELLI","266;155;145;142;108;85;85;85;85;85;85;85;85;57;43;30;26;26;26;25","ENRICO FAINARDI;VINCENZO DE SANCTIS;ENRICO GRANIERI;A POTENA;LUISA CANIATTI;MARIA ROSARIA TOLA;MASSIMILIANO CASTELLAZZI;ROBERTO FERRARI;ADRIANO PIATTELLI;CORRADO CITTANTI;DONATO MELE;ELISABETTA SETTE;EZIO PAOLINO;F GHINELLI;F. CALZOLARI;FURIO PEZZETTI;G. LELLI;GABRIELE GUARDIGLI;GIOVANNI PASANISI;J.G. CAPONE","4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ECONOMICS;CHEMISTRY;GEOGRAPHY;HISTORY;PHILOSOPHY;PSYCHOLOGY","23;6;3;2;2;1;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;PSYCHIATRY;RADIOLOGY;CARDIOLOGY;ENDOCRINOLOGY;PATHOLOGY;PEDIATRICS;SURGERY;GENETICS;ANATOMY;ARCHAEOLOGY;ECONOMIC GROWTH;EMERGENCY MEDICINE;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;NUCLEAR MEDICINE;ONCOLOGY;PALEONTOLOGY;QUANTUM MECHANICS","12;5;5;5;4;4;4;4;4;3;2;2;2;2;2;2;2;2;2;2","MULTIPLE SCLEROSIS;NEUROLOGY;ADVERSE EFFECT;CANCER;COMPUTED TOMOGRAPHY;GENE;HEALTH CARE;HEART FAILURE;HORMONE;MAGNETIC RESONANCE IMAGING;MYOCARDIAL INFARCTION;SHORT STATURE;STIMULATION;VENTRICLE;ACTION (PHYSICS);ADOLESCENT MEDICINE;AFFECT (LINGUISTICS);ALLERGY;ANGER;ANTIBODY;ANTIOXIDANT;AORTA;ASTHMA;BETA (PROGRAMMING LANGUAGE);BLOOD FLOW;CEREBRAL BLOOD FLOW;CEREBROSPINAL FLUID;CHEMOTHERAPY;CHLAMYDIA;CISTERN;COGNITION;COMORBIDITY;CYST;DIABETES MELLITUS;DISEASE;DUODENUM;DYSPHAGIA;ENDOCARDIUM;EROSION;GROWTH SPURT;GROWTH VELOCITY;HEAD TRAUMA;HEMATOMA;HUMAN IMMUNODEFICIENCY VIRUS (HIV);HYPOPARATHYROIDISM;IMPULSE (PHYSICS);INOTROPE;INSULIN;INTERFERON;INTERVENTIONAL RADIOLOGY;ISCHEMIA;LASER;LUNG CANCER;MALIGNANCY;MEDITERRANEAN CLIMATE;OBESITY;OCCUPATIONAL EXPOSURE;OXIDATIVE STRESS;PREGNANCY;QUALITY (PHILOSOPHY);REACTIVE OXYGEN SPECIES;RENDERING (COMPUTER GRAPHICS);RESPIRATORY FAILURE;RESPIRATORY SYSTEM;SEMEN;SPERM;SPINAL CORD;STENOSIS;TEST (BIOLOGY);TOXICITY;TRAUMATIC BRAIN INJURY","3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","NEURORADIOLOGY;GROWTH HORMONE;RELAPSING REMITTING;TOLERABILITY;ADENYLYL CYCLASE;ALLERGEN;AORTIC ARCH;BASAL (MEDICINE);BREAST CANCER;CARDIAC FUNCTION CURVE;CATALASE;CHLAMYDIACEAE;CHLAMYDIALES;CISPLATIN;COLORECTAL CANCER;DELAYED PUBERTY;EJECTION FRACTION;ENDOCRINE SYSTEM;EXPANDED DISABILITY STATUS SCALE;FETUS;GEMCITABINE;GENE EXPRESSION;HEALTHCARE WORKER;IMMUNOASSAY;INTERFERON BETA;MALONDIALDEHYDE;MUTATION;MYELITIS;NEUROMYELITIS OPTICA;NEUROPSYCHOLOGY;ODONTOGENIC CYST;PARKINSON'S DISEASE;PHASES OF CLINICAL RESEARCH;PHENOTYPE;PROGRESSIVE DISEASE;REIMBURSEMENT;SECOND-HARMONIC GENERATION;SPERM MOTILITY;SUPEROXIDE DISMUTASE;VOLUME RENDERING;WHITE MATTER","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ALLERGEN IMMUNOTHERAPY;AMNION;ANENCEPHALY;CARBOPLATIN;CHLAMYDOPHILA PNEUMONIAE;COLONOSCOPY;DEEP BRAIN STIMULATION;DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;DNA MICROARRAY;DOUBLE AORTIC ARCH;GENE EXPRESSION PROFILING;GROWTH HORMONE DEFICIENCY;HEREDITARY SPASTIC PARAPLEGIA;HOLOPROSENCEPHALY;IDIOPATHIC SHORT STATURE;INTERFERON BETA-1A;INTERFERON BETA-1B;MICROARRAY;MISSENSE MUTATION;SECOND-HARMONIC IMAGING MICROSCOPY;SUBLINGUAL IMMUNOTHERAPY;TERATOLOGY;VASCULAR RING","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;BRAIN;ADULT;AGED;BETA-THALASSEMIA;MULTIPLE SCLEROSIS, RELAPSING-REMITTING;HYPOGONADISM;ADOLESCENT;BREAST NEOPLASMS;COLORECTAL NEOPLASMS;ENDOCRINE SYSTEM DISEASES;HEART FAILURE;HIV INFECTIONS;ITALY;MAGNETIC RESONANCE IMAGING;MYOCARDIAL INFARCTION;NEUROMYELITIS OPTICA","20;17;13;11;10;9;8;7;6;5;4;4;4;4;4;4;4;4;4;4","DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN LUNG CANCER RESEARCH;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;CLASSIFICATION AND MANAGEMENT OF ODONTOGENIC TUMORS;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;DEVELOPMENT AND DISORDERS OF FETAL BRAIN;GENETIC BASIS OF NEUROPATHIES AND RELATED DISORDERS;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;GLOBAL TRENDS IN OBESITY AND OVERWEIGHT RESEARCH;HEMOSTATIC AGENTS AND TECHNIQUES;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;METABOLIC DISORDERS AND BIOCHEMICAL GENETICS;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION","3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","NEURORADIOLOGY;DIAGNOSIS;RELAPSING REMITTING;THALASSEMIA;TOLERABILITY;ADOLESCENT MEDICINE;ADOLESCENTS;AFFECT (LINGUISTICS);ALLERGEN IMMUNOTHERAPY;AMELOBLASTOMA;AMNION;ANENCEPHALY;AORTIC DISSECTION;BASAL (MEDICINE);BETA (PROGRAMMING LANGUAGE);BREAST CANCER;BREAST CANCER SCREENING;BREAST TUMOURS;CANCER INCIDENCE;CANCER SURVIVAL","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MULTIPLE SCLEROSIS;AD AUMENTATO;ADOLESCENT MEDICINE;ADOLESCENTS LIVING;ALLERGIC RHINITIS;ALLERGOID SUBLINGUAL;AMELOBLASTIC CARCINOMA;ANALISI COSTO-BENEFICIO;ANDOR ASTHMA;ANENCEPHALY MRI;ANTIOXIDANT CAPACITY;AORTIC ARCH;ASINTOMATICI AD;AUMENTATO RISCHIO;AUTOMATED EXTRACTION;BEHAVIOR RELATED;BENEFICIAL EFFECT;BILATERAL SUBTHALAMIC;BLOOD FLOW;BRAIN MAGNETIC;BREAST CANCER;CAGLIARI ITALY;CANCER DEFINITIVE;CANCRO DEL;CARDIAC FUNCTION;CARE UNITS;CASTRIADAS CAGLIARI;CELL LUNG;CENTRIFUGAL DISTRIBUTION;CEREBRAL BLOOD","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",4,0.17,6,4.25,4,0,0,0,3.75,0,1.75,4.25,0,0,1,0,0,0,0,1,0,0,0,107.25,107.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,5.67,646.75,8,0,0,42.5,0,0,1,0,1,0,2,0,0,4,0,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3209 NEUROSCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","4;4;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;HEART DISEASE;CHRONIC PAIN;COMPARATIVE EFFECTIVENESS RESEARCH;HEART DISEASE - CORONARY HEART DISEASE;HYPERTENSION;NEURODEGENERATIVE;NEUROSCIENCES;PAIN RESEARCH;PERIPHERAL NEUROPATHY","4;4;3;3;1;1;1;1;1;1;1;1","CARDIOVASCULAR","3","6.1 PHARMACEUTICALS","3",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_FERRARA",2005,28,11.0714285714286,3.64285714285714,0.5,0.428571428571429,0.5,1.24390243902439,1.27272727272727,1.09090909090909,1.27272727272727,0.357142857142857,1,15,4,5,2,0.54,0.14,0.18,0.07,54.32,1.02602196656059,NA,0.214285714285714,0.928571428571429,0.345,0.321,0.253,0.321,"MARCO VALGIMIGLI;ENRICO FAINARDI;ROBERTO FERRARI;ARTURO CHIEREGATO;GIAN MATTEO RIGOLIN;ENDRI MAURO;GIANFRANCO PERCOCO;CHIARA FRAULINI;ANDREA SALETTI;MASSIMO BORRELLI;EMILIANO TAMBURINI;CRISTIANO AZZINI;DAVIDE TASSINARI;GABRIELE GUARDIGLI;SERGIO SARTORI;R. SCHIVALOCCHI;FRANCESCO CARINCI;ANNA MARIA BUGLI;B. POGGI;ALESSANDRO COZZI‐LEPRI","4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","PETER VILMANN;MARCO VALGIMIGLI;PATRICK W. SERRUYS;ENRICO FAINARDI;ROBERTO FERRARI;CLAUDIA AIMONI;FRANCESCO CARINCI;ARTURO CHIEREGATO;GIANFRANCO PERCOCO;GIAN MATTEO RIGOLIN;ENDRI MAURO;EMILIANO TAMBURINI;DAVIDE TASSINARI;SERGIO SARTORI;B. POGGI;VINCENZO BETTOLI;LUCA ZUCCARINO;ROBERTO CENZI;ALESSANDRO BORGHI;ANNAROSA VIRGILI","1;0.79;0.5;0.47;0.46;0.4;0.38;0.34;0.29;0.28;0.28;0.27;0.27;0.27;0.27;0.25;0.25;0.25;0.25;0.25","MARCO VALGIMIGLI;ENRICO FAINARDI;ROBERTO FERRARI;GIAN MATTEO RIGOLIN;ENDRI MAURO;GIANFRANCO PERCOCO;CHIARA FRAULINI;ANDREA SALETTI;MASSIMO BORRELLI;CRISTIANO AZZINI;GABRIELE GUARDIGLI;SERGIO SARTORI;R. SCHIVALOCCHI;FRANCESCO CARINCI;ANNA MARIA BUGLI;CATERINA BORGNA‐PIGNATTI;L ANSANI;MONIA RUSSO;PATRIZIA MALAGUTTI;GIANLUCA CAMPO","4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PETER VILMANN;MARCO VALGIMIGLI;PATRICK W. SERRUYS;ENRICO FAINARDI;ROBERTO FERRARI;FRANCESCO CARINCI;GIANFRANCO PERCOCO;GIAN MATTEO RIGOLIN;ENDRI MAURO;SERGIO SARTORI;VINCENZO BETTOLI;ALESSANDRO BORGHI;ANNAROSA VIRGILI;MARCELLO FERRONI;CATERINA BORGNA‐PIGNATTI;GABRIELE GUARDIGLI;GIANLUCA CAMPO;CHIARA FRAULINI;S BIGHI;ANDREA SALETTI","1;0.79;0.5;0.47;0.46;0.38;0.29;0.28;0.28;0.27;0.25;0.25;0.25;0.25;0.24;0.23;0.23;0.22;0.2;0.2","FRANCESCO CARINCI;GIANFRANCO PERCOCO;MARCO VALGIMIGLI;ROBERTO FERRARI;L ANSANI;PATRIZIA MALAGUTTI;ANTONIO GRAZIANO;FABIO NARO;GIANPAOLO PAPACCIO;GIUSEPPE PIROZZI;GREGORIO LAINO;RICCARDO D’AQUINO;VLADIMIRO LANZA;ENDRI MAURO;GIAN MATTEO RIGOLIN;GIANLUIGI CASTOLDI;ANNA MARIA BUGLI;GABRIELE GUARDIGLI;GIANLUCA CAMPO;ALESSANDRO BETTINI","575;532;532;532;530;530;449;449;449;449;449;449;449;331;331;331;328;315;315;313","FRANCESCO CARINCI;GIANFRANCO PERCOCO;L ANSANI;PATRIZIA MALAGUTTI;ROBERTO FERRARI;ALESSANDRO BETTINI;DARIO BARBIERI;ERIC BOERSMA;EUGÈNE MCFADDEN;F. MERLINI;FABRIZIO FERRARI;GABRIELE GUARDIGLI;GIANLUCA CAMPO;GIORDANO CICCHITELLI;GIOVANNI PARRINELLO;MARCO VALGIMIGLI;SALVATORE CURELLO;ANNA MARIA BUGLI;ANTONIO CUNEO;CHIARA FRAULINI","575;530;530;530;530;313;313;313;313;313;313;313;313;313;313;219;217;111;111;111","ENRICO FAINARDI;MARCO VALGIMIGLI;ROBERTO FERRARI;ANDREA SALETTI;CATERINA BORGNA‐PIGNATTI;CRISTIANO AZZINI;FRANCESCO CARINCI;GIANFRANCO PERCOCO;L ANSANI;MASSIMO BORRELLI;MONIA RUSSO;PATRIZIA MALAGUTTI;R TAMAROZZI;R. SCHIVALOCCHI;SERGIO SARTORI;STEFANO CERUTI;ALAN R. COHEN;ALESSANDRO BETTINI;ANNA MARIA BUGLI;ANTONIO CUNEO","4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;HISTORY;MATHEMATICS;PHYSICS;PSYCHOLOGY","28;6;3;1;1;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;GASTROENTEROLOGY;SURGERY;ANESTHESIA;BIOCHEMISTRY;IMMUNOLOGY;RADIOLOGY;PATHOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;PHARMACOLOGY;CANCER RESEARCH;DERMATOLOGY;ENDOCRINOLOGY;NUCLEAR MEDICINE;ONCOLOGY;PSYCHIATRY;ARCHAEOLOGY;ASTROBIOLOGY;CLINICAL PSYCHOLOGY;DENTISTRY;GENERAL SURGERY;MEDICAL PHYSICS;MICROBIOLOGY;NEUROSCIENCE;NURSING;PEDIATRICS;PROGRAMMING LANGUAGE;STATISTICS;VIROLOGY","24;8;6;6;5;5;5;5;4;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;MYOCARDIAL INFARCTION;POPULATION;STEM CELL;ANEMIA;ANTIGEN;BONE MARROW;HEMATOMA;IN VITRO;LUNG CANCER;MAGNETIC RESONANCE IMAGING;SUBARACHNOID HEMORRHAGE;THALASSEMIA;ABDOMINAL PAIN;ACNE;ANTICHOLINERGIC;APOPTOSIS;ASPIRIN;ASTHMA;ATRIAL FIBRILLATION;BIOPSY;BLOOD PRESSURE;BLOOD TRANSFUSION;BOLUS (DIGESTION);BONE AGE;CARCINOMA;CEREBROSPINAL FLUID;CHRONIC SUPPURATIVE OTITIS MEDIA;COHORT STUDY;COLONIC DISEASES;CONFIDENCE INTERVAL;CRANIOFACIAL;CYTOKINE;DIABETES MELLITUS;DIALYSIS;DISTRESS;DYSPHAGIA;ENDOSCOPIC ULTRASOUND;GENE;GENERAL ANAESTHESIA;GRANULOCYTE;GUAR GUM;HEART FAILURE;HEMODIALYSIS;HEMOGLOBIN;HEPATITIS C;HEPATOLOGY;HORMONE;IMPLANT;INTRATHECAL;INTUBATION;IRRITABLE BOWEL SYNDROME;ISCHEMIA;KIDNEY DISEASE;LARYNX;LEUKEMIA;LIPOSOME;LOTION;LUNG;LYMPHOMA;MAXILLA;MENINGITIS;MOBILIZATION;MULTIPLE MYELOMA;MULTIPLE SCLEROSIS;MULTIVARIATE ANALYSIS;MULTIVARIATE STATISTICS;MYELOID;MYELOID LEUKEMIA;NAUSEA;NEUROIMAGING;NOSE;ODDS RATIO;OTITIS;PERFUSION;PLATELET;PROPORTIONAL HAZARDS MODEL;PULMONARY FUNCTION TESTING;QUALITY OF LIFE (HEALTHCARE);RANDOMIZED CONTROLLED TRIAL;RECEIVER OPERATING CHARACTERISTIC;REFRACTORY (PLANETARY SCIENCE);RENAL REPLACEMENT THERAPY;RETROSPECTIVE COHORT STUDY;SALICYLIC ACID;SEDATION;SIALORRHEA;SIDE EFFECT (COMPUTER SCIENCE);SINUSITIS;SIROLIMUS;STENT;STROMAL CELL;THYROID;TONSILLECTOMY;TRANSDERMAL;TRANSPLANTATION;TUMOR NECROSIS FACTOR ALPHA;VIRUS;VOMITING","4;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INTRACEREBRAL HEMORRHAGE;ACUTE CORONARY SYNDROME;ACUTE OTITIS MEDIA;BACTERIAL MENINGITIS;BONE MARROW STEM CELL;BREAST CANCER;CARDIOVERSION;CD34;CD44;CLOPIDOGREL;COINFECTION;COLORECTAL CANCER;CONVENTIONAL PCI;DENTAL PULP STEM CELLS;DIFFUSION MRI;DOXORUBICIN;EFFECTIVE DIFFUSION COEFFICIENT;ERYTHROPOIESIS;FINE-NEEDLE ASPIRATION;FIXATION (POPULATION GENETICS);GEMCITABINE;GLYCOPHORIN;GRANULOCYTE COLONY-STIMULATING FACTOR;GROWTH HORMONE;HAEMATOPOIESIS;HAZARD RATIO;HEPATITIS C VIRUS;HUMAN LEUKOCYTE ANTIGEN;HYPERPHOSPHATEMIA;IMPLANT FAILURE;LUNG FUNCTION;METASTASIS;MIDAZOLAM;MYELODYSPLASTIC SYNDROMES;NEBIVOLOL;NECK DISSECTION;OSTEOBLAST;PERCUTANEOUS CORONARY INTERVENTION;PERFUSION SCANNING;PERIPHERAL BLOOD MONONUCLEAR CELL;PLATELET ACTIVATION;PLATELET AGGREGATION INHIBITOR;RECOMBINANT DNA;RESTENOSIS;SINUS RHYTHM;SPIROMETRY;THYROID CARCINOMA;THYROID CARTILAGE;THYROIDECTOMY;UNIVARIATE;UNIVARIATE ANALYSIS;VIRAL DISEASE;VIRAL LOAD","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ABCIXIMAB;TIROFIBAN;ANTHRACYCLINE;COLONOSCOPY;DIFFUSING CAPACITY;DRUG-ELUTING STENT;FLAVIVIRIDAE;HEPACIVIRUS;HUMAN GROWTH HORMONE;INEFFECTIVE ERYTHROPOIESIS;PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;SIDA;SPONTANEOUS INTRACEREBRAL HEMORRHAGE","2;2;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;;AGED;BETA-THALASSEMIA;TREATMENT OUTCOME;ANTIGENS, CD34;MYOCARDIAL INFARCTION;STEM CELLS;AGED, 80 AND OVER;AORTIC DISEASES;BRAIN ISCHEMIA;BREAST NEOPLASMS, MALE;CALCINOSIS;CARCINOMA, SMALL CELL;CARCINOMA, SQUAMOUS CELL;CRANIOCEREBRAL TRAUMA","19;16;16;12;11;9;8;6;6;5;5;5;4;4;4;4;4;4;4;4","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;MULTIPOTENT MESENCHYMAL STEM CELLS;;ANESTHESIA AND SEDATION MANAGEMENT;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;AORTIC ATHEROSCLEROTIC DISEASE AND EMBOLIC EVENTS;ATRIAL FIBRILLATION;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;CANCER OF UNKNOWN PRIMARY SITE;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHRONIC RHINOSINUSITIS AND NASAL POLYPS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND TREATMENT OF LUNG CANCER;FUNCTIONAL BOWEL DISORDERS AND GASTROINTESTINAL HEALTH;GENETIC AND CLINICAL STUDIES OF OCULAR DEVELOPMENT;HEPATITIS C INFECTION AND TREATMENT;IMMUNOLOGICAL MECHANISMS IN PREGNANCY AND FETAL-MATERNAL INTERFACE;MANAGEMENT AND PATHOPHYSIOLOGY OF ACNE AND ROSACEA;MANAGEMENT AND PATHOPHYSIOLOGY OF INTRACEREBRAL HEMORRHAGE","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TREATMENT;ABCIXIMAB;INTRACEREBRAL HEMORRHAGE;TIROFIBAN;TRANSFUSION THERAPY;;ACUTE OTITIS MEDIA;ANEURYSM SCREENING;ANTIRETROVIRAL THERAPY;AORTIC ANEURYSMS;AORTIC DISSECTION;AORTIC ROOT REPLACEMENT;BACTERIAL MENINGITIS;BARE-METAL STENT;BOLUS (DIGESTION);BREAST CANCER;CARDIAC OUTPUT;CARDIAC REPAIR;CARDIOVASCULAR EVALUATION;CEREBRAL BLOOD FLOW","4;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","THALASSEMIA MAJOR;ACUTE MYOCARDIAL;ACUTE SPONTANEOUS;INTRACEREBRAL HEMATOMA;MAJOR PATIENTS;MYOCARDIAL INFARCTION;SPONTANEOUS INTRACEREBRAL;ACID LOTION;ACNE RESOLUTION;ADC ABNORMALITIES;ADULT DENTAL;ADVANCED HODGKIN;ANGIOGRAPHIC SAFETY;ANTIRETROVIRAL-NAIVE HIV-INFECTED;AORTIC ARCH;APOPTOSIS-INDUCING LIGAND;ARCH CALCIFICATION;ARTERIOVENOUS DIFFERENCES;AUTOLOGOUS FIBROUS;BACTERIAL MENINGITIS;BARE-METAL STENT;BONE MARROW;BONE TISSUE;BOWEL SYNDROME;BREAST INVOLVEMENT;CANCER PATIENTS;CELL CARCINOMA;CELL LUNG;CELL MOBILIZATION;CEREBRAL RESPIRATORY","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MYOCARDIAL INFARCTION;CULTURE SUPERNATANTS;FIBROUS BONE;PRETRANSFUSION HEMOGLOBIN;SIGNIFICANTLY LOWER;STEM CELLS;BARE-METAL STENT;BOLUS TIROFIBAN;DENTAL PULP;ENDOTHELIAL CELLS;HEMOGLOBIN CONTENT;MARKEDLY POSITIVE;MINERALIZED TISSUE;SIROLIMUS-ELUTING STENT;SIROLIMUS-ELUTING STENTING;THALASSEMIA MAJOR;ADULT DENTAL;ANTIRETROVIRAL THERAPY;AUTOLOGOUS FIBROUS;BARE-METAL STENTING;BINARY RESTENOSIS;BLOOD DONORS;BMMC CULTURE;BONE LAB;BONE MARROW;BONE PRODUCING;BONE REGENERATION;BONE TISSUE;C-KITCDCD CELL;CD COUNT","5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2",3,0.11,11.57,8,0,1,0,0,7,0,1,8,0,0,0,0,0,0,0,0,0,0.5,0,108.5,109,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,6.33,877.67,3.95,2,0.67,87.67,0,0,0,0,2,0,0,1,0,2,1,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,"Germany;United States","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","3;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;HEMATOLOGY;HYPERTENSION;MUCOPOLYSACCHARIDOSES (MPS);PATIENT SAFETY;RARE DISEASES","3;2;1;1;1;1;1;1","BLOOD;CARDIOVASCULAR","1;1","6.1 PHARMACEUTICALS","2",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_FERRARA",2006,23,8.65217391304348,2.21739130434783,0.304347826086957,0.217391304347826,0.304347826086957,1.275,1.16666666666667,1,1.16666666666667,0.173913043478261,0,6,6,3,7,0.26,0.26,0.13,0.3,53.39,1.04528540242672,NA,0.173913043478261,0.91304347826087,0.352,0.436,0.417,0.436,"ENRICO FAINARDI;ARTURO CHIEREGATO;A. TANFANI;ROSARIO PASCARELLA;L. TARGA;CHRISTIAN COMPAGNONE;FERNANDA TAGLIAFERRI;FRANCESCO CARINCI;MAURIZIO RAVALDINI;ROBERTO FERRARI;MASSIMO BORRELLI;M. FRATTARELLI;GIANPAOLO PAPACCIO;ANTONIO GRAZIANO;FRANCESCO COCCIOLO;RICCARDO D’AQUINO;ALFREDO DE ROSA;DARDO MENDITTI;GREGORIO LAINO;ROBERTO BATTAGLIA","7;6;5;5;5;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2","ENRICO FAINARDI;ARTURO CHIEREGATO;A. TANFANI;ROSARIO PASCARELLA;L. TARGA;CHRISTIAN COMPAGNONE;ELISABETTA ROSSI;A FRANCHELLA;FERNANDA TAGLIAFERRI;ROBERTO FERRARI;MAURIZIO RAVALDINI;MASSIMO BORRELLI;FRANCESCO CARINCI;ELENA MENNUCCI;GIOVANNI SCANELLI;MARCO BORGONZONI;CLAUDIA AIMONI;PHILIPPE GABRÍEL STEG;KIM FOX;ANDREA LO MONACO","0.76;0.64;0.54;0.54;0.54;0.54;0.5;0.5;0.44;0.38;0.32;0.3;0.29;0.25;0.25;0.25;0.25;0.2;0.2;0.2","ENRICO FAINARDI;FRANCESCO CARINCI;ROBERTO FERRARI;MASSIMO BORRELLI;ILARIA CASETTA;FRANÇOIS REGOLI;EZIO PAOLINO;ELEONORA BALDI;GIOVANNI PASANISI;ANDREA SALETTI;DONATO MELE;MASSIMILIANO CASTELLAZZI;ELISABETTA ROSSI;ELENA BESCO;R. SCHIVALOCCHI;SILVIA VERTUANI;A FRANCHELLA;ELENA MENNUCCI;ENRICO GRANIERI;SUSANNA LAVEZZI","7;3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ENRICO FAINARDI;ELISABETTA ROSSI;A FRANCHELLA;ROBERTO FERRARI;MASSIMO BORRELLI;FRANCESCO CARINCI;ELENA MENNUCCI;GIOVANNI SCANELLI;MARCO BORGONZONI;CLAUDIA AIMONI;ELENA BESCO;SILVIA VERTUANI;LUISA CANIATTI;ADRIANO VERZOLA;MONICA FORTINI;MARIA RITA GAMBERINI;ILARIA CASETTA;EZIO PAOLINO;ELEONORA BALDI;MASSIMILIANO CASTELLAZZI","0.76;0.5;0.5;0.38;0.3;0.29;0.25;0.25;0.25;0.25;0.2;0.2;0.2;0.14;0.12;0.12;0.11;0.11;0.11;0.11","FRANCESCO CARINCI;ALFREDO DE ROSA;ANTONIO GRAZIANO;DARDO MENDITTI;GIANPAOLO PAPACCIO;GREGORIO LAINO;RICCARDO D’AQUINO;GIUSEPPE PIROZZI;MARIA FRANCESCA GRAZIANO;ROBERTO FERRARI;ENRICO FAINARDI;F GOMBOS;FILIPPO CARUSO;LUIGI GUIDA;R RULLO;VLADIMIRO LANZA;ELEONORA BALDI;ENRICO GRANIERI;EZIO PAOLINO;FRANCO DALLOCCHIO","442;415;415;415;415;415;415;276;276;240;178;139;139;139;139;139;138;138;138;138","FRANCESCO CARINCI;ROBERTO FERRARI;ENRICO FAINARDI;ELEONORA BALDI;ENRICO GRANIERI;EZIO PAOLINO;ILARIA CASETTA;MASSIMILIANO CASTELLAZZI;ALESSANDRO FUCILLI;ANTONELLA BERGONZONI;NINO BASAGLIA;SUSANNA LAVEZZI;DONATO MELE;GIOVANNI PASANISI;GIANLUIGI BAJOCCHI;MARIA GRAZIA CATANOSO;NICOLÒ PIPITONE;PIERLUIGI MACCHIONI;FRANÇOIS REGOLI;TIZIANO TOSELLI","442;240;178;138;138;138;138;138;109;105;105;105;103;103;78;78;78;78;52;52","ENRICO FAINARDI;ROBERTO FERRARI;FRANCESCO CARINCI;MASSIMO BORRELLI;A FRANCHELLA;ADRIANO VERZOLA;ALESSANDRO FUCILLI;ANDREA SALETTI;ANTONELLA BERGONZONI;DONATO MELE;ELENA BESCO;ELEONORA BALDI;ELISABETTA ROSSI;ENRICO GRANIERI;EZIO PAOLINO;FRANÇOIS REGOLI;GIANLUIGI BAJOCCHI;GIOVANNI PASANISI;ILARIA CASETTA;LUISA CANIATTI","7;3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;ECONOMICS;ENGINEERING;MATHEMATICS;PHILOSOPHY;PHYSICS","23;5;3;1;1;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;BIOCHEMISTRY;RADIOLOGY;ANESTHESIA;ENDOCRINOLOGY;PATHOLOGY;CELL BIOLOGY;SURGERY;ENVIRONMENTAL HEALTH;GENETICS;IMMUNOLOGY;NUCLEAR MEDICINE;PSYCHIATRY;ANATOMY;AUDIOLOGY;BIOTECHNOLOGY;DENTISTRY;ECONOMY;FOOD SCIENCE;GASTROENTEROLOGY;LINGUISTICS;MECHANICAL ENGINEERING;MEDICAL EMERGENCY;MOLECULAR BIOLOGY;NURSING;OPTICS;ORGANIC CHEMISTRY;PEDIATRICS;PHARMACOLOGY;PHYSICAL THERAPY;STATISTICS","13;9;5;5;4;4;4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","SUBARACHNOID HEMORRHAGE;CEREBRAL BLOOD FLOW;HEART FAILURE;BLOOD FLOW;GENE;MAGNETIC RESONANCE IMAGING;ANEURYSM;BLOOD PRESSURE;CEREBROSPINAL FLUID;DISEASE;HORMONE;IN VITRO;ISCHEMIA;POPULATION;STEM CELL;TRANSPLANTATION;ALTERNATIVE MEDICINE;AMPUTATION;ANTIOXIDANT;ARTERY;ATTENUATION;BONE REMODELING;BONE RESORPTION;CELL CULTURE;CEREBRAL EDEMA;CLINICAL PRACTICE;CLIPPING (MORPHOLOGY);CORONARY ARTERY DISEASE;COSMETICS;DAY CARE;DAY HOSPITAL;DIFFERENTIAL DIAGNOSIS;DISSECTION (MEDICAL);ELECTROCARDIOGRAPHY;EMBRYO;ENZYME;EXTRACELLULAR MATRIX;HEMATOMA;IN VIVO;INFLAMMATION;INGREDIENT;INTERNAL CAROTID ARTERY;MATRIX METALLOPROTEINASE;MEMBRANE;MESENCHYMAL STEM CELL;MOLAR;MULTIPLE SCLEROSIS;NEUROLOGY;NEUROMA;NEUROSURGERY;OXIDATIVE STRESS;PERCENTILE;PROSPECTIVE COHORT STUDY;PULP (TOOTH);QRS COMPLEX;RANDOMIZED CONTROLLED TRIAL;RECEPTOR;REHABILITATION;SECONDARY PALATE;SERVICE (BUSINESS);SIGNAL TRANSDUCTION;STROKE (ENGINE);STROMAL CELL;THALASSEMIA;TINNITUS;TRANSFORMING GROWTH FACTOR;VERTIGO;VESTIBULAR SYSTEM","5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EJECTION FRACTION;DENTAL PULP STEM CELLS;MIDDLE CEREBRAL ARTERY;VASCULITIS;ALKALINE PHOSPHATASE;ALLELE;ANTERIOR COMMUNICATING ARTERY;ANTIOXIDANT CAPACITY;BEHCET'S DISEASE;BYPASS GRAFTING;CALCEIN;CD34;CD44;CELLULAR DIFFERENTIATION;CRYOPRESERVATION;DEFERIPRONE;DIASTOLE;DIFFUSION MRI;DILATED CARDIOMYOPATHY;DOWNREGULATION AND UPREGULATION;EFFECTIVE DIFFUSION COEFFICIENT;FIBROBLAST;FIBROBLAST GROWTH FACTOR;FIBRONECTIN;FUNCTIONAL INDEPENDENCE MEASURE;GENOTYPE;GROWTH HORMONE;HEART RATE;HYPERINTENSITY;INFLAMMATORY RESPONSE;INTRAPARENCHYMAL HEMORRHAGE;NEBIVOLOL;NEUROHORMONES;NEURORADIOLOGY;OSTEOBLAST;OXIDATIVE DAMAGE;PENUMBRA;PLACEBO;RETINOIC ACID;RIGHT BUNDLE BRANCH BLOCK;WHITE MATTER","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIAC RESYNCHRONIZATION THERAPY;ANTERIOR CEREBRAL ARTERY;DIASTOLIC HEART FAILURE;GIANT CELL ARTERITIS;IVABRADINE;LEFT MAIN CORONARY ARTERY DISEASE;OSTEOCALCIN;STROKE VOLUME;SYSTOLE","2;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;BRAIN;SUBARACHNOID HEMORRHAGE;BRAIN ISCHEMIA;MIDDLE AGED;VENTRICULAR DYSFUNCTION, LEFT;ADULT;OSTEOBLASTS;CEREBRAL HEMORRHAGE;HEART FAILURE;AGED;BIOMARKERS;STEM CELLS;AMBULATORY CARE;ANTIOXIDANTS;BEHCET SYNDROME;CARDIOMYOPATHY, DILATED;CENTRAL NERVOUS SYSTEM DISEASES","22;19;17;13;12;11;11;10;9;8;6;6;5;5;5;4;4;4;4;4","PATHOPHYSIOLOGY AND MANAGEMENT OF CEREBRAL ANEURYSMS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;INSULIN-LIKE GROWTH FACTORS IN HEALTH AND DISEASE;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;MULTIPOTENT MESENCHYMAL STEM CELLS;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;DIAGNOSIS AND MANAGEMENT OF CARPAL TUNNEL SYNDROME;DIAGNOSIS AND TREATMENT OF HEART FAILURE;EDUCATION AND PEDAGOGY RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF OCULAR INFLAMMATORY DISEASES;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENETIC AND ENVIRONMENTAL INFLUENCES ON CLEFT LIP AND PALATE;IMPACT OF RESTING HEART RATE ON CARDIOVASCULAR HEALTH;MANAGEMENT AND PATHOPHYSIOLOGY OF INTRACEREBRAL HEMORRHAGE;MECHANISMS OF SKIN AGING AND PHOTODAMAGE;ROLE OF MATRIX METALLOPROTEINASES IN CANCER AND PHYSIOLOGY","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CEREBRAL BLOOD FLOW;CARDIAC RESYNCHRONIZATION THERAPY;ECHOCARDIOGRAPHY;ANEURYSMAL SUBARACHNOID HEMORRHAGE;ANTERIOR CEREBRAL ARTERY;ANTERIOR COMMUNICATING ARTERY;BONE REMODELING;CALCEIN;CELL SIGNALING;CEREBRAL EDEMA;CLINICAL PRACTICE;CLIPPING (MORPHOLOGY);DAY HOSPITAL;DEFERIPRONE;DEOXYPYRIDINOLINE;DIASTOLIC HEART FAILURE;DIFFUSION MRI;DILATED CARDIOMYOPATHY;DISEASE-MODIFYING ANTIRHEUMATIC DRUGS;DYSSYNCHRONY","5;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BLOOD FLOW;CEREBRAL BLOOD;SUBARACHNOID HEMORRHAGE;HEART FAILURE;LEFT VENTRICULAR;CARDIAC RESYNCHRONIZATION;DENTAL PULP;RESYNCHRONIZATION THERAPY;SERUM LEVELS;STEM CELLS;VENTRICULAR DYSFUNCTION;ACID GABA-ERGIC;ACTIVE MATRIX;ACUTE PERIHEMATOMAL;AMPUTATION NEUROMA;ANEURYSMAL SUBARACHNOID;ANTIOXIDANT CAPACITY;APPARENT DIFFUSION;ARTERY DISEASE;ARTERY LOW;BEAUTIFUL STUDY;BEHÇET DISEASE;BONE METABOLISM;BONE PRODUCTION;CAPACITY IACSSUPSUP;CARDIAC SUPRAVENTRICULAR;CELL SOURCE;CELLS DERIVED;CELLS SBPDPSCS;CEREBRAL ARTERY","4;4;4;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CLP-SP FIBROBLASTS;MRNA EXPRESSION;HEART FAILURE;TGF-BETA RECEPTOR;IGF-I LEVELS;ISCHEMIC STROKE;RECEPTOR TYPE;ADJUSTED DIFFERENCE;CLEFT PALATE;DECELERATION TIME;E-WAVE DECELERATION;EA RATIO;EJECTION FRACTION;GABRB MRNA;GENE EXPRESSION;GH-IGF-I AXIS;LEFT VENTRICULAR;MODIFIED RANKING;N-SP CELLS;N-SP FIBROBLASTS;NEBIVOLOL REDUCES;RA TREATMENT;RANKING SCALE;RARA GENE;SIGNALING SYSTEMS;SYSTOLIC LV;TGF-BETA MRNA;VENTRICULAR LV;ABNORMAL PHENOTYPE;ABSTRACT CONTEXT","5;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1",3,0.13,7.75,5.5,0,0,0,0,6.25,0,1,5.5,0,0,1,0,1,0,0,1,0,0.5,0,74.5,74.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,3.8,789.4,12.5,1,0.2,55.6,0,0,1,0,2,0,2,0,0,5,0,0,0,0,0,0,0,5,0,0,5,0,0,0,0,0,0,0,0,0,"Germany;Italy;Switzerland","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","5;3;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;ASSISTIVE TECHNOLOGY;ATHEROSCLEROSIS;AUTOIMMUNE DISEASE;BIOENGINEERING;BRAIN DISORDERS;CANCER;HEMATOLOGY;HYPERTENSION;MULTIPLE SCLEROSIS;NEURODEGENERATIVE;NEUROSCIENCES;PATIENT SAFETY;PEDIATRIC;RARE DISEASES","5;4;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR","2","6.1 PHARMACEUTICALS;3.3 NUTRITION AND CHEMOPREVENTION","5;1","LEUKEMIA / LEUKAEMIA","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_FERRARA",2007,43,9.09302325581395,2.27906976744186,0.581395348837209,0.0930232558139535,0.558139534883721,1.15294117647059,1.13636363636364,0.8,1.14285714285714,0.232558139534884,3,17,7,4,12,0.4,0.16,0.09,0.28,36.4,0.689619430899974,NA,0.186046511627907,0.697674418604651,0.545,0.214,0.25,0.22,"ROBERTO REVERBERI;ENRICO GRANIERI;ROBERTO FERRARI;L REVERBERI;GIOVANNI SCANELLI;ENRICO FAINARDI;ROBERTO NARDI;R. QUATRALE;MASSIMILIANO CASTELLAZZI;E. GASTALDO;V. TUGNOLI;A FRANCHELLA;PAOLO MARCHETTI;CESARE GRIDELLI;FABIO FABBIAN;TIZIANO TOSELLI;LUCIO TREVISANI;FRANCESCO TROTTA;GRAZIA DEVIGILI;IDO IORI","4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","ROBERTO REVERBERI;L REVERBERI;LUCIO TREVISANI;FABIO FABBIAN;RITA PREVIATI;ROBERTO FERRARI;A FRANCHELLA;ENRICO GRANIERI;ENRICO FAINARDI;FRANCESCO TROTTA;TIZIANO TOSELLI;GIOVANNI SCANELLI;ROBERTO NARDI;JESSICA POLITO;P PAVANELLO;ELISABETTA ROSSI;MARINA VERENINI;FRANCESCO CARINCI;ANTONIO LUIGI PASTORE;MAURIZIO GOVONI","1.83;1.5;1.2;1.14;1;0.65;0.53;0.49;0.49;0.38;0.37;0.34;0.34;0.33;0.33;0.33;0.33;0.33;0.33;0.33","ROBERTO REVERBERI;ENRICO GRANIERI;ROBERTO FERRARI;GIOVANNI SCANELLI;ENRICO FAINARDI;R. QUATRALE;MASSIMILIANO CASTELLAZZI;V. TUGNOLI;A FRANCHELLA;PAOLO MARCHETTI;FABIO FABBIAN;TIZIANO TOSELLI;LUCIO TREVISANI;B. MASSIDDA;MARIA ROSARIA TOLA;GIANFRANCO PERCOCO;CHIARA FRAULINI;VINCENZO BETTOLI;SILVIA FANARO;PAOLO SQUASI","4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","ROBERTO REVERBERI;LUCIO TREVISANI;FABIO FABBIAN;RITA PREVIATI;ROBERTO FERRARI;A FRANCHELLA;ENRICO GRANIERI;ENRICO FAINARDI;TIZIANO TOSELLI;GIOVANNI SCANELLI;ELISABETTA ROSSI;FRANCESCO CARINCI;GIANFRANCO PERCOCO;R. QUATRALE;V. TUGNOLI;ANNAROSA VIRGILI;MATTEO COLINA;ULRICH WIENAND;MARIA ROSARIA TOLA;MASSIMILIANO CASTELLAZZI","1.83;1.2;1.14;1;0.65;0.53;0.49;0.49;0.37;0.34;0.33;0.33;0.28;0.25;0.25;0.25;0.25;0.25;0.25;0.24","ROBERTO REVERBERI;L REVERBERI;GIOVANNI SCANELLI;ROBERTO NARDI;B TUMIATI;GIULIO ZUCCOLI;JAUME CAPELLADES;JESSICA MANDRIOLI;LUANA REGNICOLO;MARCO BERTOLINI;MICHELE GALLUCCI;T. CABADA GIADÁS;W. BOTTARI;IDO IORI;GIOVANNI MATHIEU;ROBERTO CATALDI AMATRIAN;SALVATORE CORRAO;ROBERTO FERRARI;AMEDEO BERTOCCHI;ANNA CARLI","292;265;181;181;175;175;175;175;175;175;175;175;175;161;122;122;122;109;103;103","ROBERTO REVERBERI;GIOVANNI SCANELLI;B TUMIATI;ROBERTO FERRARI;AMEDEO BERTOCCHI;L. CAVAZZINI;NINO BASAGLIA;MATTEO COLINA;ALICE FRANGIONE;FABRIZIO FERRARI;GIANFRANCO PERCOCO;GIANLUCA CAMPO;MARCO VALGIMIGLI;MATTEO TEBALDI;S LUCCARELLI;NICOLÒ PIPITONE;ENRICO FAINARDI;BENEDETTA BOARI;MASSIMO GALLERANI;RAFFAELLA SALMI","292;181;175;107;103;103;103;90;89;89;89;89;89;89;89;87;80;75;75;75","ROBERTO REVERBERI;ENRICO FAINARDI;GIOVANNI SCANELLI;MARIA ROSARIA TOLA;GIANFRANCO PERCOCO;LUCIO TREVISANI;R. QUATRALE;ROBERTO FERRARI;V. TUGNOLI;A FRANCHELLA;A POTENA;ALICE FRANGIONE;AMEDEO BERTOCCHI;ANNAROSA VIRGILI;ANTONIO CUNEO;B TUMIATI;BENEDETTA BOARI;CHIARA FRAULINI;CHRISTIAN MOLINO;CRISTIANO DE ANGELI","4;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS;PSYCHOLOGY;BUSINESS;ECONOMICS;POLITICAL SCIENCE;SOCIOLOGY;ART;GEOGRAPHY;HISTORY","42;9;7;6;3;3;3;2;2;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;DERMATOLOGY;ONCOLOGY;PATHOLOGY;PSYCHIATRY;CARDIOLOGY;EMERGENCY MEDICINE;FAMILY MEDICINE;PHARMACOLOGY;ANESTHESIA;BIOCHEMISTRY;GENETICS;NURSING;OPTICS;PEDIATRICS;ADVERTISING;CANCER RESEARCH;ECOLOGY;ECONOMIC GROWTH;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;LAW;PHYSICAL THERAPY;QUANTUM MECHANICS","28;11;9;6;6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","DISEASE;CANCER;CLINICAL TRIAL;ANTIBODY;CHEMOTHERAPY;HEALTH CARE;HEART FAILURE;PLATELET;RANDOMIZED CONTROLLED TRIAL;ANTIGEN;ENDOSCOPY;GENE;INCIDENCE (GEOMETRY);KINETICS;LESION;LICHEN SCLEROSUS;NEUROLOGY;POPULATION;PRESENTATION (OBSTETRICS);RECEPTOR;SECTION (TYPOGRAPHY);SPLEEN;THROMBOSIS;TRANSPLANTATION","5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CYCLOPHOSPHAMIDE;SPLENECTOMY;ALCOHOLIC LIVER DISEASE;ANTAGONIST;ANTERIOR PITUITARY;ANTIBIOTIC THERAPY;ANTIGEN-ANTIBODY COMPLEX;ANTIPHOSPHOLIPID SYNDROME;APHERESIS;AUTOIMMUNE DISEASE;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CALCINEURIN;CARDIORENAL SYNDROME;CD34;CELL CYCLE;CHEMOKINE;CHROMOSOME;CLINICAL GOVERNANCE;CLOPIDOGREL;COLORECTAL CANCER;EJECTION FRACTION;EMERGENCY PHYSICIAN;EPIDERMAL GROWTH FACTOR RECEPTOR;ESOPHAGOGASTRODUODENOSCOPY;FOOD ALLERGY;FUNCTIONAL CONSTIPATION;FUNCTIONAL INDEPENDENCE MEASURE;GELATINASE;GENE ISOFORM;GENOTYPE;GESTATIONAL AGE;GLASGOW OUTCOME SCALE;GRANULOCYTE COLONY-STIMULATING FACTOR;GROWTH HORMONE;HEALTH ADMINISTRATION;HEALTH INFORMATICS;HUMAN GENETICS;HUMAN LEUKOCYTE ANTIGEN;INTRACLASS CORRELATION;LUPUS ERYTHEMATOSUS;MANDIBLE (ARTHROPOD MOUTHPART);NEPHROCALCINOSIS;OLFACTORY RECEPTOR;OSTEITIS;PERCUTANEOUS CORONARY INTERVENTION;PLASMAPHERESIS;PORTAL VEIN THROMBOSIS;PROGENITOR CELL;PROPIONIBACTERIUM ACNES;PSORIATIC ARTHRITIS;RELAPSING REMITTING;RESTENOSIS;RETROPHARYNGEAL SPACE;SYSTEMIC DISEASE;SYSTEMIC LUPUS ERYTHEMATOSUS;TACROLIMUS;TENOFOVIR;THIAMINE DEFICIENCY;THROMBOCYTOSIS;THROMBOTIC THROMBOCYTOPENIC PURPURA;TYROSINE-KINASE INHIBITOR;VIABILITY ASSAY;VIRAL LOAD;VON WILLEBRAND FACTOR;WERNICKE ENCEPHALOPATHY;WHITE MATTER","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ABCIXIMAB;ANTHRACYCLINE;ANTIPLATELET DRUG;ANTIRETROVIRAL THERAPY;BARE METAL;BASDAI;CARDIAC RESYNCHRONIZATION THERAPY;CHEMOKINE RECEPTOR;CHROMOSOME 4;CONNECTIVE TISSUE DISEASE;DRUG-ELUTING STENT;EGFR INHIBITORS;EPIRUBICIN;ERLOTINIB;FILGRASTIM;GEFITINIB;GELATINASES;GROWTH HORMONE DEFICIENCY;INTRAVENTRICULAR HEMORRHAGE;IRINOTECAN;KARYOTYPE;MOLECULAR MEDICINE;OXALIPLATIN;PERIVENTRICULAR LEUKOMALACIA;PIMECROLIMUS;POLYMORPHISM (COMPUTER SCIENCE);PUSTULOSIS;TICLOPIDINE;TIROFIBAN;WERNICKE'S ENCEPHALOPATHY","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;;AGED;HEART FAILURE;BRAIN;BRAIN INJURIES;ITALY;TREATMENT OUTCOME;ADOLESCENT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;GASTROINTESTINAL DISEASES;KIDNEY FAILURE, CHRONIC;ANTINEOPLASTIC AGENTS;CHILD;MAGNETIC RESONANCE IMAGING;PULMONARY DISEASE, CHRONIC OBSTRUCTIVE","32;21;19;15;15;11;10;9;7;7;7;7;6;6;6;6;5;5;5;5","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;EPIDEMIOLOGY AND IMPLICATIONS OF MULTIMORBIDITY IN HEALTHCARE;MALE CIRCUMCISION FOR HIV PREVENTION AND PENILE HEALTH;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;AUTOINFLAMMATORY BONE DISORDERS;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;CLINICAL AND MOLECULAR ASPECTS OF NOCARDIOSIS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;DIAGNOSIS AND MANAGEMENT OF WERNICKE-KORSAKOFF SYNDROME;EMERGENCY DEPARTMENT CROWDING;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;FUNCTIONAL BOWEL DISORDERS AND GASTROINTESTINAL HEALTH;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENOMIC REARRANGEMENTS AND COPY NUMBER VARIATIONS;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PATIENT COMPLEXITY;PLATELET REACTIVITY;PRESENTATION (OBSTETRICS);PULMONARY DISEASE;SECTION (TYPOGRAPHY);TRANSFUSION THERAPY;ABCIXIMAB;ACTINOMYCOSIS;ACUTE NECROTIZING ENCEPHALOPATHY;ALCOHOLIC NEUROPATHY;ANKYLOSING SPONDYLITIS;ANTIBIOTIC THERAPY;ANTIBODY ENGINEERING;ANTIFUNGAL THERAPY;ANTIGEN-ANTIBODY COMPLEX;ANTIPLATELET DRUG;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BALANITIS;BARE METAL;BARE-METAL STENT","3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INTERNAL MEDICINE;BREAST CANCER;CANCER PATIENTS;LICHEN SCLEROSUS;MEDICINE PATIENTS;REMOVAL KINETICS;SOLUBLE HLA-G;ACUTE MYELOID;ADVANCED BREAST;ADVANCED COLORECTAL;ALLERGIC DISEASES;ANTAGONIST NUTLIN-;ANTERIOR PITUITARY;ANTIGEN-ANTIBODY REACTION;ARTERIO-VENOUS LACTATE;ARTERIO-VENOUS PCO;AUTOLOGOUS TRANSPLANTATION;BARE-METAL STENT;BOLUS DOSE;BOWEL SYNDROME;BRAIN INJURY;BRAIN MATURATION;CARDIAC RESYNCHRONIZATION;CARDIORENAL SYNDROME;CARDIOVERTER DEFIBRILLATORS;CELL EVOLUTION;CELL LUNG;CEREBRAL ARTERIO-VENOUS;CHRONIC RENAL;CLASS-EFFECT MECHANISM","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CELL COUNT;CELLSMM CI;COUNT SLOPE;INFECTIVE ENDOCARDITIS;LICHEN SCLEROSUS;WERNICKE ENCEPHALOPATHY;ALCOHOL ABUSE;INTERNAL MEDICINE;MAMILLARY BODIES;ORGANISATIONAL CLIMATE;CELL DECREASE;CLINICAL PRACTICE;COMPLEX PATIENTS;CONTRAST ENHANCEMENT;COUNT EVOLUTION;DIAGNOSTIC EGD;ECONOMIC RESOURCES;HEALTHCARE INSTITUTIONS;HEALTHCARE ORGANISATIONS;HIV PLASMA;HL- CELLS;LOWER CD;MATURATIONAL ACTIVITY;NADIR CD;NUTLIN- INDUCED;OBJECTIVE PARAMETERS;PARADOXICAL CD;PLASMA VIRAL;PRINCIPAL COMPONENT;PROAPOPTOTIC ACTIVITY","9;4;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",6,0.14,4.56,1.75,1,1,0,2,32.75,0,1,1.75,0,1,4.5,0,1,0,1,3.5,1,0,0,33.5,33.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,6.25,500.5,4.88,1,0.25,97.25,0,0,1,0,2,0,1,0,0,4,0,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"Germany","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","3;2;2;2","CLINICAL RESEARCH;CARDIOVASCULAR;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;AGING;ATHEROSCLEROSIS;PREVENTION","3;2;2;2;1;1;1","CARDIOVASCULAR","2","6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_FERRARA",2008,33,7.45454545454545,2.75757575757576,0.484848484848485,0.363636363636364,0.515151515151515,1.21333333333333,1.14285714285714,1.2,1.13333333333333,0.121212121212121,3,13,8,2,8,0.39,0.24,0.06,0.24,18.42,0.335768440063159,NA,0.121212121212121,0.696969696969697,0.431,0.243,0.314,0.236,"ENRICO FAINARDI;ROBERTO FERRARI;CLAUDIO CECONI;M. MANCA;G. FERRARESI;ALBERTO LEARDINI;DONATO MELE;MASSIMILIANO CASTELLAZZI;ARTURO CHIEREGATO;DAVIDE TASSINARI;MARIA GRAZIA BISCONTE;ALESSANDRA GHINOI;ANDREA LO MONACO;CARLO SALVARANI;SERGIO SARTORI;ROBERTO REVERBERI;ALBERTO NICOLINI;PAOLA TOMBESI;ENRICO GRANIERI;CATERINA BORGNA‐PIGNATTI","4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ROBERTO REVERBERI;FRANCESCO CAVAZZINI;DAVIDE TASSINARI;SERGIO SARTORI;PAOLA TOMBESI;ENRICO FAINARDI;ROBERTO FERRARI;RENATA STRUMÌA;M. MANCA;G. FERRARESI;FRANCESCO FELETTI;CLAUDIO CECONI;A POTENA;ALESSANDRA GHINOI;CARLO SALVARANI;ALBERTO NICOLINI;NICOLÒ PIPITONE;LUIGI CATIZONE;ALBERTO LEARDINI;N STABELLINI","2;1;0.58;0.58;0.58;0.54;0.5;0.5;0.5;0.5;0.5;0.44;0.36;0.34;0.34;0.34;0.34;0.33;0.33;0.33","ENRICO FAINARDI;ROBERTO FERRARI;CLAUDIO CECONI;M. MANCA;G. FERRARESI;DONATO MELE;MASSIMILIANO CASTELLAZZI;ANDREA LO MONACO;SERGIO SARTORI;ROBERTO REVERBERI;ALBERTO NICOLINI;PAOLA TOMBESI;ENRICO GRANIERI;CATERINA BORGNA‐PIGNATTI;A POTENA;GIANLUCA CAMPO;FRANCESCO TROTTA;GIANFRANCO PERCOCO;LUCIA RITROVATO;CARMINE TAMBORINO","4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","ROBERTO REVERBERI;FRANCESCO CAVAZZINI;SERGIO SARTORI;PAOLA TOMBESI;ENRICO FAINARDI;ROBERTO FERRARI;RENATA STRUMÌA;M. MANCA;G. FERRARESI;CLAUDIO CECONI;A POTENA;ALBERTO NICOLINI;FABIO FABBIAN;DONATO MELE;MASSIMILIANO CASTELLAZZI;ENRICO GRANIERI;ANDREA LO MONACO;FRANCESCO TROTTA;LUCIA RITROVATO;LICIA BALLERIN","2;1;0.58;0.58;0.54;0.5;0.5;0.5;0.5;0.44;0.36;0.34;0.33;0.28;0.27;0.27;0.25;0.25;0.25;0.25","LOREDANA MELCHIORRI;MARINA STIGNANI;ROBERTA RIZZO;ENRICO FAINARDI;CATERINA BORGNA‐PIGNATTI;D. GALLISAI;DIANA ROFAIL;IPPAZIO STEFÀNO;L SCALONE;LG MANTOVANI;LUCIANO PROSSOMARITI;MARIA DOMENICA CAPPELLINI;MARIA GRAZIA BISCONTE;MARIEKE KROL;P CIANCIULLI;S RAVERA;ZELIA BORSELLINO;ANTONIO CUNEO;DIANA CAMPIONI;FRANCESCO ALVIANO","111;111;111;100;93;93;93;93;93;93;93;93;93;93;93;93;93;75;75;75","ENRICO FAINARDI;CATERINA BORGNA‐PIGNATTI;ANTONIO CUNEO;DIANA CAMPIONI;FRANCESCO LANZA;SABRINA MORETTI;GIANLUCA CAMPO;ANDREA SALETTI;CRISTIANO AZZINI;MASSIMO BORRELLI;MICHELE ALESSANDRO CAVALLO;R TAMAROZZI;R. SCHIVALOCCHI;STEFANO CERUTI;ROBERTO REVERBERI;ANTONIO SARTORI;FIORELLA ILARIUCCI;LUCA CAPPUCCINI;LUCA CIMINO;LUCIANO MASINI","100;93;75;75;75;75;44;42;42;42;42;42;42;42;41;39;39;39;39;39","ENRICO FAINARDI;G. FERRARESI;M. MANCA;A POTENA;ALBERTO NICOLINI;CLAUDIO CECONI;DONATO MELE;GIANLUCA CAMPO;PAOLA TOMBESI;ROBERTO FERRARI;ROBERTO REVERBERI;SERGIO SARTORI;A. ZELANTE;ANDREA LO MONACO;ANDREA SALETTI;ANTONELLA LOCAPUTO;ANTONIO CUNEO;ANTONIO SARTORI;BENEDETTA BOARI;CARMINE TAMBORINO","4;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","MEDICINE;ENGINEERING;PHYSICS;BIOLOGY;COMPUTER SCIENCE;MATHEMATICS;POLITICAL SCIENCE;ART;BUSINESS;CHEMISTRY;PHILOSOPHY;PSYCHOLOGY","31;5;5;3;3;2;2;1;1;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;PATHOLOGY;SURGERY;IMMUNOLOGY;RADIOLOGY;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;PHYSICAL THERAPY;DERMATOLOGY;ENVIRONMENTAL HEALTH;MECHANICAL ENGINEERING;PHYSICAL MEDICINE AND REHABILITATION;QUANTUM MECHANICS;ANESTHESIA;BIOCHEMISTRY;CELL BIOLOGY;LAW;MOLECULAR BIOLOGY;NUCLEAR MEDICINE;NURSING;PEDIATRICS;PROGRAMMING LANGUAGE","19;9;8;6;5;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2","DISEASE;HEART FAILURE;ALTERNATIVE MEDICINE;MULTIPLE MYELOMA;MYOCARDIAL INFARCTION;POPULATION;THALASSEMIA;ANTIGEN;ARTERITIS;BLOOD PRESSURE;CEREBRAL BLOOD FLOW;CEREBROSPINAL FLUID;CHEMOTHERAPY;FOOT (PROSODY);IMMUNE SYSTEM;ISCHEMIA;MAGNETIC RESONANCE IMAGING;MULTIPLE SCLEROSIS;STROKE (ENGINE);SUBARACHNOID HEMORRHAGE;TERM (TIME)","4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","THALIDOMIDE;BETA THALASSEMIA;EJECTION FRACTION;PERCUTANEOUS CORONARY INTERVENTION;PROTOCOL (SCIENCE);VASCULITIS;ACUTE CORONARY SYNDROME;ALKALINE PHOSPHATASE;AORTIC DISSECTION;CACHEXIA;CARDIOMYOPATHY;CD14;CD34;CHELATION THERAPY;CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION;CISPLATIN;CLOPIDOGREL;COELIAC DISEASE;CONVENTIONAL PCI;DEFERASIROX;DEFERIPRONE;DEMYELINATING DISEASE;DENTAL PULP STEM CELLS;DIASTOLE;ENDOTHELIN RECEPTOR;GAIT ANALYSIS;GENE EXPRESSION;HUMAN LEUKOCYTE ANTIGEN;INTRACEREBRAL HEMORRHAGE;ISOANTIBODIES;MAGNETIC RESONANCE ANGIOGRAPHY;MAJOR HISTOCOMPATIBILITY COMPLEX;MYOCARDIAL FIBROSIS;NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY;NEUROINFLAMMATION;NEURORADIOLOGY;NEUTROPENIA;OCCULT;OVERWEIGHT;PENUMBRA;PERFUSION SCANNING;PERIPHERAL BLOOD MONONUCLEAR CELL;PHASES OF CLINICAL RESEARCH;PLATELET AGGREGATION INHIBITOR;RELIABILITY (SEMICONDUCTOR);RENAL BIOPSY;RESTENOSIS;SCOPUS;ST SEGMENT;TRAMADOL;WEIGHT LOSS;WHIPPLE'S DISEASE","3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GIANT CELL ARTERITIS;BOSENTAN;CANCER CACHEXIA;CARDIAC RESYNCHRONIZATION THERAPY;CORONARY STENTING;DOPPLER ECHOCARDIOGRAPHY;DOPPLER IMAGING;DRUG-ELUTING STENT;FEBRILE NEUTROPENIA;FRACTIONAL SHORTENING;INTESTINAL MALABSORPTION;RESTRICTIVE CARDIOMYOPATHY;TIROFIBAN;VINORELBINE","2;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;MYOCARDIAL INFARCTION;;ANGIOGENESIS INHIBITORS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;GIANT CELL ARTERITIS;MULTIPLE SCLEROSIS, RELAPSING-REMITTING;THALIDOMIDE;AGED, 80 AND OVER;FOLLOW-UP STUDIES;HEART FAILURE;TEMPORAL ARTERIES;TREATMENT OUTCOME;BIOMARKERS;BRAIN EDEMA","26;21;19;18;11;10;8;7;6;6;6;6;6;5;5;5;5;5;4;4","CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;IMMUNOLOGICAL MECHANISMS IN PREGNANCY AND FETAL-MATERNAL INTERFACE;PREVENTION AND MANAGEMENT OF DIABETIC FOOT ULCERS;ADVANCEMENTS IN LUNG CANCER RESEARCH;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CANCER STEM CELLS AND TUMOR METASTASIS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CHALLENGES IN PAIN MANAGEMENT AND TREATMENT;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;DISEASES RELATED TO BLOOD GROUP VARIANTS;EFFECTS OF BARIATRIC SURGERY ON OBESITY AND DIABETES;IMPACT OF CLIMATE CHANGE ON HUMAN HEALTH;LYMPHOID NEOPLASMS;MALE CIRCUMCISION FOR HIV PREVENTION AND PENILE HEALTH;MANAGEMENT AND PATHOPHYSIOLOGY OF INTRACEREBRAL HEMORRHAGE;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ARTERITIS;BETA THALASSEMIA;CEREBRAL BLOOD FLOW;FOOT (PROSODY);GIANT CELL ARTERITIS;HLA-G;IMAGING IN VASCULITIS;POSTURAL STABILITY;STROKE (ENGINE);ABUTMENT;ACETAMINOPHEN;ANEURYSM RUPTURE;ANTICOAGULATION THERAPY;ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;BETA (PROGRAMMING LANGUAGE);CANCER CACHEXIA;CARDIAC METABOLISM;CARDIAC RESYNCHRONIZATION THERAPY;CARDIAC SCREENING;CARDIOVASCULAR RISK","2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","BETA-THALASSEMIA MAJOR;CELL ARTERITIS;GIANT CELL;MULTIPLE SCLEROSIS;SOLUBLE HLA-G;ACUTE PHASE;ACUTE RENAL;ACUTE SPONTANEOUS;ADVANCED NON-SMALL;ALVEOLAR BONE;ANDOR RESISTANCE;ANEURYSMAL SUBARACHNOID;ANKLE FOOT;AORTIC DISEASES;ARTERITIS COMPARISON;ARTERITIS EVOLVING;ASPIRIN ANDOR;ASYMPTOMATIC PATIENTS;BIVENTRICULAR FUNCTION;BLOOD FLOW;BONE SITES;CANCER CACHEXIA;CARDIAC RESYNCHRONIZATION;CARDIOVASCULAR RISK;CELL ALLOANTIBODIES;CELL LINES;CELL LUNG;CEREBRAL BLOOD;CEREBROSPINAL FLUID;CHELATION THERAPY","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACUTE AORTIC;PUBMED SCOPUS;BLOOD PRESSURE;AORTIC ANEURYSM;ANEURYSM RUPTURED;AORTIC DISEASES;CROSSREF PUBMED;CT SCAN;SURG -ABSTRACT;UNSPECIFIED SITE;ABDOMINAL AORTA;ADRIATIC SEA;ALCHRONOBIOLOGICAL PATTERNS;ANEURYSMSJ VASC;AORTA ABDOMINAL;AORTA THORACOABDOMINAL;AORTA UNSPECIFIED;AORTIC ANEURYSMSJ;AORTIC DISSECTIONSCIRCULATION;DISCHARGE HOSPITAL;DISSECTION RUPTURE;DISSECTIONSCIRCULATION -CROSSREF;GAIT ANALYSIS;HOSPITAL ADMISSIONS;INCREASED BLOOD;MALE SUBJECTS;RH MANFREDINI;SCHOLAR MANFREDINI;SEASONAL PATTERN;SEASONAL VARIATION","7;7;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",3,0.09,3,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,80,80,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,6.44,372.56,12.16,1,0.11,27.56,0,1,0,1,1,0,1,5,0,7,2,0,0,0,0,0,0,9,0,0,9,0,0,0,0,0,0,0,0,0,"Italy;Spain","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3204 IMMUNOLOGY;4203 HEALTH SERVICES AND SYSTEMS;4207 SPORTS SCIENCE AND EXERCISE","7;5;2;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;BEHAVIORAL AND SOCIAL SCIENCE;HIV/AIDS;INFECTIOUS DISEASES;RARE DISEASES;ANTIMICROBIAL RESISTANCE;ASSISTIVE TECHNOLOGY;ATHEROSCLEROSIS;BASIC BEHAVIORAL AND SOCIAL SCIENCE;BIOENGINEERING;BIOMEDICAL IMAGING;BIOTECHNOLOGY;CANCER;CARDIOVASCULAR;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HEMATOLOGY","9;4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;RESPIRATORY","2;2;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES;6.7 PHYSICAL;7.1 INDIVIDUAL CARE NEEDS;7.3 MANAGEMENT AND DECISION MAKING","3;1;1;1;1;1;1;1","LEUKEMIA / LEUKAEMIA","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_FERRARA",2009,36,10.7777777777778,3,0.5,0.277777777777778,0.527777777777778,1.61194029850746,1.38461538461538,1.11111111111111,1.46153846153846,0.333333333333333,3,8,10,6,5,0.22,0.28,0.17,0.14,35.81,0.774053300986032,NA,0.166666666666667,0.861111111111111,0.439,0.379,0.301,0.379,"ROBERTO FERRARI;MASSIMILIANO CASTELLAZZI;ENRICO FAINARDI;CARMINE TAMBORINO;ILARIA ZOLLINO;STEFANO URSINO;F. CARTEI;ANTONIO STEFANELLI;RICCARDO GUIDI;ENRICO GRANIERI;GIOVANNI SCANELLI;MASSIMILIANO BERRETTA;VANIA RAMPONI;FRANCESCO FIORICA;UMBERTO TIRELLI;FRANCESCO CARINCI;ILARIA CASETTA;STEFANO VOLPATO;PAOLO SQUASI;LAURA ARDUIN","7;6;6;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2","ROBERTO FERRARI;DAVIDE TASSINARI;RICCARDO GUIDI;FRANCESCO CARINCI;ILARIA ZOLLINO;MASSIMILIANO CASTELLAZZI;ENRICO FAINARDI;MATTEO DANZA;CARMINE TAMBORINO;ENRICO GRANIERI;GIOVANNI SCANELLI;VANIA RAMPONI;LAURA ARDUIN;ROBERTO CENZI;FRANCESCO CARINCI;GIORGIO BRUNELLI;STEFANO VOLPATO;CLAUDIO CECONI;FEDERICA CORALLINI;GIORGIO ZAULI","2.58;1.14;0.62;0.62;0.62;0.61;0.61;0.5;0.43;0.41;0.4;0.36;0.33;0.33;0.33;0.29;0.27;0.27;0.27;0.27","ROBERTO FERRARI;MASSIMILIANO CASTELLAZZI;ENRICO FAINARDI;CARMINE TAMBORINO;ILARIA ZOLLINO;STEFANO URSINO;F. CARTEI;ANTONIO STEFANELLI;ENRICO GRANIERI;GIOVANNI SCANELLI;VANIA RAMPONI;FRANCESCO FIORICA;FRANCESCO CARINCI;ILARIA CASETTA;PAOLO SQUASI;LAURA ARDUIN;CLAUDIO PRATOLA;ANGELICA LUPATO;CESARE COLOSIMO;DAVIDE TASSINARI","7;6;6;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2","ROBERTO FERRARI;DAVIDE TASSINARI;FRANCESCO CARINCI;ILARIA ZOLLINO;MASSIMILIANO CASTELLAZZI;ENRICO FAINARDI;CARMINE TAMBORINO;ENRICO GRANIERI;GIOVANNI SCANELLI;VANIA RAMPONI;LAURA ARDUIN;ROBERTO CENZI;FRANCESCO CARINCI;GIORGIO BRUNELLI;CLAUDIO CECONI;PAOLO SQUASI;CLAUDIO PRATOLA;PASQUALE NOTARSTEFANO;PAOLO ARTALE;TIZIANO TOSELLI","2.58;1.14;0.62;0.62;0.61;0.61;0.43;0.41;0.4;0.36;0.33;0.33;0.33;0.29;0.27;0.25;0.25;0.25;0.25;0.25","STEFANO VOLPATO;ENRICO FAINARDI;MASSIMILIANO CASTELLAZZI;ROBERTO FERRARI;GIOVANNI SCANELLI;ALESSANDRO MARTINI;ANDREA CIORBA;CHIARA BIANCHINI;CLAUDIA AIMONI;MICHELA BORIN;R. FELLIN;CLAUDIO CECONI;FEDERICA CORALLINI;GIORGIO ZAULI;PAOLA SECCHIERO;FRANCESCO CARINCI;ALESSANDRO TESTORI;ANTONELLA VECCHIATO;CARLO RICCARDO ROSSI;DARIO CASARA","247;233;217;201;186;160;160;160;160;160;160;152;152;152;152;133;128;128;128;128","ENRICO FAINARDI;ROBERTO FERRARI;GIOVANNI SCANELLI;CLAUDIO CECONI;FRANCESCO CARINCI;PAOLO CARCOFORO;CARMINE TAMBORINO;MASSIMILIANO CASTELLAZZI;L SIGHINOLFI;CARLO FILIERI;ETTORE C. DEGLI UBERTI;FEDERICO TAGLIATI;MARCELLO LAPPARELLI;MARIA CHIARA ZATELLI;MARIA ROSARIA AMBROSIO;MARIELLA MINOIA;MATTIA BURATTO;ANTONIO STEFANELLI;F. CARTEI;STEFANO URSINO","233;193;186;152;133;128;104;104;84;81;81;81;81;81;81;81;81;78;78;78","ENRICO FAINARDI;ROBERTO FERRARI;FRANCESCO CARINCI;CARMINE TAMBORINO;MASSIMILIANO CASTELLAZZI;VANIA RAMPONI;ANTONIO STEFANELLI;F. CARTEI;GIOVANNI SCANELLI;STEFANO URSINO;ANGELICA LUPATO;CESARE COLOSIMO;CLAUDIO CECONI;CLAUDIO PRATOLA;ENRICO GRANIERI;FRANCESCO FIORICA;FRANCESCO GAROFANO;GIUSEPPE DE SANTIS;ILARIA CASETTA;PAOLO ARTALE","7;6;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;MATHEMATICS;ENGINEERING;PHILOSOPHY;COMPUTER SCIENCE;ECONOMICS;POLITICAL SCIENCE;PSYCHOLOGY","36;5;5;4;4;3;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;CARDIOLOGY;DENTISTRY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;OPTICS;ORTHODONTICS;PEDIATRICS;ANESTHESIA;PSYCHIATRY;BIOCHEMISTRY;CANCER RESEARCH;GASTROENTEROLOGY;ONCOLOGY;PHARMACOLOGY;RADIOLOGY;BOTANY;MATHEMATICAL ANALYSIS","25;13;9;7;5;5;5;5;5;5;5;4;4;3;3;3;3;3;3;2;2","POPULATION;CANCER;INCIDENCE (GEOMETRY);MYOCARDIAL INFARCTION;PROPORTIONAL HAZARDS MODEL;RADIATION THERAPY;CEREBROSPINAL FLUID;DIABETES MELLITUS;DISEASE;IMPLANT;MULTIPLE SCLEROSIS;ANTIGEN;ATRIAL FIBRILLATION;BLOOD PRESSURE;CHEMOTHERAPY;CLINICAL SIGNIFICANCE;CLINICAL TRIAL;CONDYLE;CONFIDENCE INTERVAL;CORONARY ARTERY DISEASE;DISCONTINUATION;FAMILY HISTORY;GENUS;HEART FAILURE;HORMONE;IMMUNE SYSTEM;INTRATHECAL;MAGNETIC RESONANCE IMAGING;MATRIX METALLOPROTEINASE;RANDOMIZED CONTROLLED TRIAL;SPIRAL (RAILWAY);SUBARACHNOID HEMORRHAGE;SURVIVAL RATE;TOXICITY;TRANSDERMAL","5;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CLINICAL ENDPOINT;HAZARD RATIO;HUMAN LEUKOCYTE ANTIGEN;INTRACEREBRAL HEMORRHAGE;MANDIBLE (ARTHROPOD MOUTHPART);ACTIVATOR (GENETICS);AIR EMBOLISM;ANGINA;ANGIOTENSIN II;ANGIOTENSIN-CONVERTING ENZYME;ANOREXIA NERVOSA;APATHY;APRAXIA;AUTOIMMUNITY;BASAL (MEDICINE);BREAST CANCER;CANCER PAIN;CATHETER ABLATION;CEREBRAL BLOOD VOLUME;CORONOID PROCESS;DEMYELINATING DISEASE;DENTAL ABUTMENTS;EDENTULISM;EJECTION FRACTION;EVIDENCE-BASED MEDICINE;GENE ISOFORM;GROWTH HORMONE;HEART RATE;IMMUNOGLOBULIN G;LASER SURGERY;MANDIBULAR NERVE;MELANOCORTIN;METASTASIS;MICROGLIA;MYOCARDIAL INFARCTION DIAGNOSIS;NEPHROPATHY;NEUROFILAMENT;OVERWEIGHT;PAROXYSMAL ATRIAL FIBRILLATION;PERCUTANEOUS CORONARY INTERVENTION;PERFORMANCE STATUS;PERFUSION SCANNING;PRESBYCUSIS;PROINFLAMMATORY CYTOKINE;PROLACTIN;PROSTATE CANCER;PULMONARY TOXICITY;RADIATION TREATMENT PLANNING;RADIOFREQUENCY ABLATION;RAMIPRIL;REIMBURSEMENT;ROTAVIRUS;SEPTOPLASTY;SINUS RHYTHM;SOCIOECONOMIC STATUS;TELMISARTAN;TEMOZOLOMIDE;TOLERABILITY;TRIGLYCERIDE;UNIVARIATE ANALYSIS;UNSTABLE ANGINA;VALSARTAN;VIABILITY ASSAY;WHARTON'S JELLY","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","SPONTANEOUS INTRACEREBRAL HEMORRHAGE;ACE INHIBITOR;ACROMEGALY;ANGIOTENSIN RECEPTOR;BRAIN METASTASIS;CABERGOLINE;CARDIAC RESYNCHRONIZATION THERAPY;CHILDHOOD OBESITY;HYPERTRIGLYCERIDEMIA;IVABRADINE;MEAN TRANSIT TIME;MELANOCORTIN 4 RECEPTOR;OSTEOPROTEGERIN;RADIOFREQUENCY CATHETER ABLATION;ROTAVIRUS GASTROENTERITIS;ROTAVIRUS INFECTIONS;ROTAVIRUS VACCINE;SENTINEL LYMPH NODE;SENTINEL NODE;SINOATRIAL NODE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;ITALY;ADULT;ENZYME-LINKED IMMUNOSORBENT ASSAY;MYOCARDIAL INFARCTION;AGED, 80 AND OVER;CEREBRAL HEMORRHAGE;;BIOMARKERS;BRAIN NEOPLASMS;MANDIBULAR FRACTURES;ADOLESCENT;CARDIOVASCULAR DISEASES;HIV INFECTIONS;HYPERTENSION;TOMOGRAPHY, X-RAY COMPUTED","29;24;20;17;15;11;10;10;10;9;8;7;7;7;7;6;6;6;6;6","DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES;CHALLENGES IN PAIN MANAGEMENT AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF MAXILLOFACIAL TRAUMA;GLIOMAS;IMMUNOLOGICAL MECHANISMS IN PREGNANCY AND FETAL-MATERNAL INTERFACE;ATRIAL FIBRILLATION;BIOLOGY AND PATHOLOGY OF KERATINS AND RELATED DISORDERS;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF LUNG CANCER;EATING DISORDERS AND BODY IMAGE CONCERNS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;GASTROINTESTINAL VIRAL INFECTIONS AND VACCINES DEVELOPMENT;HEALTH ECONOMICS AND QUALITY OF LIFE ASSESSMENT;IMPACT OF RESTING HEART RATE ON CARDIOVASCULAR HEALTH;MANAGEMENT AND PATHOPHYSIOLOGY OF INTRACEREBRAL HEMORRHAGE;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","IMPLANT STABILITY;CLINICAL ENDPOINT;DENTAL IMPLANTS;DISCONTINUATION;FACIAL FRACTURES;GLIOBLASTOMA;HLA-G;IMPLANT COMPLICATIONS;INTRATHECAL;MANDIBLE (ARTHROPOD MOUTHPART);MANDIBULAR FRACTURES;PAIN ASSESSMENT TOOLS;PAIN MANAGEMENT;PAIN MODULATION;RADIOTHERAPY;SPONTANEOUS INTRACEREBRAL HEMORRHAGE;ABUTMENT;AIR EMBOLISM;ANGIOTENSIN;ANGIOTENSIN II RECEPTOR","3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","ACUTE MYOCARDIAL;MULTIPLE SCLEROSIS;MYOCARDIAL INFARCTION;ELDERLY PATIENTS;FAMILY IMPLANTS;INTRACEREBRAL HEMORRHAGE;POTENTIAL ROLE;RADIOTHERAPY TREATMENT;SERUM LEVELS;SPIRAL FAMILY;SPONTANEOUS INTRACEREBRAL;SUBACUTE PHASES;ACTIVE ANTIRETROVIRAL;ACTIVE MATRIX;ACTIVE MMP-;ACTUAL CLINICAL;ADJUVANT RADIOTHERAPY;AIR EMBOLISM;ANOREXIA NERVOSA;ANTIBODY RESPONSE;ANTIGEN-G MOLECULES;ANTIRETROVIRAL THERAPY;ANTIRETROVIRALNAÏVE PATIENTS;ARTERY DISEASE;ATRIAL FIBRILLATION;AUTHOR RESPONSE;BASED MEDICINE;BI-FRONTAL GLIOMA;BONE SITES;BRAIN TUMOR","3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL OUTCOME;OBESE CHILDREN;ARH CI;BONE QUALITY;IMPLANTS INSERTED;MCR MUTATIONS;SUCCESS RATE;CELL VIABILITY;COX REGRESSION;DELTA IAJ;EXTRACTION SOCKETS;FAMILY IMPLANTS;FRESH-FROZEN BONE;INTER-LABORATORY CV;INTERNAL MEDICINE;SERUM LEVELS;SPIRAL FAMILY;VEGF SECRETION;ANGULATED ABUTMENT;ANOREXIA NERVOSA;ANTIRETROVIRAL THERAPY;ATYPICAL PSYCHIATRIC;BABYS GENDER;BONE LOSS;CHILDREN SELECTED;CRESTAL BONE;CRITICAL FACTORS;DENTAL IMPLANTS;DEVIATION SCORES;FINITE ELEMENTS","5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2",8,0.22,3,1,0,0,0,0,9,0,1,1.25,0,1,1,0,0,0,0,1,0,0,0,80.25,97,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,4,4817.25,6.45,2,0.5,11.75,0,1,1,0,1,0,0,1,0,4,0,0,0,0,0,0,0,3,0,1,4,0,0,0,0,0,0,0,0,0,"France;Italy;United States","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;42 HEALTH SCIENCES;4207 SPORTS SCIENCE AND EXERCISE","3;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PEDIATRIC;RARE DISEASES;AGING;ATHEROSCLEROSIS;BRAIN DISORDERS;CANCER;CARDIOVASCULAR;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;DUCHENNE/ BECKER MUSCULAR DYSTROPHY;GENETICS;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HEMATOLOGY;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);LUNG;MUSCULAR DYSTROPHY;NEUROSCIENCES;PATIENT SAFETY","3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MUSCULOSKELETAL;CANCER;CARDIOVASCULAR;RESPIRATORY","2;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.7 PHYSICAL","3;1;1","LEUKEMIA / LEUKAEMIA","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_FERRARA",2010,57,9.45614035087719,2.66666666666667,0.526315789473684,0.403508771929825,0.631578947368421,1.15151515151515,1,1.0952380952381,1.09090909090909,0.31578947368421,2,20,10,6,10,0.35,0.18,0.11,0.18,17.51,0.38744283989138,NA,0.192982456140351,0.736842105263158,0.416,0.241,0.328,0.314,"ANTONIO CUNEO;MARCO VALGIMIGLI;ENRICO FAINARDI;ENRICO GRANIERI;GIANLUCA CAMPO;GIANANTONIO ROSTI;MASSIMILIANO CASTELLAZZI;GIOVANNI DEL POETA;FRANCESCO DI RAIMONDO;MICHELE BACCARANI;FABIO FABBIAN;GIORGINA SPECCHIA;ALFONSO ZACCARIA;FRANCESCO FORCONI;ROBERTO FERRARI;RITA RIZZI;SIMONA SANTANGELO;STEFANO BOLZON;GIULIANA ALIMENA;ROBIN FOÀ","7;5;5;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2","MARCO VALGIMIGLI;GIANLUCA CAMPO;ENRICO FAINARDI;SARA CICCONE;FABIO FABBIAN;LUCIO DELL’ATTI;GIOVANNI SCANELLI;ENRICO GRANIERI;P. MARCHI;LEONARDO TORQUETTI;SILVIA FORCELLINI;PAULO FERRARA;VINCENZO DE SANCTIS;CARLO DANIELE;MARIO MANCA;ROBERTO FERRARI;SAVINO OCCHIONORELLI;MASSIMILIANO CASTELLAZZI;DANIELA RESCA;ARTURO CHIEREGATO","1.47;1.43;0.84;0.83;0.8;0.75;0.53;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.47;0.4;0.34;0.33;0.33","ANTONIO CUNEO;MARCO VALGIMIGLI;ENRICO FAINARDI;ENRICO GRANIERI;GIANLUCA CAMPO;MASSIMILIANO CASTELLAZZI;FABIO FABBIAN;STEFANO BOLZON;ELISABETTA CHIODI;DONATO MELE;FRANCESCO CAVAZZINI;LUCIO DELL’ATTI;GIAN MATTEO RIGOLIN;SAVINO OCCHIONORELLI;ILARIA ZOLLINO;GIOVANNI SCANELLI;MARIA ROSARIA TOLA;ALESSIO SCHIRONE;I. CARANDINA;LUIGI CATIZONE","7;5;5;4;4;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1","MARCO VALGIMIGLI;GIANLUCA CAMPO;ENRICO FAINARDI;FABIO FABBIAN;LUCIO DELL’ATTI;GIOVANNI SCANELLI;ENRICO GRANIERI;P. MARCHI;LEONARDO TORQUETTI;SILVIA FORCELLINI;PAULO FERRARA;VINCENZO DE SANCTIS;MARIO MANCA;SAVINO OCCHIONORELLI;MASSIMILIANO CASTELLAZZI;DANIELA RESCA;ROBERTO BOVO;G LODI;ROBERTO REVERBERI;ALESSANDRO MARTINI","1.47;1.43;0.84;0.8;0.75;0.53;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.4;0.34;0.33;0.33;0.33;0.33;0.33","ENRICO FAINARDI;ENRICO GRANIERI;MASSIMILIANO CASTELLAZZI;MARIA ROSARIA TOLA;ANDREA BIONDANI;BARBARA ZAGATTI;GIOVANNA BORSELLINO;GIUSEPPE DE SANTIS;LUCA BATTISTINI;LUISA CANIATTI;MANUELA FERRACIN;MASSIMO NEGRINI;RICCARDO GAVIOLI;ROBERTO FURLAN;ANTONIO CUNEO;CARLO CONTINI;SILVA SERACENI;FRANCESCO FORCONI;GIOVANNI DEL POETA;MARCO VALGIMIGLI","302;302;285;228;193;193;193;193;193;193;193;193;193;193;126;92;92;78;78;59","ENRICO FAINARDI;ANTONIO CUNEO;ENRICO GRANIERI;MASSIMILIANO CASTELLAZZI;MARCO VALGIMIGLI;ALESSANDRO MARTINI;ANDREA CIORBA;GIAN MATTEO RIGOLIN;ROBERTO BOVO;AMEDEO BERTOCCHI;ANTONELLA BERGONZONI;NINO BASAGLIA;STEFANO CERUTI;BENEDETTA BOARI;FRANCESCO CAVAZZINI;MASSIMO GALLERANI;RAFFAELLA SALMI;ALESSANDRO PEZZOLI;ELEONORA BALDI;MARIA ROSARIA TOLA","302;126;57;57;56;55;55;55;55;38;38;38;38;36;36;36;36;35;35;35","ANTONIO CUNEO;ENRICO FAINARDI;MARCO VALGIMIGLI;GIANLUCA CAMPO;DONATO MELE;FABIO FABBIAN;FRANCESCO CARINCI;GIOVANNI SCANELLI;LUCIO DELL’ATTI;STEFANO BOLZON;VINCENZO DE SANCTIS;A CAZZUFFI;ALAIDE CHIEFFO;ALESSANDRA BORTOLUZZI;ALESSANDRO MARTINI;ALESSANDRO PEZZOLI;ALFONSO IELASI;ALFREDO DE GIORGI;AMEDEO BERTOCCHI;ANDREA CIORBA","7;5;4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;ENGINEERING;PHYSICS;COMPUTER SCIENCE;PHILOSOPHY;PSYCHOLOGY;CHEMISTRY;ECONOMICS;MATERIALS SCIENCE","56;10;3;3;2;2;2;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;PATHOLOGY;SURGERY;RADIOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;INTENSIVE CARE MEDICINE;GASTROENTEROLOGY;PEDIATRICS;GENETICS;ONCOLOGY;PSYCHIATRY;ENDOCRINOLOGY;PHYSICAL THERAPY;ANESTHESIA;BIOCHEMISTRY;CELL BIOLOGY;EMERGENCY MEDICINE;NUCLEAR MEDICINE;NURSING;PHYSICAL MEDICINE AND REHABILITATION","38;13;12;11;9;8;8;8;7;7;6;6;6;5;5;3;3;3;3;3;3;3","MYOCARDIAL INFARCTION;POPULATION;DISEASE;ADVERSE EFFECT;CHEMOTHERAPY;GENE;LEUKEMIA;HEART FAILURE;MAGNETIC RESONANCE IMAGING;ALTERNATIVE MEDICINE;ASPIRIN;BLOOD PRESSURE;CANCER;CONFIDENCE INTERVAL;CORONARY ARTERY DISEASE;DIABETES MELLITUS;MULTIPLE SCLEROSIS;MYELOID LEUKEMIA;QUALITY OF LIFE (HEALTHCARE);RANDOMIZED CONTROLLED TRIAL","9;8;6;5;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3","CHRONIC LYMPHOCYTIC LEUKEMIA;CLOPIDOGREL;CYCLOPHOSPHAMIDE;PERCUTANEOUS CORONARY INTERVENTION;IMATINIB;ACUTE CORONARY SYNDROME;CARDIAC MAGNETIC RESONANCE IMAGING;CHROMOSOMAL TRANSLOCATION;CHROMOSOME;COLORECTAL CANCER;EJECTION FRACTION;HAZARD RATIO;NEUTROPENIA;RESTENOSIS;REVASCULARIZATION;RITUXIMAB;SINUS (BOTANY);TOLERABILITY;ACTIVATOR (GENETICS);AGGLUTININ;ANGINA;ANNOYANCE;ANOREXIA NERVOSA;AUTOIMMUNE HEMOLYTIC ANEMIA;BETA THALASSEMIA;BEVACIZUMAB;BRAIN BIOPSY;CALCITRIOL;CALCIUM METABOLISM;CARDIAC FUNCTION CURVE;CARDIAC MAGNETIC RESONANCE;CD34;CENTRAL PONTINE MYELINOLYSIS;CEREBROSPINAL FLUID LEAK;CHLAMYDIACEAE;CHLAMYDOPHILA;CHRONIC MYELOGENOUS LEUKEMIA;CLINICAL ENDPOINT;COCHLEAR IMPLANTATION;COLD AGGLUTININ;COLOR DOPPLER;CONVENTIONAL PCI;CORNEAL TOPOGRAPHY;CORONARY FLOW RESERVE;CRYOPRESERVATION;CUMULATIVE INCIDENCE;DIASTOLE;DIOPTRE;DYSLIPIDEMIA;ENDOCRINE SYSTEM;EPITHELIOID CELL;ETHMOID SINUS;EXON;FERTILITY;HEPATORENAL SYNDROME;HUMAN LEUKOCYTE ANTIGEN;HYPERACUSIS;HYPERCALCIURIA;IMMUNOPHENOTYPING;INFERTILITY;INTERIM ANALYSIS;INTERVENTRICULAR SEPTUM;INTRACLASS CORRELATION;KERATOMETER;KERATOMILEUSIS;LEVOTHYROXINE;LIPOPROTEIN;LIVER TRANSPLANTATION;MAINTENANCE THERAPY;MALIGNANT PERIPHERAL NERVE SHEATH TUMOR;MEDIAN FOLLOW-UP;MICRORNA;MIDAZOLAM;MINIMAL RESIDUAL DISEASE;MUTATION;NEGATIVE-PRESSURE WOUND THERAPY;NEUROINFLAMMATION;NEURORADIOLOGY;PERFORATION;PERFORMANCE STATUS;PERINDOPRIL;PERIPHERAL BLOOD MONONUCLEAR CELL;PHASES OF CLINICAL RESEARCH;PHENOTYPE;PHOTOREFRACTIVE KERATECTOMY;PLACEBO;POPULATION AGEING;PORTAL HYPERTENSION;PROGRESSION-FREE SURVIVAL;PROSTATE;PROTEINURIA;PROTOCOL (SCIENCE);REFRACTIVE SURGERY;RELATIVE RISK;SCHEIMPFLUG PRINCIPLE;SPLANCHNIC;SPONTANEOUS BACTERIAL PERITONITIS;T CELL;TARGETED THERAPY;TRANSCRIPTION FACTOR;TRANSPLANT SURGERY;TRAUMATOLOGY;TROPONIN;TYPE 2 DIABETES;URINARY CALCIUM;VASCULAR RESISTANCE;VASCULITIS;WHITE MATTER","4;4;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PRASUGREL;FLUDARABINE;DRUG-ELUTING STENT;IGHV@;P2Y12;THIENOPYRIDINE;TICAGRELOR;TICLOPIDINE;ANTIPLATELET DRUG;AZOOSPERMIA;BARE METAL;CARDIAC RESYNCHRONIZATION THERAPY;CETUXIMAB;CHLAMYDOPHILA PNEUMONIAE;CHLORAMBUCIL;COLD AGGLUTININ DISEASE;CORNEAL PACHYMETRY;FERTILITY PRESERVATION;FOCAL SEGMENTAL GLOMERULOSCLEROSIS;GLOMERULOSCLEROSIS;GLYCATED HEMOGLOBIN;HYPERDYNAMIC CIRCULATION;IL-2 RECEPTOR;IMATINIB MESYLATE;INTRACYTOPLASMIC SPERM INJECTION;IRINOTECAN;KARYOTYPE;MALE INFERTILITY;NERVE SHEATH NEOPLASM;NILOTINIB;OSTEOPROTEGERIN;OXALIPLATIN;PHILADELPHIA CHROMOSOME;PODOCYTE;POINT MUTATION;PROSTATE BIOPSY;SPLANCHNIC CIRCULATION;TERLIPRESSIN;TIROFIBAN;ZINC FINGER","4;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;MALE;FEMALE;MIDDLE AGED;AGED;ADULT;MYOCARDIAL INFARCTION;ITALY;CORONARY ARTERY DISEASE;TREATMENT OUTCOME;BRAIN;CONSTRICTION, PATHOLOGIC;MAGNETIC RESONANCE IMAGING;TIME FACTORS;ADOLESCENT;ANGIOPLASTY, BALLOON, CORONARY;BRAIN ISCHEMIA;FOLLOW-UP STUDIES;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL","32;25;24;19;19;16;14;9;8;7;7;6;6;6;6;5;5;5;5;5","ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;EFFICACY AND RESISTANCE IN CML TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;BIOMECHANICAL PROPERTIES OF THE CORNEA AND RELATED DISEASES;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;CHOLESTEROL-LOWERING TREATMENT;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;COCHLEAR NEUROPATHY AND HEARING LOSS MECHANISMS;DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES;DIAGNOSIS AND MANAGEMENT OF EOSINOPHILIC ESOPHAGITIS;DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL BLEEDING;DIAGNOSIS AND MANAGEMENT OF HYPONATREMIA;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS","4;4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","TREATMENT;CLOPIDOGREL;BARE-METAL STENT;CARDIAC IMAGING;CARDIOVASCULAR MRI;CARDIOVASCULAR RISK ASSESSMENT;DRUG-ELUTING STENTS;IGHV@;IMATINIB;METASTATIC COLORECTAL CANCER;NEPHROLOGY;PATHOGENESIS;REGIMEN;SINUS (BOTANY);THIENOPYRIDINE;TICLOPIDINE;TOLERABILITY;ADVANCED LIFE SUPPORT;AGING;ANALGESIA","4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1","ELDERLY PATIENTS;CHRONIC LYMPHOCYTIC;CHRONIC MYELOID;CLINICAL TRIAL;COLORECTAL CANCER;HEALTH-RELATED QUALITY;LYMPHOCYTIC LEUKEMIA;METASTATIC COLORECTAL;MULTICENTER STUDY;MULTIPLE SCLEROSIS;MYELOID LEUKEMIA;PROSPECTIVE STUDY;ABNORMALITIES ADDITIONAL;ACUTE CORONARY;ACUTE PYELONEPHRITIS;ADVANCED DIAGNOSTIC;ADVANTAGES LIMITATIONS;ADVERSE CARDIAC;AGGLUTININ-INDUCED HAEMOLYTIC;ALTERED MIRNA;ANCA-ASSOCIATED VASCULITIS;ANGIOGRAPHIC FINDINGS;ANGIOPLASTICHE DELLEMILIA-ROMAGNA;ANGIOPOIETIN- PLASMA;ANOREXIA NERVOSA;ANTI-NEUTROPHIL CYTOPLASMIC;ANTIBODY ANCA-ASSOCIATED;ANTIBODY RESPONSE;ANTIPLATELET THERAPY;APOPTOSIS-INDUCING LIGAND-OSTEOPROTEGERIN","3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ICU ADMISSION;RED BLOOD;LSSC PATIENTS;ANTIPLATELET THERAPY;BLOOD CELLS;HOSPITAL ADMISSIONS;ISCHEMIC STROKE;MYOCARDIAL INFARCTION;CLINICAL PRACTICE;COLD AGGLUTININ;ELDERLY PATIENTS;FOCAL SEGMENTAL;HAZARD RATIO;HEALTHY CONTROLS;MONTHLY PREVALENCE;PLANNED ICU;SAPHENOUS VEIN;SEASONAL VARIATION;SEGMENTAL GLOMERULOSCLEROSIS;SERUM LEVELS;TARGET VESSEL;TRIPLE ANTIPLATELET;UNIVERSAL RED;VEIN GRAFTS;VESSEL REVASCULARIZATION;AGGLUTININ DISEASE;BARE-METAL STENT;BARE-METAL STENTS;BLEEDING COMPLICATIONS;CELLS RH-POSITIVE","7;7;6;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2",7,0.12,3.5,7.5,8,0,0,0,5.25,0,0,8,0,0,2.5,0,1.75,0,0,2.5,0,0,0,66,66,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,4.25,376.75,6.3,2,0.25,55.62,0,0,2,0,2,0,0,4,0,7,1,0,0,0,0,0,0,6,2,0,8,0,0,0,0,0,0,0,0,0,"Germany;Italy","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","8;3;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;PATIENT SAFETY;RARE DISEASES;CARDIOVASCULAR;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;ATHEROSCLEROSIS;BEHAVIORAL AND SOCIAL SCIENCE;BIOENGINEERING;BREAST CANCER;COMPARATIVE EFFECTIVENESS RESEARCH;COST EFFECTIVENESS RESEARCH;LYMPHOMA;OVARIAN CANCER","7;5;4;3;3;3;2;2;2;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","3;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS","7;2;1;1;1;1","LEUKEMIA / LEUKAEMIA;BREAST CANCER;OVARIAN CANCER","3;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,"PUBLIC LIBRARY OF SCIENCE","12","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;42 HEALTH SCIENCES;52 PSYCHOLOGY;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;4203 HEALTH SERVICES AND SYSTEMS;5202 BIOLOGICAL PSYCHOLOGY;5205 SOCIAL AND PERSONALITY PSYCHOLOGY","18;8;3;3;1;1;1;1;1","CLINICAL RESEARCH;IMMUNIZATION;VACCINE RELATED;PREVENTION;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;EMERGING INFECTIOUS DISEASES;GENETICS;HIV/AIDS;INFECTIOUS DISEASES;PATIENT SAFETY","9;6;5;4;3;1;1;1;1;1","INFECTION","2","6.1 PHARMACEUTICALS","2","CLINICAL;BIOMEDICAL","6;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","5;1",NA,NA,"3 GOOD HEALTH AND WELL BEING","1"
"AOU_FERRARA",2011,58,12.1551724137931,2.60344827586207,0.5,0.275862068965517,0.810344827586207,1.36036036036036,1.26086956521739,1.23076923076923,1.27027027027027,0.258620689655172,4,18,18,6,9,0.31,0.31,0.1,0.16,23.48,0.552090096929518,NA,0.120689655172414,0.827586206896552,0.479,0.278,0.295,0.307,"ANTONELLA MELONI;ELISABETTA CHIODI;ALESSIA PEPE;ANTONIO CUNEO;MASSIMO LOMBARDI;GIORGINA SPECCHIA;MONICA SICARI;S. CAVAZZA;MARIA RITA GAMBERINI;P. MARCHI;GIANANTONIO ROSTI;STEFANO URSINO;GABRIELE GUGLIOTTA;GIOVANNI DONATO AQUARO;MICHELE BACCARANI;M. MANCA;G. FERRARESI;MASSIMO BRECCIA;VINCENZO POSITANO;NINO BASAGLIA","5;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","FABIO FABBIAN;DAVIDE IMBERTI;LUCIO DELL’ATTI;GIAN ROSARIO RUSSO;GIOVANNI SCANELLI;CARLA REGINA ALTRUDA;GIOVANNI ANDREA LA MAIDA;MAURO GENTILE;ILARIA CASETTA;ENRICO FAINARDI;ANTONELLA MELONI;ELISABETTA CHIODI;ALESSIA PEPE;MASSIMO LOMBARDI;MARCO VALGIMIGLI;GIANLUCA CAMPO;S. CAVAZZA;MONICA SICARI;M. MANCA;G. FERRARESI","2;2;0.83;0.83;0.57;0.5;0.5;0.5;0.48;0.48;0.45;0.45;0.45;0.45;0.43;0.43;0.41;0.39;0.37;0.34","ELISABETTA CHIODI;ANTONIO CUNEO;MONICA SICARI;S. CAVAZZA;MARIA RITA GAMBERINI;P. MARCHI;STEFANO URSINO;M. MANCA;G. FERRARESI;NINO BASAGLIA;CARLO RICCARDO ROSSI;S. GULLINI;L. LUTZONI;E. VENTURINI;FRANCESCO CAVAZZINI;LUCIO DELL’ATTI;MARCO VALGIMIGLI;FRANCESCA GUALANDI;G FERROCCI;FABIO FABBIAN","5;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","FABIO FABBIAN;DAVIDE IMBERTI;LUCIO DELL’ATTI;GIAN ROSARIO RUSSO;GIOVANNI SCANELLI;GIOVANNI ANDREA LA MAIDA;ENRICO FAINARDI;ELISABETTA CHIODI;MARCO VALGIMIGLI;GIANLUCA CAMPO;S. CAVAZZA;MONICA SICARI;M. MANCA;G. FERRARESI;LUCA FILETI;P. MARCHI;FRANCESCO TROTTA;MARIA RITA GAMBERINI;CARLO RICCARDO ROSSI;G FERROCCI","2;2;0.83;0.83;0.57;0.5;0.48;0.45;0.43;0.43;0.41;0.39;0.37;0.34;0.33;0.32;0.31;0.3;0.29;0.29","GIANLUCA CAMPO;MARCO VALGIMIGLI;BARBARA LUNGHI;FRANCESCO BERNARDI;GIOVANNI PARRINELLO;JLENIA MARCHESINI;MATTEO MICCOLI;MATTEO TEBALDI;P. FERRARESI;ROBERTO FERRARI;BRUNO MARTINO;GIANANTONIO ROSTI;GIULIANA ALIMENA;MASSIMO BRECCIA;MICHELE BACCARANI;FRANCESCO DI RAIMONDO;LUCIANO LEVATO;LUIGIA LUCIANO;ALESSANDRO RAMBALDI;ANTONELLA RUSSO ROSSI","339;339;329;329;329;329;329;329;329;329;251;251;251;251;251;250;247;240;236;236","GIANLUCA CAMPO;MARCO VALGIMIGLI;JLENIA MARCHESINI;MATTEO MICCOLI;MATTEO TEBALDI;ROBERTO FERRARI;MELISSA DABUSTI;S. GULLINI;SERGIO BOCCIA;ANTONIO CUNEO;SILVIO SARUBBO;AMEDEO ZURLO;ANGELINA PASSARO;CRISTINA BOSI;EDOARDO DALLA NORA;FRANCESCO BONETTI;GIOVANNI ZULIANI;ANDREA LO MONACO;GIOVANNI SCANELLI;ROBERTA GAFÀ","339;339;329;329;329;329;236;101;97;86;77;53;53;53;53;53;53;48;48;48","ANTONIO CUNEO;ELISABETTA CHIODI;S. CAVAZZA;G. FERRARESI;M. MANCA;P. MARCHI;STEFANO URSINO;MARIA RITA GAMBERINI;E. VENTURINI;ENRICO FAINARDI;FRANCESCO CAVAZZINI;FRANCESCO FIORICA;G FERROCCI;GIAN ROSARIO RUSSO;GIANLUCA CAMPO;GIOVANNI SCANELLI;LUCIO DELL’ATTI;MARCO VALGIMIGLI;S. GULLINI;A MARZETTI","5;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;PSYCHOLOGY;CHEMISTRY;COMPUTER SCIENCE;ECONOMICS;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE;SOCIOLOGY;BUSINESS;GEOLOGY;MATERIALS SCIENCE","56;9;5;4;4;3;3;3;2;2;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;ONCOLOGY;PATHOLOGY;ENVIRONMENTAL HEALTH;ENDOCRINOLOGY;GASTROENTEROLOGY;ANESTHESIA;GENETICS;PEDIATRICS;RADIOLOGY;INTENSIVE CARE MEDICINE;PHYSICAL MEDICINE AND REHABILITATION;OPTICS;PHYSICAL THERAPY;PSYCHIATRY;IMMUNOLOGY;NURSING;ANATOMY;ECONOMIC GROWTH;EPISTEMOLOGY;FAMILY MEDICINE;GENERAL SURGERY;GYNECOLOGY;MECHANICAL ENGINEERING;MEDICAL EMERGENCY;OPERATIONS MANAGEMENT;ORGANIC CHEMISTRY","43;19;9;9;9;8;7;7;6;6;6;6;5;5;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2","CANCER;POPULATION;COHORT;HEART FAILURE;ADVERSE EFFECT;CHEMOTHERAPY;GENE;DIABETES MELLITUS;INCIDENCE (GEOMETRY);MAGNETIC RESONANCE IMAGING;MYELOID LEUKEMIA;PLATELET;PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;THALASSEMIA;ALTERNATIVE MEDICINE;BODY SURFACE AREA;DISEASE;HEALTH CARE;MULTIPLE SCLEROSIS;MULTIVARIATE ANALYSIS;NEUROSURGERY;OBSERVATIONAL STUDY;RADIATION THERAPY;RETROSPECTIVE COHORT STUDY","10;8;6;6;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","COLORECTAL CANCER;EJECTION FRACTION;IMATINIB;CYCLOPHOSPHAMIDE;TOLERABILITY;UNIVARIATE ANALYSIS;ALEMTUZUMAB;ALLELE;BRAIN STIMULATION;CARDIAC FUNCTION CURVE;CARDIOMYOPATHY;CHRONIC LYMPHOCYTIC LEUKEMIA;CLOPIDOGREL;DEMENTIA;FRESH FROZEN PLASMA;HEAD AND NECK CANCER;MUTATION;MYOCARDIAL FIBROSIS;PERCUTANEOUS CORONARY INTERVENTION;PHENOTYPE;VOLUME OVERLOAD;WARFARIN","4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","IMATINIB MESYLATE;CHLORAMBUCIL;COLONOSCOPY;NILOTINIB;P2Y12;PROTHROMBIN COMPLEX CONCENTRATE;STROKE VOLUME;BENZOYL PEROXIDE;BINGE-EATING DISORDER;CD38;CETUXIMAB;COMPOUND HETEROZYGOSITY;CONNECTIVE TISSUE DISEASE;CYP2C19;DYSTROGLYCAN;ERLOTINIB;ESOPHAGEAL VARICES;FLUDARABINE;FLUORESCENCE IN SITU HYBRIDIZATION;GENE MUTATION;GENETIC HETEROGENEITY;HEPATOCYTE NUCLEAR FACTORS;IGHV@;KARYOTYPE;LOSS OF HETEROZYGOSITY;MATURITY ONSET DIABETES OF THE YOUNG;MEDIAL MENISCUS;MICROCOCCACEAE;MICROSATELLITE;MISSENSE MUTATION;NUCLEAR RECEPTOR;ORAL ANTICOAGULANT;OXALIPLATIN;PORTOSYSTEMIC SHUNT;PRASUGREL;PRIMARY MOTOR CORTEX;PROSTATE BIOPSY;THIENOPYRIDINE;TICLOPIDINE;TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;UTROPHIN;VASCULAR DEMENTIA","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;ANTINEOPLASTIC AGENTS;ITALY;ADULT;AGED;COLORECTAL NEOPLASMS;MIDDLE AGED;BRAIN;TICLOPIDINE;TREATMENT OUTCOME;ANTI-BACTERIAL AGENTS;BREAST NEOPLASMS;HEPATORENAL SYNDROME;PLATELET ACTIVATION;PLATELET AGGREGATION INHIBITORS;PROSPECTIVE STUDIES;RETROSPECTIVE STUDIES","31;26;17;14;11;10;9;9;8;8;7;7;7;5;5;5;5;5;5;5","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;EFFICACY AND RESISTANCE IN CML TREATMENT;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;MANAGEMENT AND PATHOPHYSIOLOGY OF INTRACEREBRAL HEMORRHAGE;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ANALYSIS OF ELECTROMYOGRAPHY SIGNAL PROCESSING;ANTERIOR CRUCIATE LIGAMENT INJURIES IN ATHLETES;ASTHMA;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CHOLESTEROL METABOLISM AND ATHEROSCLEROSIS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;DIAGNOSIS AND TREATMENT OF HEART FAILURE;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;EATING DISORDERS AND BODY IMAGE CONCERNS;ECONOMIC BURDEN OF CANCER TREATMENT;EFFECTS OF BRAIN STIMULATION ON MOTOR CORTEX","5;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","TREATMENT;BODY SURFACE AREA;IMATINIB MESYLATE;RADIOTHERAPY;TOLERABILITY;UNIVARIATE ANALYSIS;ANGIOLOGY;ANTICOAGULANT THERAPY;BRAIN STIMULATION;CHLORAMBUCIL;CLOPIDOGREL;CONCOMITANT;FRESH FROZEN PLASMA;IMATINIB;INFARCTION TREATMENT;MYOCARDIAL FIBROSIS;NILOTINIB;PLATELET REACTIVITY;PROTHROMBIN COMPLEX CONCENTRATE;REGIMEN","4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MULTIPLE SCLEROSIS;THALASSEMIA MAJOR;BODY SURFACE;FUNCTION NORMALIZED;IRON OVERLOAD;MAJOR PATIENTS;MYOCARDIAL IRON;VENTRICULAR VOLUMES;WELL-TREATED THALASSEMIA;ACUTE INTRACEREBRAL;CASE-CONTROL STUDY;CHRONIC LYMPHOCYTIC;CHRONIC MYELOID;ELDERLY PATIENTS;GIMEMA CML;HEMIPLEGIC PATIENTS;INTRACEREBRAL HAEMORRHAGE;ITALIAN ASSOCIATION;LEFT VENTRICULAR;LYMPHOCYTIC LEUKEMIA;MOVEMENT THERAPY;MYELOID LEUKEMIA;NECK CANCER;NILOTINIB MG;OBSERVATIONAL STUDY;ONCOLOGY AIRO;ORAL ANTICOAGULATION;PATIENTS TREATED;PLATELET REACTIVITY;POSTOPERATIVE RADIOTHERAPY","4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","TM PATIENTS;CARDIAC COMPLICATIONS;IRON OVERLOAD;CAPSULE ENDOSCOPY;MYOCARDIAL IRON;ON-CLOPIDOGREL PR;CORONARY INTERVENTION;INTRAHEPATIC PORTOSYSTEMIC;MAJOR TM;PERCUTANEOUS CORONARY;PLATELET REACTIVITY;PORTOSYSTEMIC SHUNT;TRANSJUGULAR INTRAHEPATIC;BODY SURFACE;PLASMA LEVELS;S-OH-CHOL LEVELS;THALASSEMIA MAJOR;WELL-TREATED TM;ANTICOAGULANT THERAPY;BINGE EATING;BLOOD COAGULATION;CANDIDATE LOCUS;CARDIAC DYSFUNCTION;CARDIOVASCULAR MAGNETIC;CHRONIC ANEMIA;CIRRHOSIS PATIENTS;CLINICAL OUTCOMES;CLINICAL STUDIES;CML PATIENTS;COMBINING GENOTYPE","12;6;6;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2",5,0.09,7.5,4,1,0,0,0,1.75,0,1.75,4,0,0,2,0,2,1,1,1.5,0,0,0,84,84,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,6,2023.91,10,6,0.55,92.64,0,0,2,0,6,0,1,2,0,10,1,0,0,0,0,0,0,11,0,0,11,0,0,0,0,0,0,0,0,0,"Italy;United States","2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;52 PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","10;4;3;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;RARE DISEASES;CARDIOVASCULAR;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HEMATOLOGY;PREVENTION;ATHEROSCLEROSIS;LUNG;ORPHAN DRUG;PEDIATRIC;PEDIATRIC RESEARCH INITIATIVE;ASSISTIVE TECHNOLOGY;AUTOIMMUNE DISEASE;BIOENGINEERING;BREAST CANCER;CHILDHOOD LEUKEMIA","11;8;5;4;4;3;3;3;3;3;2;2;2;2;2;1;1;1;1;1","CANCER;CARDIOVASCULAR;CONGENITAL;GENERIC HEALTH RELEVANCE","4;3;1;1","6.1 PHARMACEUTICALS;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;6.7 PHYSICAL","8;1;1;1;1","BREAST CANCER;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;LIVER CANCER;LUNG CANCER;NEUROBLASTOMA","1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","4",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_FERRARA",2012,55,14.2727272727273,1.92727272727273,0.345454545454545,0.181818181818182,0.454545454545455,1.20454545454545,1.11764705882353,0.909090909090909,1.13636363636364,0.309090909090909,4,25,10,6,11,0.45,0.18,0.11,0.2,25.62,0.61333979256182,4.13973799126638,0.345454545454545,0.872727272727273,0.536,0.295,0.124,0.263,"LUCIO DELL’ATTI;GIORGINA SPECCHIA;GIANANTONIO ROSTI;LUCIANO LEVATO;MICHELE BACCARANI;FABIO STAGNO;MASSIMO BRECCIA;FRANCESCA PALANDRI;VINCENZO BETTOLI;ALESSANDRA IURLO;SIMONA SOVERINI;GIUSEPPE SAGLIO;FRANCESCO CAVAZZINI;FAUSTO CASTAGNETTI;GABRIELE GUGLIOTTA;MONIA LUNGHI;FABIO FABBIAN;FABRIZIO PANE;NICOLETTA TESTONI;ANTONIO FRASSOLDATI","5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","LUCIO DELL’ATTI;FABIO FABBIAN;GIOVANNI SCANELLI;VINCENZO BETTOLI;MAURO GENTILE;ANNAROSA VIRGILI;STEFANIA ZAULI;ANTONIO FRASSOLDATI;ROBERTO GALEOTTI;GIAN ROSARIO RUSSO;ROBERTO FERRARI;GIANLUCA CAMPO;ALFREDO DE GIORGI;MARCO PALA;ROBERTO MANFREDINI;GIOVANNI PIETRO DANIELE;GIORA WEISER;JACOPO GIULIANI;G. UGHI;CONSUELO RICCI","3.58;1.26;0.62;0.54;0.5;0.48;0.48;0.41;0.33;0.33;0.28;0.28;0.26;0.26;0.26;0.25;0.25;0.25;0.25;0.25","LUCIO DELL’ATTI;VINCENZO BETTOLI;FRANCESCO CAVAZZINI;FABIO FABBIAN;ANTONIO FRASSOLDATI;CARMINE TAMBORINO;ALFREDO DE GIORGI;ALESSIA TIEGHI;ELISABETTA CHIODI;DONATO MELE;MASSIMILIANO CASTELLAZZI;CARLO SALVARANI;MARCO VALGIMIGLI;GIAN MATTEO RIGOLIN;ANNAROSA VIRGILI;GIOVANNI SCANELLI;STEFANIA ZAULI;ENRICO FAINARDI;GIANLUCA CAMPO;FRANCESCO FIORICA","5;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LUCIO DELL’ATTI;FABIO FABBIAN;GIOVANNI SCANELLI;VINCENZO BETTOLI;ANNAROSA VIRGILI;STEFANIA ZAULI;ANTONIO FRASSOLDATI;ROBERTO FERRARI;GIANLUCA CAMPO;ALFREDO DE GIORGI;ROBERTO MANFREDINI;JACOPO GIULIANI;G. UGHI;GIOVANNA LA FAUCI;FRANCESCO FIORICA;RITA PAVASINI;ALBERTO POLLINA;LAURA PETRINI;DONATO MELE;CARMINE TAMBORINO","3.58;1.26;0.62;0.54;0.48;0.48;0.41;0.28;0.28;0.26;0.26;0.25;0.25;0.25;0.2;0.2;0.2;0.2;0.18;0.18","VINCENZO BETTOLI;MARCO VALGIMIGLI;ALAIDE CHIEFFO;ALBERTO MENOZZI;ANDREJS ĒRGLIS;ANTONIO COLOMBO;AZEEM LATIB;BERNHARD REIMERS;CHOURMOUZIOS A. ARAMPATZIS;CHRISTOPHE CAUSSIN;FERDINANDO VARBELLA;FINA MAURI;FLAVIO AIROLDI;FRANCESCO ROMEO;GHADA MIKHAIL;MANUEL SABATÉ;MIKA LAINE;PATRIZIA PRESBITERO;PHILIP MACCARTHY;RAMÓN LÓPEZ‐PALOP","298;233;231;231;231;231;231;231;231;231;231;231;231;231;231;231;231;231;231;231","VINCENZO BETTOLI;MARCO VALGIMIGLI;GIAN MATTEO RIGOLIN;SARA MARTINELLI;FRANCESCO CAVAZZINI;ENRICO FAINARDI;GIOVANNA LA FAUCI;CARMINE TAMBORINO;MASSIMILIANO CASTELLAZZI;ANTONELLA BARDI;ANTONIO CUNEO;ELENA SACCENTI;ELISA TAMMISO;FRANCESCA CIBIEN;LARA RIZZOTTO;LUCA FORMIGARO;MARIA CICCONE;CARLO SALVARANI;NICOLÒ PIPITONE;PIERLUIGI MACCHIONI","274;233;101;101;92;91;79;74;74;72;72;72;72;72;72;72;72;64;64;64","FRANCESCO CAVAZZINI;LUCIO DELL’ATTI;ENRICO FAINARDI;ALESSIA TIEGHI;ANTONIO FRASSOLDATI;CARMINE TAMBORINO;ELISABETTA CHIODI;FRANCESCO FIORICA;GIAN MATTEO RIGOLIN;GIANLUCA CAMPO;MARCO VALGIMIGLI;MASSIMILIANO CASTELLAZZI;SARA MARTINELLI;VINCENZO BETTOLI;ALBERTO POLLINA;ALESSANDRO TRENTINI;ALFREDO DE GIORGI;ANDREA LO MONACO;ANNAROSA VIRGILI;ANTONELLA BARDI","4;4;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;PSYCHOLOGY;ART;MATERIALS SCIENCE;MATHEMATICS;PHILOSOPHY","54;8;7;5;3;3;3;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;ONCOLOGY;BIOCHEMISTRY;RADIOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;GENETICS;IMMUNOLOGY;PATHOLOGY;PSYCHIATRY;ENDOCRINOLOGY;UROLOGY;CANCER RESEARCH;DERMATOLOGY;MECHANICAL ENGINEERING;NUCLEAR MEDICINE;NURSING;OPTICS;PEDIATRICS;PHYSICAL THERAPY","48;16;11;10;8;7;6;5;5;5;5;5;4;4;3;3;3;3;3;3;3;3","GENE;CANCER;MYOCARDIAL INFARCTION;DISEASE;RANDOMIZED CONTROLLED TRIAL;KIDNEY DISEASE;MYELOID LEUKEMIA;OBSERVATIONAL STUDY;POPULATION;ACNE;ADVERSE EFFECT;CLINICAL TRIAL;CONFIDENCE INTERVAL;ENZYME;HEART FAILURE;INCIDENCE (GEOMETRY);MAGNETIC RESONANCE IMAGING;MALIGNANCY;PULMONARY EMBOLISM;QUALITY OF LIFE (HEALTHCARE);RENAL FUNCTION;RETROSPECTIVE COHORT STUDY;STROKE (ENGINE);THROMBOSIS","9;7;7;6;6;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","CLINICAL ENDPOINT;IMATINIB;ACUTE CORONARY SYNDROME;COLORECTAL CANCER;GENOTYPE;PERCUTANEOUS CORONARY INTERVENTION;ANTAGONIST;CHROMOSOME;CUMULATIVE INCIDENCE;DEEP VEIN;EJECTION FRACTION;HAZARD RATIO;HUMAN LEUKOCYTE ANTIGEN;NEURORADIOLOGY;SEPTIC SHOCK;SORAFENIB;UNIVARIATE ANALYSIS;ABDOMINAL AORTIC ANEURYSM;ACITRETIN;ACUTE TOXICITY;AGONIST;ALKALINE PHOSPHATASE;ALLELE;AORTIC ANEURYSM;B CELL;BASAL CELL CARCINOMA;BEHCET'S DISEASE;BINGE EATING;BLOT;BONE DENSITY;BONE MINERAL;BORTEZOMIB;BREAST CANCER;BULIMIA NERVOSA;CARBON MONOXIDE;CARBON MONOXIDE POISONING;CARDIAC MAGNETIC RESONANCE;CARDIOGENIC SHOCK;CARDIOMYOPATHY;CD8;CHEMOKINE;CHRONIC LYMPHOCYTIC LEUKEMIA;CINAHL;CLONE (JAVA METHOD);CLOPIDOGREL;CO POISONING;COLORECTAL SURGERY;CONVENTIONAL PCI;CRANIOPLASTY;CROHN'S DISEASE;CYCLOPHOSPHAMIDE;DECOMPRESSIVE CRANIECTOMY;DILATED CARDIOMYOPATHY;DNA REPAIR;DOWNREGULATION AND UPREGULATION;END STAGE RENAL DISEASE;FINE-NEEDLE ASPIRATION;GELATINASE;HEART TRANSPLANTATION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HIP ARTHROPLASTY;IMMUNOPRECIPITATION;IMPUTATION (STATISTICS);INFARCTION;INFERTILITY;ISOTRETINOIN;LAPAROSCOPIC SURGERY;LARYNGOSCOPY;MEGLUMINE;METALLOPROTEINASE;MUTATION;NADPH OXIDASE;NECK OF URINARY BLADDER;NEPHROGENIC SYSTEMIC FIBROSIS;OVERWEIGHT;PALSY;PERFORATION;PERFUSION SCANNING;PI3K/AKT/MTOR PATHWAY;PLACEBO;PLATELET ACTIVATION;POISSON REGRESSION;PROLACTIN;PROSTATE;PROSTATE CANCER;RECURRENT LARYNGEAL NERVE;RELAPSING REMITTING;RESTENOSIS;RETINOIC ACID;REVASCULARIZATION;RHEUMATOID FACTOR;RITUXIMAB;SKIN CANCER;ST ELEVATION;SUPEROXIDE;THROMBIN;THYROID CANCER;THYROID CARCINOMA;THYROID NODULES;TLR4;TOLERABILITY;TOPIRAMATE;ULCERATIVE COLITIS;VASCULAR ENDOTHELIAL GROWTH FACTOR;VASCULITIS;VENTRICULAR REMODELING;VIABILITY ASSAY;VIRAL LOAD;VOCAL CORD DYSFUNCTION;VOCAL CORD PARALYSIS;WESTERN BLOT;ZYMOGRAPHY","6;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","IMATINIB MESYLATE;NILOTINIB;CARDIAC RESYNCHRONIZATION THERAPY;ANTIRETROVIRAL THERAPY;B-CELL ACTIVATING FACTOR;BINGE-EATING DISORDER;CABERGOLINE;CARBOXYHEMOGLOBIN;CD3;CHILDHOOD OBESITY;COLECTOMY;CORONARY STENT;CYTOGENETICS;DASATINIB;FLUORESCENCE IN SITU HYBRIDIZATION;GENOTYPING;GIANT CELL ARTERITIS;HAPLOTYPE;HLA-G;KARYOTYPE;KOUNIS SYNDROME;LOWER URINARY TRACT SYMPTOMS;MACE;NEVOID BASAL-CELL CARCINOMA SYNDROME;OSTEOCALCIN;PAPILLARY THYROID CANCER;PROCTITIS;PROSTATIC DISEASES;RETINOID;RETROGRADE EJACULATION;STROKE VOLUME;SULPIRIDE;TAKOTSUBO SYNDROME;TARGET LESION;TLR2;TRASTUZUMAB;V600E;VARICOCELE;XERODERMA PIGMENTOSUM","3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;;MIDDLE AGED;AGED;ADULT;TREATMENT OUTCOME;AGED, 80 AND OVER;ITALY;RETROSPECTIVE STUDIES;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;PROSPECTIVE STUDIES;RENAL INSUFFICIENCY, CHRONIC;ACNE VULGARIS;ADOLESCENT;CARCINOMA;CORONARY ARTERY DISEASE;YOUNG ADULT;ANTINEOPLASTIC AGENTS","32;27;24;23;17;16;14;12;8;8;8;7;7;7;6;6;6;6;6;5","EFFICACY AND RESISTANCE IN CML TREATMENT;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MANAGEMENT AND PATHOPHYSIOLOGY OF ACNE AND ROSACEA;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;ATRIAL FIBRILLATION;BIOLOGICAL AND CLINICAL EFFECTS OF IONIZING RADIATION;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF FOOD ALLERGY;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND TREATMENT OF DIVERTICULITIS;DIAGNOSIS AND TREATMENT OF RENAL ARTERY STENOSIS;DIAGNOSIS AND TREATMENT OF VOICE DISORDERS","4;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL ENDPOINT;IMATINIB;IMATINIB MESYLATE;STROKE (ENGINE);TREATMENT;CARDIAC RESYNCHRONIZATION THERAPY;CUMULATIVE INCIDENCE;DIAGNOSIS;DISCONTINUATION;ERYTHROCYTE SEDIMENTATION RATE;INTERQUARTILE RANGE;INTERVENTIONAL RADIOLOGY;LEFT VENTRICULAR DYSFUNCTION;NEURORADIOLOGY;POLYCYTHEMIA VERA;UNIVARIATE ANALYSIS;ACITRETIN;ANEURYSM RUPTURE;ANEURYSM SCREENING;ANTI-OBESITY DRUGS","6;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","CHRONIC MYELOID;MYELOID LEUKEMIA;LEUKEMIA PATIENTS;BCR-ABL TRANSCRIPT;CHRONIC KIDNEY;CHRONIC LYMPHOCYTIC;CML WP;CYTO-PV TRIAL;GIMEMA CML;HEPATOCELLULAR CARCINOMA;KIDNEY DISEASE;PATIENTS TREATED;POLYCYTHEMIA VERA;PROSPECTIVE COHORT;STENT IMPLANTATION;TREATED FRONTLINE;ABDOMINAL AORTIC;ABERRATIONS DETECTED;ABSTRACT VORAPAXAR;ACNE PATIENTS;ACTIVITY DETECTED;ACUTE CORONARY;ACUTE PROCTITIS;ADVANCED HEPATOCELLULAR;ANALYSIS IDENTIFIES;ANGIOGRAPHY GUIDED;ANGIOPLASTICHE EMILIA-ROMAGNA;ANTICOAGULATION UNDERGOING;ANTITHROMBOTIC MANAGEMENT;AORTIC ANEURYSM","4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BLYS PROMOTER;CROHNS DISEASE;THYROID CANCER;HOSPITAL STAFF;RA PATIENTS;ANTITNF AGENTS;BRAF VE;CHRONIC LYMPHOCYTIC;DISEASE ACTIVITY;LYMPHOCYTIC LEUKEMIA;MUTATION ANALYSIS;NARGHILE SMOKING;PRIMARY ENDPOINT;PRO MEASURES;PROMOTER HAPLOTYPE;RESPONDERS VERSUS;SEVERE SEPSISSEPTIC;TREATMENT ARM;TTTT BLYS;VE MUTATION;ABNORMAL KARYOTYPE;ACUTE CORONARY;ALLERGIC MYOCARDIAL;ANALYSIS RESULTS;ARMS AB;AXILLARY NODES;BINGE EATING;BLYS SERUM;BRAF MUTATION;BREAST CANCER","6;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2",12,0.22,5.25,4.5,2.25,1,0,6,1,0,1,5.5,0,1,5.25,5,4,0,2.5,2.75,1,0,0,66.5,66.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,5.12,636.29,20,5,0.29,48.59,0,0,5,0,1,0,3,8,0,12,5,0,0,0,0,0,0,12,5,0,17,0,0,0,0,0,0,0,0,0,"Belgium;Italy;United States","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","16;6;6;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;PATIENT SAFETY;PEDIATRIC;NEUROSCIENCES;BRAIN DISORDERS;BREAST CANCER;CARDIOVASCULAR;CHILDHOOD LEUKEMIA;GENETICS;HEART DISEASE;NEURODEGENERATIVE;PEDIATRIC CANCER;STEM CELL RESEARCH;STROKE;AGING;ASSISTIVE TECHNOLOGY","17;9;8;6;5;5;4;3;2;2;2;2;2;2;2;2;2;2;1;1","CANCER;CARDIOVASCULAR;NEUROLOGICAL;STROKE","7;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;7.3 MANAGEMENT AND DECISION MAKING;8.1 ORGANISATION AND DELIVERY OF SERVICES","10;2;2;1;1;1;1","LEUKEMIA / LEUKAEMIA;BREAST CANCER;CERVICAL CANCER;COLON AND RECTAL CANCER;ENDOMETRIAL CANCER;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER","5;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","9;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,"KARGER PUBLISHERS","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","2;1","ASSISTIVE TECHNOLOGY;BIOENGINEERING;BRAIN DISORDERS;CLINICAL RESEARCH;DYSTONIA;NEURODEGENERATIVE;NEUROSCIENCES;RARE DISEASES;REHABILITATION","1;1;1;1;1;1;1;1;1","NEUROLOGICAL","1",NA,NA,"CLINICAL","1","CLINICAL MEDICINE AND SCIENCE","1",NA,NA,NA,NA
"AOU_FERRARA",2013,70,12.1857142857143,2.32857142857143,0.357142857142857,0.242857142857143,0.385714285714286,1.58252427184466,1.38888888888889,1.41666666666667,1.42105263157895,0.485714285714286,4,32,10,18,2,0.46,0.14,0.26,0.03,20.23,0.579738738267562,4.11450381679389,0.214285714285714,0.814285714285714,0.48,0.373,0.368,0.38,"GIOVANNI SCANELLI;ANTONIO CUNEO;ANTONELLA MELONI;ALESSIA PEPE;MASSIMO LOMBARDI;ROBERTO MANFREDINI;ALFREDO DE GIORGI;ELISABETTA CHIODI;MARCO VALGIMIGLI;FABIO FABBIAN;GIANLUCA CAMPO;VINCENZO POSITANO;L. GULINO;MARCO PALA;LUCIO DELL’ATTI;MARCELLO GOVONI;PASCAL VRANCKX;IDO IORI;ROBERTO FERRARI;GELORMA BELMONTE","8;8;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;3","LUCIO DELL’ATTI;GIOVANNI SCANELLI;YURI BATTAGLIA;ANTONIO CUNEO;ROBERTO MANFREDINI;ALFREDO DE GIORGI;FABIO FABBIAN;ANTONIO CUNEO;MARCO PALA;ANTONELLA MELONI;ALESSIA PEPE;MASSIMO LOMBARDI;GIANLUCA CAMPO;GIOVANNI CIANCÌO;FRANCESCO TROTTA;RAFFAELLA SALMI;ELISABETTA CHIODI;VINCENZO POSITANO;ROBERTO FERRARI;MARCELLO GOVONI","3;1.8;1.17;1;0.81;0.61;0.61;0.55;0.51;0.5;0.5;0.5;0.46;0.44;0.44;0.43;0.41;0.41;0.39;0.38","GIOVANNI SCANELLI;ANTONIO CUNEO;ROBERTO MANFREDINI;ALFREDO DE GIORGI;ELISABETTA CHIODI;MARCO VALGIMIGLI;FABIO FABBIAN;GIANLUCA CAMPO;MARCO PALA;LUCIO DELL’ATTI;MARCELLO GOVONI;IDO IORI;ROBERTO FERRARI;MATTEO TEBALDI;LUCA FORMIGARO;MARIA RITA GAMBERINI;MAURIZIO CAVALLARI;FRANCESCO PORTALUPPI;MASSIMILIANO CASTELLAZZI;FRANCESCO STOMEO","8;8;6;5;5;5;5;5;4;4;4;4;4;3;2;2;2;2;2;2","LUCIO DELL’ATTI;GIOVANNI SCANELLI;YURI BATTAGLIA;ANTONIO CUNEO;ROBERTO MANFREDINI;ALFREDO DE GIORGI;FABIO FABBIAN;ANTONIO CUNEO;MARCO PALA;GIANLUCA CAMPO;GIOVANNI CIANCÌO;FRANCESCO TROTTA;ELISABETTA CHIODI;ROBERTO FERRARI;MARCELLO GOVONI;CLAUDIA AIMONI;MARCO VALGIMIGLI;IDO IORI;GIOVANNI ZULIANI;FRANCESCO STOMEO","3;1.8;1.17;1;0.81;0.61;0.61;0.55;0.51;0.46;0.44;0.44;0.41;0.39;0.38;0.38;0.37;0.36;0.34;0.29","ROBERTO FERRARI;MARCO VALGIMIGLI;PASCAL VRANCKX;GIANLUCA CAMPO;LUIGI MEMO;GASPARE PARRINELLO;MARCO VIGNETTI;MATTEO TEBALDI;ANTOINE TOUZÉ;AUDREY CARPENTIER;ELISA MAZZONI;GIOVANNI CARANDINA;JÉRÔME NICOL;MAURO TOGNON;PIERRE COURSAGET;RÉMY ROBINOT;STEFANIA GAMBETTI;ADA PIEPOLI;ALESSANDRA VIEL;ALESSANDRO STELLA","308;306;292;233;225;214;190;185;145;145;145;145;145;145;145;145;141;136;136;136","ROBERTO FERRARI;MATTEO TEBALDI;MARCO VALGIMIGLI;GIOVANNI CARANDINA;CRISTINA HOST;ANTONIO CUNEO;GIANLUCA CAMPO;MELISSA DABUSTI;MARCO BORGHESI;ENRICO FAINARDI;FEDERICA VAGNARELLI;MARCELLO GOVONI;CARLO TUMSCITZ;SIMONE BISCAGLIA;MARIA RITA GAMBERINI;ELISABETTA CHIODI;NICOLA BOTTONI;ROBERTA BURNELLI;LARA RIZZOTTO;ALFREDO DE GIORGI","201;185;181;145;136;129;126;125;107;105;89;64;60;60;57;56;55;49;42;35","ANTONIO CUNEO;GIOVANNI SCANELLI;ELISABETTA CHIODI;FABIO FABBIAN;GIANLUCA CAMPO;LUCIO DELL’ATTI;MARCELLO GOVONI;ROBERTO MANFREDINI;MATTEO TEBALDI;ALFREDO DE GIORGI;MARCO PALA;MARCO VALGIMIGLI;ROBERTO FERRARI;ENRICO FAINARDI;ENRICO LISTA;FRANCESCA CIBIEN;FRANCESCO PORTALUPPI;GIAN MATTEO RIGOLIN;GIOVANNI CIANCÌO;GIULIA DAGHIA","10;8;5;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;PSYCHOLOGY;SOCIOLOGY;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;MATHEMATICS;POLITICAL SCIENCE;GEOLOGY;HISTORY;PHILOSOPHY","67;15;7;5;4;4;3;3;3;3;2;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;PATHOLOGY;SURGERY;IMMUNOLOGY;BIOCHEMISTRY;ONCOLOGY;GENETICS;GASTROENTEROLOGY;PSYCHIATRY;ENVIRONMENTAL HEALTH;PEDIATRICS;CELL BIOLOGY;FAMILY MEDICINE;NURSING;RADIOLOGY;ECONOMIC GROWTH;EMERGENCY MEDICINE;INTENSIVE CARE MEDICINE;OPTICS;PALEONTOLOGY;PHARMACOLOGY;UROLOGY","53;15;15;15;13;9;9;8;7;7;6;6;4;4;4;4;3;3;3;3;3;3;3","COHORT;CANCER;HEART FAILURE;ADVERSE EFFECT;ALTERNATIVE MEDICINE;DISEASE;GENE;POPULATION;RETROSPECTIVE COHORT STUDY;ANTIBODY;ARTHRITIS;CHEMOTHERAPY;LEUKEMIA;RANDOMIZED CONTROLLED TRIAL;RHEUMATOID ARTHRITIS;CONFIDENCE INTERVAL;IMMUNE SYSTEM;IN VITRO;INFLAMMATION;MYOCARDIAL INFARCTION;ODDS RATIO;PREGNANCY;THALASSEMIA","10;9;7;6;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4","RITUXIMAB;CHRONIC LYMPHOCYTIC LEUKEMIA;CLINICAL ENDPOINT;MYOCARDIAL FIBROSIS;BREAST CANCER;EJECTION FRACTION;OVERWEIGHT;UNIVARIATE ANALYSIS;ALEMTUZUMAB;CD20;CD8;CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;GENOTYPE;HAZARD RATIO;HUMAN LEUKOCYTE ANTIGEN;IMATINIB;NEURORADIOLOGY;PERCUTANEOUS CORONARY INTERVENTION;PERIPHERAL BLOOD MONONUCLEAR CELL;PROSTATE;RESTENOSIS;RHEUMATOID FACTOR;SYNOVITIS;TADALAFIL;TAMSULOSIN","5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","IMATINIB MESYLATE;LOWER URINARY TRACT SYMPTOMS;ABDOMINAL OBESITY;ACUTE PROMYELOCYTIC LEUKEMIA;ANAPLASTIC LYMPHOMA KINASE;ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY;ANTIRETROVIRAL THERAPY;APREPITANT;BASDAI;BENDAMUSTINE;BENIGN PROSTATIC HYPERPLASIA (BPH);BK VIRUS;BRADYCARDIA;BRONCHUS;CANAKINUMAB;CAPECITABINE;CARBOPLATIN;CARDIAC RESYNCHRONIZATION THERAPY;CD146;CD28;CD90;CERTOLIZUMAB PEGOL;CHILDHOOD OBESITY;CHIMERIC ANTIGEN RECEPTOR;CTL*;DEBULKING;DECORIN;DRUG-ELUTING STENT;FLUDARABINE;GENE EXPRESSION PROFILING;GERMLINE MUTATION;GROWTH HORMONE DEFICIENCY;HORMONAL THERAPY;HUMAN GROWTH HORMONE;IDARUBICIN;KRAS;MERKEL CELL;MERKEL CELL POLYOMAVIRUS;METASTATIC BREAST CANCER;MIRABEGRON;NILOTINIB;OBINUTUZUMAB;OFATUMUMAB;OXALIPLATIN;PALONOSETRON;PHARMACOGENETICS;PNEUMONIA SEVERITY INDEX;PRENATAL DIAGNOSIS;PUSTULOSIS;RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS;RETINOPATHY OF PREMATURITY;SEROPREVALENCE;STROKE VOLUME;SYNOVIAL FLUID;TILT TABLE TEST;TRANSCRIPTOME;UNDERWEIGHT","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;AGED;ITALY;MIDDLE AGED;ADULT;MYOCARDIAL INFARCTION;STROKE;TICLOPIDINE;HEART FAILURE;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;POSTOPERATIVE COMPLICATIONS;TREATMENT OUTCOME;ACUTE CORONARY SYNDROME;AGED, 80 AND OVER;BIOMARKERS;CORONARY RESTENOSIS;DYSPNEA","35;35;31;28;22;18;17;12;12;11;10;8;8;8;8;7;7;7;7;7","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;EFFICACY AND RESISTANCE IN CML TREATMENT;IMMUNOLOGICAL MECHANISMS IN PREGNANCY AND FETAL-MATERNAL INTERFACE;IMPACT OF HOSPITAL HANDOFFS ON PATIENT CARE;STANDARDISATION OF LOWER URINARY TRACT FUNCTION;THERAPEUTIC ANTIBODIES: DEVELOPMENT, ENGINEERING, AND APPLICATIONS;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVERSE DRUG REACTIONS AND PHARMACOVIGILANCE;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;AUTOINFLAMMATORY BONE DISORDERS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;DEVELOPMENTAL PHARMACOLOGY IN PEDIATRIC DRUG USE;DIAGNOSIS AND MANAGEMENT OF CEREBRAL VEIN THROMBOSIS;DIAGNOSIS AND MANAGEMENT OF HEREDITARY HEMORRHAGIC TELANGIECTASIA","5;5;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL ENDPOINT;MANTLE CELL LYMPHOMA;MYOCARDIAL FIBROSIS;CONCOMITANT;DRUG-ELUTING STENTS;REGIMEN;UNIVARIATE ANALYSIS;ETIOLOGY;FC? RECEPTORS;HLA-G;IMATINIB MESYLATE;IMMUNE RESPONSES;INFLAMMATION;MULTISLICE;NEURORADIOLOGY;RHEUMATOID FACTOR;SPECIALTY;TAMSULOSIN;THALASSEMIA;TREATMENT","4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","RHEUMATOID ARTHRITIS;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;THALASSEMIA MAJOR;DUAL ANTIPLATELET;INTERNAL MEDICINE;LEUKEMIA PATIENTS;MAJOR PATIENTS;MULTICENTRE STUDY;ACUTE CORONARY;ANTI-CD ANTIBODY;ANTIPLATELET THERAPY;ARTHRITIS RESULTS;BREAST CANCER;CANCER PATIENTS;CARDIAC COMPLICATIONS;CLL PATIENTS;CMR LGE;EMILIA-ROMAGNA REGION;ENDEAVOR SPRINT;FCGAMMA RECEPTOR;FERRARA ITALY;IN-HOSPITAL MORTALITY;IRON OVERLOAD;ITALIAN MULTICENTRE;LEUKEMIA CLL;LUTS SECONDARY;MULTIPLE SCLEROSIS;MYOCARDIAL FIBROSIS;PATIENTS PREVIOUSLY","5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MYOCARDIAL FIBROSIS;INTERNAL MEDICINE;TM PATIENTS;COLOUR CODE;IRON OVERLOAD;CD CD;COLLAGEN VI;LEAD STABILIZATION;MYOCARDIAL IRON;CARDIAC COMPLICATIONS;CLL PATIENTS;CV MORTALITY;HPYV HPYV;LEAD DISLODGEMENT;LEFT VENTRICULAR;PATIENTS ADMITTED;PEDIATRIC PATIENTS;THERAPEUTIC EDUCATION;VEIN ANATOMY;ACUTE PROMYELOCYTIC;ALL-CAUSE MORTALITY;CD CELLS;CD- CLL;CELL HYPERACTIVATION;CHRONIC LYMPHOCYTIC;COMPLEX PATIENTS;CONFIDENCE INTERVAL;CONGENITAL MUSCULAR;CONSECUTIVE PATIENTS;DETECT MYOCARDIAL","15;10;8;7;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3",17,0.24,3.5,3,3.25,1,0,1.75,2,0,1,3,0,1,2,1,0,1,1,2,0,0,0,59,59,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,4.92,1814.17,12.77,4,0.33,57.33,0,0,0,1,4,0,0,7,0,6,6,0,0,0,0,0,0,9,3,0,12,0,0,0,0,0,0,0,0,0,"Italy;United States","5;3","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;4203 HEALTH SERVICES AND SYSTEMS","12;8;4;2;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BREAST CANCER;PATIENT SAFETY;LUNG;DIGESTIVE DISEASES;PREVENTION;ARTHRITIS;AUTOIMMUNE DISEASE;BIOMEDICAL IMAGING;CARDIOVASCULAR;COLO-RECTAL CANCER;COMPARATIVE EFFECTIVENESS RESEARCH;LUNG CANCER;PAIN RESEARCH;RARE DISEASES","10;8;7;5;4;3;2;2;1;1;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE;INFLAMMATORY AND IMMUNE SYSTEM","8;1;1","6.1 PHARMACEUTICALS;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS","5;2;1;1;1;1","BREAST CANCER;COLON AND RECTAL CANCER;LUNG CANCER;STOMACH CANCER;THYROID CANCER","4;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;1.4 CANCER PROGRESSION AND METASTASIS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;3;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,"PUBLIC LIBRARY OF SCIENCE","7","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;49 MATHEMATICAL SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;4603 COMPUTER VISION AND MULTIMEDIA COMPUTATION;4901 APPLIED MATHEMATICS","7;3;2;2;1;1;1;1","INFECTIOUS DISEASES;CARDIOVASCULAR;ESTROGEN;RARE DISEASES","2;1;1;1","CARDIOVASCULAR","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","BIOMEDICAL;CLINICAL","1;1","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE","1;1",NA,NA,NA,NA
"AOU_FERRARA",2014,65,14.3692307692308,2.01538461538462,0.246153846153846,0.138461538461538,0.446153846153846,1.55952380952381,1.14285714285714,1,1.45,0.584615384615385,3,26,19,12,2,0.4,0.29,0.18,0.03,29.09,0.76980677942314,4.10652920962199,0.307692307692308,0.923076923076923,0.445,0.422,0.423,0.436,"GIAN MATTEO RIGOLIN;ANTONIO CUNEO;ESTER GARNE;HELEN DOLK;ELISA CALZOLARI;MARIE‐CLAUDE ADDOR;ANTONELLA MELONI;ELISABETTA CHIODI;DIANA WELLESLEY;ALESSIA PEPE;AURELIO MAGGIO;DAVID TUCKER;KARI KLUNGSØYR;ANNA PIERINI;BABAK KHOSHNOOD;LARRAITZ ARRIOLA;JUDITH RANKIN;INGEBORG BARIŠIĆ;MARIA RITA GAMBERINI;ANKE RIßMANN","8;8;7;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;4;4","LUCIO DELL’ATTI;GIAN MATTEO RIGOLIN;ANTONIO CUNEO;G. UGHI;ROBERTA RIZZO;ANTONELLA MELONI;ALESSIA PEPE;ENRICO FAINARDI;ELISABETTA CHIODI;ROBERTA GAFÀ;GIOVANNI ZULIANI;GIORGIO VASQUEZ;SAVINO OCCHIONORELLI;L. CAPPELLARI;ROCCO STANO;ESTER GARNE;CARMINE TAMBORINO;GIORGIO ZAULI;PAOLA SECCHIERO;HELEN DOLK","3.5;0.56;0.56;0.5;0.5;0.42;0.42;0.4;0.4;0.39;0.37;0.37;0.37;0.37;0.37;0.36;0.34;0.29;0.29;0.29","GIAN MATTEO RIGOLIN;ANTONIO CUNEO;ELISA CALZOLARI;ELISABETTA CHIODI;MARIA RITA GAMBERINI;LUCIO DELL’ATTI;ENRICO FAINARDI;YURI BATTAGLIA;GIOVANNI ZULIANI;MARIA ROSARIA TOLA;LUIGI CATIZONE;STEFANO VOLPATO;ELEONORA BALDI;ANTONIO BARILLÀ;CRISTIANO AZZINI;JUANA MARÍA SANZ;FRANCESCO CAVAZZINI;MARCO VALGIMIGLI;OLGA SOFRITTI;GIORGIO VASQUEZ","8;8;6;5;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2","LUCIO DELL’ATTI;GIAN MATTEO RIGOLIN;ANTONIO CUNEO;G. UGHI;ENRICO FAINARDI;ELISABETTA CHIODI;GIOVANNI ZULIANI;GIORGIO VASQUEZ;SAVINO OCCHIONORELLI;L. CAPPELLARI;ROCCO STANO;JUANA MARÍA SANZ;ELISA CALZOLARI;RITA ROSSI;MARIA RITA GAMBERINI;FRANCESCO CAVAZZINI;OLGA SOFRITTI;GIULIA DAGHIA;CRISTIANO AZZINI;ALESSANDRO DE VITO","3.5;0.56;0.56;0.5;0.4;0.4;0.37;0.37;0.37;0.37;0.37;0.29;0.29;0.29;0.23;0.22;0.22;0.22;0.21;0.21","ESTER GARNE;HELEN DOLK;ANNA PIERINI;KARI KLUNGSØYR;ELISA CALZOLARI;MARIE‐CLAUDE ADDOR;DIANA WELLESLEY;BABAK KHOSHNOOD;INGEBORG BARIŠIĆ;JUDITH RANKIN;ANKE RIßMANN;MARIA LOANE;DAVID TUCKER;LARRAITZ ARRIOLA;ANNETTE QUEIßER‐LUFT;ANTONIO CUNEO;GIAN MATTEO RIGOLIN;BOB MCDONNELL;CATHERINE ROUNDING;JORIEKE E. H. BERGMAN","498;475;442;417;393;393;377;370;370;370;354;321;318;318;314;314;314;295;279;274","ELISA CALZOLARI;ANTONIO CUNEO;GIAN MATTEO RIGOLIN;AMANDA J. NEVILLE;ENRICO FAINARDI;A. NEVILLE;ANTONIO BARILLÀ;LUIGI CATIZONE;YURI BATTAGLIA;MARIA RITA GAMBERINI;MARCO VALGIMIGLI;AMEDEO ZURLO;ALESSANDRO DE VITO;CRISTIANO AZZINI;ELEONORA BALDI;MARIA ROSARIA TOLA;ELISABETTA CHIODI;LUCIO DELL’ATTI;ELEONORA ARONICA;ANDREA SALETTI","393;300;300;143;141;105;103;103;103;79;71;65;63;63;59;59;53;53;47;46","ANTONIO CUNEO;GIAN MATTEO RIGOLIN;ELISA CALZOLARI;ELISABETTA CHIODI;MARIA RITA GAMBERINI;ENRICO FAINARDI;LUCIO DELL’ATTI;MARIA ROSARIA TOLA;YURI BATTAGLIA;ALESSANDRO DE VITO;AMANDA J. NEVILLE;ANTONIO BARILLÀ;CRISTIANO AZZINI;ELEONORA BALDI;GIANLUCA CAMPO;GIORGIO VASQUEZ;GIOVANNI SCANELLI;L. CAPPELLARI;LUIGI CATIZONE;MARCO VALGIMIGLI","7;7;6;5;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;COMPUTER SCIENCE;CHEMISTRY;PHYSICS;ART;BUSINESS;ENGINEERING;MATHEMATICS;ECONOMICS;PHILOSOPHY;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY","65;24;5;4;4;2;2;2;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;PATHOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;PEDIATRICS;RADIOLOGY;CARDIOLOGY;BIOCHEMISTRY;CANCER RESEARCH;ENDOCRINOLOGY;ONCOLOGY;PSYCHIATRY;DERMATOLOGY;PALEONTOLOGY;ANATOMY;ANESTHESIA;NUCLEAR MEDICINE;NURSING;OBSTETRICS;OPTICS;PHARMACOLOGY;VIROLOGY","47;23;17;15;12;11;11;9;9;8;6;5;5;5;5;4;4;3;3;3;3;3;3;3;3","POPULATION;GENE;DISEASE;PREGNANCY;LEUKEMIA;CANCER;THALASSEMIA;ALTERNATIVE MEDICINE;HEART FAILURE;MAGNETIC RESONANCE IMAGING;MYOCARDIAL INFARCTION;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;EPIDEMIOLOGY;PROSPECTIVE COHORT STUDY;RECEPTOR;VIRUS;CHEMOTHERAPY;CONFIDENCE INTERVAL;DEFEROXAMINE;IN VITRO;INCIDENCE (GEOMETRY);LESION;LYMPHOMA;MULTIPLE SCLEROSIS;REGIMEN","11;10;8;8;7;6;6;5;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3","CHRONIC LYMPHOCYTIC LEUKEMIA;DEFERASIROX;DEFERIPRONE;CARDIAC FUNCTION CURVE;GENOTYPE;HEPATITIS C VIRUS;RITUXIMAB;ALZHEIMER'S DISEASE;BETA THALASSEMIA;CHELATION THERAPY;CYCLOPHOSPHAMIDE;FETUS;GESTATIONAL AGE;MDM2;MULTISLICE COMPUTED TOMOGRAPHY;MUTATION;MYELODYSPLASTIC SYNDROMES;MYOCARDIAL FIBROSIS;PERCUTANEOUS CORONARY INTERVENTION;PROSTATE;THROMBOLYSIS;VIRAL LOAD","6;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;FLUDARABINE;IGHV@;PRENATAL DIAGNOSIS;SINGLE-NUCLEOTIDE POLYMORPHISM;BENDAMUSTINE;BRAIN-DERIVED NEUROTROPHIC FACTOR;CHEMOIMMUNOTHERAPY;CHLORAMBUCIL;CHRONIC MYELOMONOCYTIC LEUKEMIA;CILIOPATHY;COPY-NUMBER VARIATION;CORONAVIRUS DISEASE 2019 (COVID-19);DNA METHYLATION;LOWER URINARY TRACT SYMPTOMS;MACE;MODIFIED RANKIN SCALE;OBINUTUZUMAB;PLACENTAL ABRUPTION;POLYMORPHISM (COMPUTER SCIENCE);PROSTATE BIOPSY;RETROGRADE EJACULATION;RIBAVIRIN;RIGHT-TO-LEFT SHUNT;RYANODINE RECEPTOR 2;SEROTONIN REUPTAKE INHIBITOR;TRETINOIN;V600E;VASCULAR DEMENTIA","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;AGED;MIDDLE AGED;ADULT;EUROPE;ABNORMALITIES, MULTIPLE;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;REGISTRIES;AGED, 80 AND OVER;TREATMENT OUTCOME;PREGNANCY;ALZHEIMER DISEASE;MULTIPLE SCLEROSIS, RELAPSING-REMITTING;MYELODYSPLASTIC SYNDROMES;STROKE;KIDNEY FAILURE, CHRONIC;MUTATION","41;37;36;24;20;20;16;14;13;11;10;9;9;8;7;7;7;7;6;6","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;EFFECTS OF MEDICATION ON PREGNANCY OUTCOMES;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EPIDEMIOLOGY AND MANAGEMENT OF FUNGAL INFECTIONS;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;MOLECULAR MECHANISMS OF KIDNEY DEVELOPMENT AND DISEASE;ACUTE MYELOID LEUKEMIA;AGE-RELATED MACULAR DEGENERATION RESEARCH;BIOLOGICAL AND CLINICAL EFFECTS OF IONIZING RADIATION;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DEVELOPMENT AND EVALUATION OF CLINICAL GUIDELINES;DIAGNOSIS AND MANAGEMENT OF APPENDICITIS;DIAGNOSIS AND TREATMENT OF HEART FAILURE;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF SEXUAL DYSFUNCTION","7;6;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","DEFERASIROX;DEFERIPRONE;IRON OVERLOAD;PREGNANCY;DIALYSIS;REGIMEN;TREATMENT;ANTIRETROVIRAL THERAPY;BETA THALASSEMIA;BIRTH OUTCOMES;CHELATION THERAPY;CONCOMITANT;HEART FAILURE;HIV;IGHV@;MULTISLICE;MULTISLICE COMPUTED TOMOGRAPHY;MYOCARDIAL FIBROSIS;P53;PLATELET REACTIVITY","4;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;MULTIPLE SCLEROSIS;PRENATAL DIAGNOSIS;THALASSEMIA MAJOR;CLINICAL FEATURES;CONGENITAL ANOMALIES;EXCITE TRIAL;HEART FAILURE;HEPATIC IRON;IRON OVERLOAD;MAJOR PATIENTS;MYOCARDIAL IRON;PATIENTS TREATED;PLATELET REACTIVITY;PREVALENCE PRENATAL;REGISTRY-BASED STUDY;ULCERATED LESION;ABDOMEN DUE;ABSTRACT VASCULAR;ACNE VULGARIS;ACTIVATOR R-TPA;ACUTE ABDOMEN;ACUTE CORONARY;ACUTE ISCHEMIC;ACUTE RESPIRATORY;ADDING BLOOD;ADVERSE CARDIOVASCULAR;AGITATED SALINE;ALZHEIMERS DISEASE","5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","IRON OVERLOAD;CONGENITAL ANOMALIES;HEART FAILURE;TM PATIENTS;CELL PROLIFERATION;CHRONIC HEART;MS GT;VIRAL LOAD;ALZHEIMERS DISEASE;CARDIAC IRON;CARDIOVASCULAR EVENTS;MYOCARDIAL IRON;OCULO-AURICULO-VERTEBRAL SPECTRUM;TP MUTATED;BDNF PLASMA;CONGENITAL HEART;ELECTRONIC HEALTHCARE;ENDOTHELIAL CELL;HEALTHCARE DATABASES;HETEROGENEOUS MIO;HIV RNA;LATE ONSET;LYMPHOCYTIC LEUKEMIA;MAJOR TM;MUTATED B-CLL;MYOCARDIAL FIBROSIS;ONSET ALZHEIMERS;RISK FACTORS;SSRI PRESCRIBING;STUDY POPULATION","9;8;8;7;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",23,0.35,4.5,2.5,1,1,1,3,10,0,1.25,2.5,0,0,3,0,2,1.25,1,2,1,0,0,88.5,88.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,6.93,1220.64,17.72,7,0.5,50.71,0,0,3,0,2,0,0,9,0,8,6,0,0,0,0,0,0,10,3,1,14,0,0,0,0,0,0,0,0,0,"Italy;United States","4;3","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3202 CLINICAL SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;4202 EPIDEMIOLOGY;51 PHYSICAL SCIENCES;5105 MEDICAL AND BIOLOGICAL PHYSICS","14;7;4;3;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;BREAST CANCER;RARE DISEASES;CARDIOVASCULAR;HEALTH SERVICES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;PATIENT SAFETY;AGING;ATHEROSCLEROSIS;BIOMEDICAL IMAGING;BRAIN DISORDERS;COMPARATIVE EFFECTIVENESS RESEARCH;GENETICS;HEMATOLOGY;LUNG;NEUROSCIENCES;PEDIATRIC","14;9;7;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","CANCER;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;RESPIRATORY","7;3;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","6;2;2;2","BREAST CANCER;LEUKEMIA / LEUKAEMIA;MELANOMA;NOT SITE-SPECIFIC CANCER","4;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","6;2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,"PUBLIC LIBRARY OF SCIENCE","14","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3107 MICROBIOLOGY;42 HEALTH SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;4202 EPIDEMIOLOGY;4203 HEALTH SERVICES AND SYSTEMS;49 MATHEMATICAL SCIENCES;4905 STATISTICS","21;4;3;3;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;KIDNEY DISEASE;CARDIOVASCULAR;RARE DISEASES;ATHEROSCLEROSIS;AUTOIMMUNE DISEASE;BRAIN DISORDERS;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;NEURODEGENERATIVE;NEUROSCIENCES;PREVENTION;AGING;ALS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;EMERGING INFECTIOUS DISEASES;HEMATOLOGY;HIV/AIDS;HYPERTENSION","6;4;4;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","CANCER;RENAL AND UROGENITAL;CARDIOVASCULAR;INFECTION;NEUROLOGICAL","5;4;2;2;2","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;7.1 INDIVIDUAL CARE NEEDS","6;2;1;1;1","CLINICAL","7","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","9;1","NOT SITE-SPECIFIC CANCER;HODGKIN'S DISEASE;KAPOSI'S SARCOMA;LIVER CANCER;NON-HODGKIN'S LYMPHOMA","2;1;1;1;1",NA,NA
"AOU_FERRARA",2015,89,15.5280898876404,3.33707865168539,0.258426966292135,0.280898876404494,0.449438202247191,1.52577319587629,1.04545454545455,1.31578947368421,1.33333333333333,0.561797752808989,3,54,16,6,8,0.61,0.18,0.07,0.09,21.9,0.587602078367374,4.05810397553517,0.348314606741573,0.910112359550562,0.516,0.356,0.358,0.381,"ENRICO FAINARDI;ELISABETTA CHIODI;ANTONELLA MELONI;ALESSIA PEPE;ANTONIO CUNEO;VINCENZO POSITANO;ILARIA CASETTA;MARIA RITA GAMBERINI;MARIACHIARA SENSI;MASSIMILIANO CASTELLAZZI;GIAN MATTEO RIGOLIN;ENRICO GRANIERI;GIANLUCA CAMPO;ELEONORA BALDI;AURELIO MAGGIO;FRANCESCO CAVAZZINI;ALESSANDRO TRENTINI;MELISSA PADOVAN;MARCELLO GOVONI;TIZIANA BELLINI","11;7;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4","MATTEO TEBALDI;LUCIO DELL’ATTI;M BANDI;ENRICO FAINARDI;ELISABETTA CHIODI;MELISSA PADOVAN;MARCELLO GOVONI;ANTONIO FRASSOLDATI;ALESSANDRA BORTOLUZZI;MARIACHIARA SENSI;ANTONIO CUNEO;CHRISTOPHER D. D’ESTERRE;MAURIZIA CAPUZZO;MARGHERITA BIANCONI;I. CARANDINA;ANTONELLA MELONI;ALESSIA PEPE;VINCENZO POSITANO;ROBERTO MANFREDINI;GIANLUCA CAMPO","1.24;1;1;0.86;0.62;0.59;0.59;0.58;0.53;0.53;0.53;0.51;0.5;0.5;0.49;0.48;0.48;0.48;0.43;0.41","ENRICO FAINARDI;ELISABETTA CHIODI;ANTONELLA MELONI;ALESSIA PEPE;ANTONIO CUNEO;VINCENZO POSITANO;ILARIA CASETTA;MARIA RITA GAMBERINI;MARIACHIARA SENSI;GIAN MATTEO RIGOLIN;GIANLUCA CAMPO;ELEONORA BALDI;AURELIO MAGGIO;FRANCESCO CAVAZZINI;MELISSA PADOVAN;MARCELLO GOVONI;ELISABETTA GROPPO;ANTONIO FRASSOLDATI;ROBERTA RIZZO;MATTEO TEBALDI","11;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4","MATTEO TEBALDI;LUCIO DELL’ATTI;M BANDI;ENRICO FAINARDI;ELISABETTA CHIODI;MELISSA PADOVAN;MARCELLO GOVONI;ANTONIO FRASSOLDATI;ALESSANDRA BORTOLUZZI;MARIACHIARA SENSI;ANTONIO CUNEO;MARGHERITA BIANCONI;I. CARANDINA;ANTONELLA MELONI;ALESSIA PEPE;VINCENZO POSITANO;ROBERTO MANFREDINI;GIANLUCA CAMPO;RITA TANAS;CARLO ALBERTO VOLTA","1.24;1;1;0.86;0.62;0.59;0.59;0.58;0.53;0.53;0.53;0.5;0.49;0.48;0.48;0.48;0.43;0.41;0.4;0.39","GIANLUCA CAMPO;MATTEO TEBALDI;ALBERTO MENOZZI;STEFANO TONDI;ANTONIO CUNEO;ANTONIO DELLAVALLE;ATHANASIOS PATIALIAKAS;ATTILA THURY;CARLO BRIGUORI;EMANUELE MELIGA;EUGÈNE MCFADDEN;FLAVIO AIROLDI;FRANCESCO LIÏSTRO;HENRIQUE MESQUITA GABRIEL;IMRE UNGI;LUCA TESTA;MARCO FERLINI;MARCO ROFFI;MARCO VALGIMIGLI;NICOLETTA DE CESARE","401;335;305;305;262;261;261;261;261;261;261;261;261;261;261;261;261;261;261;261","GIANLUCA CAMPO;MATTEO TEBALDI;ANTONIO CUNEO;ATHANASIOS PATIALIAKAS;GIAN MATTEO RIGOLIN;AMANDA J. NEVILLE;ENRICO FAINARDI;RITA TANAS;MARIA RITA GAMBERINI;ALESSANDRA FERLINI;FRANCESCA GUALANDI;ALDO FILOSA;ALESSIA PEPE;ANTONELLA MELONI;ANTONELLA QUARTA;AURELIO MAGGIO;CRISTINA SALVATORI;DOMENICO GIUSEPPE D’ASCOLA;GIANLUCA VALERI;GIOVANNI PALAZZI","372;335;262;261;216;215;189;103;99;83;83;72;72;72;72;72;72;72;72;72","ENRICO FAINARDI;ELISABETTA CHIODI;ANTONIO CUNEO;GIAN MATTEO RIGOLIN;MARIA RITA GAMBERINI;MARIACHIARA SENSI;ANTONIO FRASSOLDATI;ELEONORA BALDI;GIANLUCA CAMPO;MATTEO TEBALDI;FRANCESCO CAVAZZINI;MARCELLO GOVONI;MELISSA PADOVAN;ROBERTO MANFREDINI;MARIA CICCONE;AMANDA J. NEVILLE;ELISABETTA GROPPO;I. CARANDINA;VITTORIO RISPOLI;A. MORETTI","14;7;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;2","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;CHEMISTRY;ENGINEERING;COMPUTER SCIENCE;GEOLOGY;MATHEMATICS;PHILOSOPHY;ECONOMICS;POLITICAL SCIENCE;ART;BUSINESS;SOCIOLOGY","88;12;8;8;7;7;4;3;3;3;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;PSYCHIATRY;RADIOLOGY;PEDIATRICS;ENVIRONMENTAL HEALTH;PATHOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;ONCOLOGY;GENETICS;ANESTHESIA;MECHANICAL ENGINEERING;NUCLEAR MEDICINE;BIOCHEMISTRY;PHYSICAL MEDICINE AND REHABILITATION;OPTICS;PHYSICAL THERAPY;EMERGENCY MEDICINE;GERONTOLOGY;INTENSIVE CARE MEDICINE;NURSING","73;24;21;18;18;15;12;12;10;10;10;9;8;7;7;6;6;5;5;4;4;4;4","DISEASE;MAGNETIC RESONANCE IMAGING;MYOCARDIAL INFARCTION;POPULATION;COHORT;CHEMOTHERAPY;HEART FAILURE;CANCER;GENE;THALASSEMIA;LEUKEMIA;LYMPHOMA;OBESITY;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;ANTIBODY;CLINICAL TRIAL;INCIDENCE (GEOMETRY);OBSERVATIONAL STUDY;PERFUSION;PROSPECTIVE COHORT STUDY;STROKE (ENGINE)","12;11;11;11;9;8;8;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5","CHRONIC LYMPHOCYTIC LEUKEMIA;PERFUSION SCANNING;CARDIAC FUNCTION CURVE;CLINICAL ENDPOINT;CORONARY ANGIOGRAPHY;CYCLOPHOSPHAMIDE;MOVEMENT DISORDERS;OVERWEIGHT;RITUXIMAB;WEIGHT LOSS;BETA THALASSEMIA;CHELATION THERAPY;COLORECTAL CANCER;GENE EXPRESSION;ISCHEMIC STROKE;THROMBOLYSIS;ACUTE STROKE;BEVACIZUMAB;FIXATION (POPULATION GENETICS);IMATINIB;INCISIONAL HERNIA;INFARCTION;INJURY PREVENTION;MUTATION;NEURORADIOLOGY;NEUTROPENIA;PARKINSON'S DISEASE;PENUMBRA;PERCUTANEOUS CORONARY INTERVENTION;PROGRESSION-FREE SURVIVAL;RESTENOSIS;REVASCULARIZATION;SEROLOGY;SUICIDE PREVENTION;SYSTEMIC LUPUS ERYTHEMATOSUS;TIDAL VOLUME;WHITE MATTER","6;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","FLUDARABINE;DASATINIB;DEEP BRAIN STIMULATION;DNA METHYLATION;DRUG-ELUTING STENT;FRACTIONAL FLOW RESERVE;IBRUTINIB;IGHV@;IMATINIB MESYLATE;OBINUTUZUMAB;WEIGHT CHANGE;ABATACEPT;ADIPONECTIN;ARTIFICIAL VENTILATION;BENDAMUSTINE;CARBOPLATIN;CD23;CD38;CHLORAMBUCIL;CONNECTIVE TISSUE DISEASE;CORONARY ARTERY ANEURYSM;CORONARY ARTERY ECTASIA;CORONARY STENT;DIETING;EXTRAMEDULLARY HEMATOPOIESIS;FIRST TRIMESTER;GENOME INSTABILITY;HAPLOTYPE;HMG-COA REDUCTASE;INEFFECTIVE ERYTHROPOIESIS;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;LACUNAR STROKE;LAMIVUDINE;LMNA;LONG NON-CODING RNA;LOSS OF HETEROZYGOSITY;MACE;MODIFIED RANKIN SCALE;NEURAL TUBE DEFECT;OFATUMUMAB;OXALIPLATIN;PEAK INSPIRATORY PRESSURE;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RIGHT CORONARY ARTERY;SPECKLE TRACKING ECHOCARDIOGRAPHY;TIMP1;TRANSCRIPTOME;VENETOCLAX","3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;;MALE;MIDDLE AGED;AGED;ITALY;ADULT;STROKE;MYOCARDIAL INFARCTION;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;BETA-THALASSEMIA;BRAIN;CORONARY ARTERY DISEASE;MYOCARDIUM;OBESITY;PROSPECTIVE STUDIES;TOMOGRAPHY, X-RAY COMPUTED","47;43;41;39;31;26;24;22;18;13;12;11;10;9;9;9;8;8;8;8","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;EFFICACY AND RESISTANCE IN CML TREATMENT;HERNIA REPAIR TECHNIQUES AND MATERIALS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;ROLE OF MATRIX METALLOPROTEINASES IN CANCER AND PHYSIOLOGY;WEIGHT STIGMA AND OBESITY MANAGEMENT;ACUTE MYELOID LEUKEMIA;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;BULLYING BEHAVIORS AND PSYCHOLOGICAL IMPACT;CHOLESTEROL-LOWERING TREATMENT;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE","7;6;4;4;4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1","INFARCTION TREATMENT;PERFUSION IMAGING;STROKE (ENGINE);CLINICAL ENDPOINT;MOVEMENT DISORDERS;BETA THALASSEMIA;CHELATION THERAPY;IRON OVERLOAD;MAGNETIC RESONANCE IMAGING;OBESITY STIGMA;PREGNANCY;TRANSFUSION THERAPY;ACUTE STROKE;ANGIOLOGY;ATTRITION;BARE-METAL STENT;CARDIOVASCULAR MRI;CHRISTIAN MINISTRY;CONCOMITANT;DEEP BRAIN STIMULATION","6;5;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;CT PERFUSION;INTERNAL MEDICINE;ISCHEMIC STROKE;LEFT VENTRICULAR;MULTIPLE SCLEROSIS;THALASSEMIA MAJOR;ACUTE INFARCT;BRAIN STIMULATION;CARDIAC IRON;CENTER MIDLINE;CHILDHOOD-ONSET GENERALIZED;CML WP;DECISION SUPPORT;DEEP BRAIN;DYTPRKRA FOUNDER;ELDERLY PATIENTS;EUROPEAN LEUKEMIANET;FIRST-LINE IMATINIB;FIXATIONIN CENTER;FLOW RESERVE;FOUNDER MUTATION;FRACTIONAL FLOW;GENERALIZED DYSTONIA;GIMEMA CML;HERNIA EASY;HOSPITAL ADMISSIONS;INCISIONAL HERNIA;INFARCT CORE","6;6;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","FEG DW;MG FEG;IRON OVERLOAD;THALASSEMIA MAJOR;MAGNETIC RESONANCE;MEDIAN MG;CLINICAL PRACTICE;SPEAKERS BUREAU;CHOI CRITERIA;LIVER IRON;MYOCARDIAL IRON;NEUROPATHIC COMPONENT;RESONANCE IMAGING;SCAR TISSUE;TRANSMURAL SCAR;WEIGHT LOSS;ACTIVE MMP-;CURVE ANALYSIS;MATERNAL AGE;MYOCARDIAL INFARCTION;SERUM FERRITIN;CARDIAC IRON;CARE UNIT;CELL DISEASE;DEAD PATIENTS;HR CI-;LOSS GOALS;OBSERVATIONAL STUDY;OPERATING CHARACTERISTIC;POSITIVE TN","18;18;12;11;10;10;8;8;7;7;7;7;7;7;7;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5",30,0.34,7.57,5.25,2,1,1.5,2,2,0,1,5.25,1,0,4,1,0,1,2.5,3.75,2.5,0,0,73.5,73.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,4,740.2,8.47,4,0.27,62.33,0,0,5,0,3,0,1,6,0,13,2,0,0,0,0,0,0,12,3,0,15,0,0,0,0,0,0,0,0,0,"Italy;Australia;Denmark;Netherlands;United States","3;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;3213 PAEDIATRICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","13;6;5;3;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;BREAST CANCER;CARDIOVASCULAR;HEART DISEASE;LUNG;BIOENGINEERING;HEART DISEASE - CORONARY HEART DISEASE;RARE DISEASES;ASSISTIVE TECHNOLOGY;ATHEROSCLEROSIS;AGING;ALS;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN DISORDERS;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;COMPARATIVE EFFECTIVENESS RESEARCH;GENETICS","14;12;7;5;4;4;4;4;3;3;3;2;2;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;RESPIRATORY;GENERIC HEALTH RELEVANCE;NEUROLOGICAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","6;3;2;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;6.7 PHYSICAL","11;2;1;1","BREAST CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER","4;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","5",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,"PUBLIC LIBRARY OF SCIENCE","3","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","4;2","ESTROGEN","1",NA,NA,"6.1 PHARMACEUTICALS","1",NA,NA,"CLINICAL MEDICINE AND SCIENCE","2",NA,NA,NA,NA
"AOU_FERRARA",2016,98,16.9387755102041,2.8469387755102,0.244897959183673,0.275510204081633,0.36734693877551,1.58522727272727,1.26315789473684,1.5,1.24137931034483,0.520408163265306,0,58,20,2,10,0.59,0.2,0.02,0.1,26.82,0.82554930799786,4.1767955801105,0.275510204081633,0.918367346938776,0.434,0.312,0.392,0.343,"ENRICO FAINARDI;ANTONIO FRASSOLDATI;CARLO ALBERTO VOLTA;GIANLUCA CAMPO;ILARIA CASETTA;ANTONELLA MELONI;GIAN MATTEO RIGOLIN;ANNAROSA VIRGILI;ANTONIO CUNEO;MATTEO TEBALDI;VINCENZO POSITANO;I. CARANDINA;CARMINE TAMBORINO;MARIA RITA GAMBERINI;ALESSANDRO TURRA;ALESSIA PEPE;ANGELO MICHELE CARELLA;DONATO MANNINA;PATRIZIA TOSI;SAVINO SPADARO","8;8;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4","ANNAROSA VIRGILI;ANTONIO FRASSOLDATI;STEFANIA ZAULI;ALESSANDRO TURRA;LAWRENCE G. MANCO;GIULIA TONI;BETTOLI;ENRICO FAINARDI;VINCENZO BETTOLI;CARLO ALBERTO VOLTA;GIANLUCA CAMPO;MICHELA BOZZOLAN;MARCO DA ROIT;PIERLUIGI BALLARDINI;I. CARANDINA;ELISA MAIETTI;SAVINO SPADARO;SIMONE BISCAGLIA;MATTEO TEBALDI;ILARIA CASETTA","1.2;1.18;1.03;0.81;0.76;0.7;0.7;0.66;0.64;0.62;0.55;0.5;0.5;0.5;0.47;0.43;0.43;0.41;0.4;0.38","ENRICO FAINARDI;ANTONIO FRASSOLDATI;CARLO ALBERTO VOLTA;GIANLUCA CAMPO;ILARIA CASETTA;GIAN MATTEO RIGOLIN;ANTONIO CUNEO;MATTEO TEBALDI;I. CARANDINA;CARMINE TAMBORINO;MARIA RITA GAMBERINI;ALESSANDRO TURRA;SAVINO SPADARO;MARINA PADRONI;FRANCESCO CAVAZZINI;SIMONE BISCAGLIA;ELISA MAIETTI;VINCENZO BETTOLI;GIORGIA VALPIANI;RITA PAVASINI","8;8;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3","ANTONIO FRASSOLDATI;ALESSANDRO TURRA;LAWRENCE G. MANCO;BETTOLI;ENRICO FAINARDI;VINCENZO BETTOLI;CARLO ALBERTO VOLTA;GIANLUCA CAMPO;MICHELA BOZZOLAN;PIERLUIGI BALLARDINI;I. CARANDINA;ELISA MAIETTI;SAVINO SPADARO;SIMONE BISCAGLIA;MATTEO TEBALDI;ILARIA CASETTA;ROBERTO MANFREDINI;SILVIA VERTUANI;STEFANO MANFREDINI;I. TOMA","1.18;0.81;0.76;0.7;0.66;0.64;0.62;0.55;0.5;0.5;0.47;0.43;0.43;0.41;0.4;0.38;0.38;0.35;0.35;0.32","MATTEO TEBALDI;ALEXANDRA J. LANSKY;ANGELA FERRARA;CLEMENS VON BIRGELEN;EMANUELE BARBATO;HOLGER NEF;JELMER WESTRA;JOHAN H. C. REIBER;JUNQING YANG;LIEFKE C. VAN DER HEIJDEN;MARIANO PELLICANO;NIELS RAMSING HOLM;SHENGXIAN TU;WILLIAM WIJNS;YOSHINOBU MURASATO;YURI BATTAGLIA;A ZUCCALÀ;ADAMASCO CUPISTI;ANNA MARIA MALAGONI;ANTONIO BARILLÀ","640;463;463;463;463;463;463;463;463;463;463;463;463;463;463;334;330;330;330;330","MATTEO TEBALDI;YURI BATTAGLIA;ANTONIO BARILLÀ;LUIGI CATIZONE;GIANLUCA CAMPO;CARLO ALBERTO VOLTA;FRANCESCO FIORICA;SIMONE BISCAGLIA;ENRICO FAINARDI;SAVINO SPADARO;ELISABETTA MARANGONI;RICCARDO RAGAZZI;AMANDA J. NEVILLE;CHIARA ZAMBONI;VINCENZO BETTOLI;MARCELLO GOVONI;MASSIMO BORRELLI;ALESSANDRO DE VITO;CRISTIANO AZZINI;RITA PAVASINI","640;334;330;330;285;226;145;133;132;129;124;124;121;116;113;91;91;79;79;74","ANTONIO FRASSOLDATI;ENRICO FAINARDI;GIANLUCA CAMPO;ANTONIO CUNEO;CARLO ALBERTO VOLTA;GIAN MATTEO RIGOLIN;MATTEO TEBALDI;I. CARANDINA;MARIA RITA GAMBERINI;SAVINO SPADARO;SIMONE BISCAGLIA;BETTOLI;ILARIA CASETTA;RITA PAVASINI;VINCENZO BETTOLI;ELISABETTA MARANGONI;FEDERICA LANCIA;FRANCESCO CAVAZZINI;I. TOMA;LORENZO BELLUOMINI","8;7;6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;ENGINEERING;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;PSYCHOLOGY;MATHEMATICS;SOCIOLOGY;ECONOMICS;POLITICAL SCIENCE;ART;BUSINESS;ENVIRONMENTAL SCIENCE;HISTORY;MATERIALS SCIENCE;PHILOSOPHY","94;26;16;11;10;7;4;3;3;2;2;1;1;1;1;1;1","INTERNAL MEDICINE;PATHOLOGY;ONCOLOGY;SURGERY;CARDIOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;GENETICS;MECHANICAL ENGINEERING;NUCLEAR MEDICINE;PHYSICAL THERAPY;DERMATOLOGY;ENDOCRINOLOGY;IMMUNOLOGY;NURSING;PALEONTOLOGY;ANESTHESIA;BIOCHEMISTRY;PSYCHIATRY","73;19;17;17;15;15;14;14;13;11;9;9;7;7;7;7;7;6;6;6","CANCER;POPULATION;CLINICAL TRIAL;DISEASE;MYOCARDIAL INFARCTION;COHORT;CONFIDENCE INTERVAL;GENE;THALASSEMIA;ACNE;MULTIVARIATE ANALYSIS;ODDS RATIO;QUALITY OF LIFE (HEALTHCARE);CHEMOTHERAPY;EPIDEMIOLOGY;LYMPHOMA;PREGNANCY;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;STROKE (ENGINE)","15;14;8;8;8;7;7;7;7;6;6;6;6;5;5;5;5;5;5;5","CLINICAL ENDPOINT;BREAST CANCER;UNIVARIATE ANALYSIS;COLORECTAL CANCER;PERCUTANEOUS CORONARY INTERVENTION;TYPE 2 DIABETES;CHRONIC LYMPHOCYTIC LEUKEMIA;DEFERASIROX;DEFERIPRONE;GENOTYPE;HIDRADENITIS SUPPURATIVA;ISCHEMIC STROKE;ALLELE;ANAPLASTIC LARGE-CELL LYMPHOMA;AUTOANTIBODY;BETA THALASSEMIA;BONE MINERAL;CEREBRAL BLOOD VOLUME;CHROMOSOME;CONVENTIONAL PCI;CYCLOPHOSPHAMIDE;DEMENTIA;GESTATIONAL AGE;HODGKIN LYMPHOMA;IMATINIB;INTEGRATIVE MEDICINE;MUTATION;PERFUSION SCANNING;POISSON REGRESSION;REVASCULARIZATION;RITUXIMAB;TIDAL VOLUME;VIRAL LOAD","7;6;6;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","IGHV@;MODIFIED RANKIN SCALE;ANTIRETROVIRAL THERAPY;BRENTUXIMAB VEDOTIN;FLUDARABINE;FLUORESCENCE IN SITU HYBRIDIZATION;IMATINIB MESYLATE;IRINOTECAN;KARYOTYPE;TRASTUZUMAB;ABATACEPT;ACTIVE TUBERCULOSIS;ANTHRACYCLINE;BASAL GANGLIA DISEASE;BENZOYL PEROXIDE;BREAKPOINT;CAPECITABINE;CETUXIMAB;CHLORAMBUCIL;CLASSICAL HODGKIN LYMPHOMA;DASATINIB;DIFFUSION IMAGING;DRUG-ELUTING STENT;DUCTAL CARCINOMA;DYNAMIC HYPERINFLATION;ENTHESITIS;FRACTIONAL FLOW RESERVE;FRAGILITY FRACTURE;GENE MUTATION;GENOTYPING;GIANT CELL ARTERITIS;HMG-COA REDUCTASE;INEFFECTIVE ERYTHROPOIESIS;INTERLEUKIN 12;INTERLEUKIN 21;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KRAS;LDL RECEPTOR;MEAN TRANSIT TIME;METASTATIC BREAST CANCER;MICROSATELLITE;NEONATAL RESPIRATORY DISTRESS SYNDROME;NILOTINIB;OSTEOPOROTIC FRACTURE;OXALIPLATIN;PAPULOPUSTULAR;PATELLAR LIGAMENT;PRENATAL DIAGNOSIS;QUANTITATIVE COMPUTED TOMOGRAPHY;RUXOLITINIB;SINGLE-NUCLEOTIDE POLYMORPHISM;SOLITARY FIBROUS TUMOR;TAXANE;TICAGRELOR;TICLOPIDINE;TRIPLE-NEGATIVE BREAST CANCER;TUMOR-INFILTRATING LYMPHOCYTES;V600E;VASCULAR DEMENTIA","3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ADULT;ITALY;STROKE;DIABETES MELLITUS, TYPE 2;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;PERCUTANEOUS CORONARY INTERVENTION;PROSPECTIVE STUDIES;AGED, 80 AND OVER;HIV INFECTIONS;RISK FACTORS;TIME FACTORS;TREATMENT OUTCOME;ACUTE CORONARY SYNDROME;BIOMARKERS","55;47;46;43;36;32;25;15;14;12;12;11;11;9;9;9;9;9;8;8","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;IMMUNOLOGICAL MECHANISMS IN ATHEROSCLEROSIS DEVELOPMENT;MANAGEMENT AND PATHOPHYSIOLOGY OF ACNE AND ROSACEA;TREATMENT AND PATHOGENESIS OF HIDRADENITIS SUPPURATIVA;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CHOLESTEROL-LOWERING TREATMENT;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;HEALTH RISKS OF MEDICAL IMAGING RADIATION EXPOSURE;HERBAL MEDICINE USE AND SAFETY MONITORING;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;LYMPHOID NEOPLASMS;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;ACUTE MYELOID LEUKEMIA","6;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1","CLINICAL ENDPOINT;UNIVARIATE ANALYSIS;POSITIVE END-EXPIRATORY PRESSURE;STROKE (ENGINE);REGIMEN;ACNE INVERSA;CANCER THERAPY;CARDIAC IMAGING;DEFERASIROX;DEFERIPRONE;HIDRADENITIS SUPPURATIVA;IGHV@;PRESENTATION (OBSTETRICS);REFRACTORY (PLANETARY SCIENCE);SIDEROSIS;ALTERNATIVE MEDICINE;ANAPLASTIC LARGE-CELL LYMPHOMA;ANGIOLOGY;BETA THALASSEMIA;BRENTUXIMAB VEDOTIN","7;6;5;5;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2","CANCER PATIENTS;OBSERVATIONAL STUDY;PATIENTS TREATED;TYPE DIABETES;ACUTE ISCHEMIC;BREAST CANCER;CLINICAL TRIAL;ISCHEMIC STROKE;MULTIPLE SCLEROSIS;PROSPECTIVE STUDY;THALASSEMIA MAJOR;ABDOMINAL SURGERY;ACNE MECHANICA;ALTERNATIVE MEDICINE;ATI SCORE;BRENTUXIMAB VEDOTIN;CARDIAC IRON;CHRONIC LYMPHOCYTIC;CHRONIC MYELOID;ELEVATION MYOCARDIAL;EXPIRATORY FLOW;HIDRADENITIS SUPPURATIVA-ACNE;INTERVENTIONAL PROCEDURES;ITALIAN MULTICENTER;ITALIAN REAL;LIFE EXPERIENCE;LIVER IRON;LYMPHOCYTIC LEUKEMIA;MATRIX METALLOPROTEINASE-;MECHANICA PROBABLE","4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BETHESDA SYSTEM;REPORTING THYROID;THYROID CYTOPATHOLOGY;CYTOPATHOLOGY CLASS;EXPIRATORY FLOW;SERUM CHOLESTEROL;ANTI-APOA- IGG;CARDIAC INVOLVEMENT;RISK FACTORS;CONFIDENCE INTERVAL;FLOW LIMITATION;POSTOPERATIVE PULMONARY;RECEIVING TREATMENT;TOTAL SERUM;ACTIVE MMP-;CTP ASPECTS;EBSTEINS ANOMALY;ITALY DEPARTMENT;MECHANICAL VENTILATION;MEDIAN AGE;PULMONARY COMPLICATIONS;SKIN REACTIONS;STAGE II;ACTIVE TB;BASAL GANGLIA;BRAF MUTATION;CLASS III;EDUCATIONAL LEVEL;III- III-;ISCHEMIC LGE","13;13;13;11;9;9;8;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5",32,0.33,9.31,6,2.75,1.5,0,8,0,0,1,7.25,1,0,5,0,0,1,1.25,4,4,0,0,111,111,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,4.48,438.67,12.65,5,0.24,34.62,0,0,4,0,3,0,1,13,0,12,9,0,0,0,0,0,0,19,0,2,21,0,0,0,0,0,0,0,0,0,"United States;Canada;Italy","4;2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;3208 MEDICAL PHYSIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;51 PHYSICAL SCIENCES","18;8;7;3;3;3;2;2;1","CLINICAL RESEARCH;RARE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BIOENGINEERING;CANCER;CARDIOVASCULAR;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HEMATOLOGY;LUNG;ASSISTIVE TECHNOLOGY;ATHEROSCLEROSIS;PATIENT SAFETY;PEDIATRIC;BIOMEDICAL IMAGING;BRAIN DISORDERS;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);LYMPHOMA;MUSCULAR DYSTROPHY;NEUROSCIENCES","20;12;8;7;7;6;6;5;5;5;4;4;4;3;2;2;2;2;2;2","CANCER;CARDIOVASCULAR;RESPIRATORY","5;5;2","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;5.3 MEDICAL DEVICES;6.4 SURGERY","9;4;1;1;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;HEAD AND NECK CANCER;NON-HODGKIN'S LYMPHOMA;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER","5;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","6",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"PUBLIC LIBRARY OF SCIENCE","8","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3107 MICROBIOLOGY;3207 MEDICAL MICROBIOLOGY;41 ENVIRONMENTAL SCIENCES;44 HUMAN SOCIETY;4403 DEMOGRAPHY","11;5;4;3;1;1;1;1","STROKE;BRAIN DISORDERS;NEUROSCIENCES;ANTIMICROBIAL RESISTANCE;BIOMEDICAL IMAGING;CLINICAL RESEARCH;COMPLEMENTARY AND INTEGRATIVE HEALTH;INFECTIOUS DISEASES;PREVENTION","4;3;2;1;1;1;1;1;1","STROKE;INFECTION","5;2",NA,NA,"CLINICAL","2","CLINICAL MEDICINE AND SCIENCE;HEALTH SERVICES RESEARCH","5;1",NA,NA,NA,NA
"AOU_FERRARA",2017,96,17.75,3.3125,0.3125,0.229166666666667,0.302083333333333,1.63076923076923,1.07142857142857,1.375,1.03571428571429,0.677083333333333,1,53,19,8,8,0.55,0.2,0.08,0.08,21.26,0.721302701271697,3.97641509433962,0.385416666666667,0.927083333333333,0.363,0.325,0.41,0.338,"ANTONIO FRASSOLDATI;FRANCESCO CAVAZZINI;MARCELLO GOVONI;ANTONIO CUNEO;SAVINO SPADARO;GIAN MATTEO RIGOLIN;GIANLUCA CAMPO;ROBERTO FERRARI;FABIO SILVIO TACCONE;MATTEO BERTINI;MARCO VALGIMIGLI;I. TOMA;DIK HEG;LORENZO BELLUOMINI;LUCA MARTELLA;FEDERICA LANCIA;MATTEO TEBALDI;MASSIMO NEGRINI;V PEREZ FONTANA;PAOLO CALABRÒ","13;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3","I PORTIOLI;ANTONIO FRASSOLDATI;MARCELLO GOVONI;ROBERTO FERRARI;SAVINO SPADARO;GIANLUCA CAMPO;MATTEO BERTINI;FABIO SILVIO TACCONE;V PEREZ FONTANA;ANTONIO CUNEO;ALESSANDRO BORGHI;ANNAROSA VIRGILI;MONICA CORAZZA;FRANCESCO CAVAZZINI;ANNAMARIA DEL FRANCO;FRANCESCO GALLO;MATTEO TEBALDI;MICHELE MALAGÙ;LUCA MARTELLA;FEDERICA LANCIA","1;0.81;0.66;0.52;0.49;0.45;0.4;0.39;0.39;0.38;0.37;0.37;0.37;0.35;0.35;0.35;0.34;0.33;0.33;0.33","ANTONIO FRASSOLDATI;FRANCESCO CAVAZZINI;MARCELLO GOVONI;ANTONIO CUNEO;SAVINO SPADARO;GIAN MATTEO RIGOLIN;GIANLUCA CAMPO;ROBERTO FERRARI;MATTEO BERTINI;I. TOMA;LORENZO BELLUOMINI;LUCA MARTELLA;FEDERICA LANCIA;MATTEO TEBALDI;V PEREZ FONTANA;CRISTIAN BASSI;LUCA FORMIGARO;MAURIZIO CAVALLARI;MARIACHIARA SENSI;ANNAMARIA DEL FRANCO","13;6;6;6;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3","I PORTIOLI;ANTONIO FRASSOLDATI;MARCELLO GOVONI;ROBERTO FERRARI;SAVINO SPADARO;GIANLUCA CAMPO;MATTEO BERTINI;V PEREZ FONTANA;ANTONIO CUNEO;MONICA CORAZZA;FRANCESCO CAVAZZINI;ANNAMARIA DEL FRANCO;FRANCESCO GALLO;MATTEO TEBALDI;MICHELE MALAGÙ;LUCA MARTELLA;FEDERICA LANCIA;I. TOMA;VINCENZO LORUSSO;GAETANO CARUSO","1;0.81;0.66;0.52;0.49;0.45;0.4;0.39;0.38;0.37;0.35;0.35;0.35;0.34;0.33;0.33;0.33;0.32;0.31;0.31","MARCO CONTOLI;AMANDA J. NEVILLE;ANKE RIßMANN;DAVID TUCKER;ESTER GARNE;HANITRA RANDRIANAIVO;HELEN DOLK;INGEBORG BARIŠIĆ;MARIE‐CLAUDE ADDOR;VERA NELEN;GAETANO CARAMORI;PAOLO CASOLARI;ALBERTO PAPI;ANNA LATOS‐BIELEŃSKA;ANNETTE QUEIßER-WAHRENDORF;ANNUKKA RITVANEN;BEN WREYFORD;BOB MCDONNELL;BREIDGE BOYLE;CARLOS MATIAS DIAS","241;211;211;211;211;211;211;211;211;211;194;194;189;176;176;176;176;176;176;176","AMANDA J. NEVILLE;MARIA RITA ROSSI;FRANCESCO CAVAZZINI;GIANLUCA CAMPO;ILARIA CASETTA;MARIO MANCA;ROBERTA ROSSI;MARCELLO GOVONI;MATTEO TEBALDI;ANTONIO FRASSOLDATI;PIO MANISCALCO;SAVINO SPADARO;GIORGIA VALPIANI;NINO BASAGLIA;P. MARCHI;VINCENZO LORUSSO;MARIA ROSARIA TOLA;MARIACHIARA SENSI;ROBERTO FERRARI;ALESSANDRO DE VITO","211;142;118;116;114;109;105;99;98;94;94;93;89;88;88;88;77;77;74;73","ANTONIO FRASSOLDATI;ANTONIO CUNEO;FRANCESCO CAVAZZINI;GIAN MATTEO RIGOLIN;GIANLUCA CAMPO;I. TOMA;MARCELLO GOVONI;SAVINO SPADARO;FEDERICA LANCIA;LUCA MARTELLA;MATTEO BERTINI;MATTEO TEBALDI;ROBERTO FERRARI;LORENZO BELLUOMINI;AMANDA J. NEVILLE;ANNAMARIA DEL FRANCO;CARLO ALBERTO VOLTA;ELENA SACCENTI;FRANCESCO GALLO;ILARIA FARINA","13;6;6;5;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;MATHEMATICS;PSYCHOLOGY;CHEMISTRY;COMPUTER SCIENCE;POLITICAL SCIENCE;ART;ECONOMICS;PHILOSOPHY;SOCIOLOGY;BUSINESS;GEOLOGY","93;26;10;7;6;6;4;4;4;3;3;3;2;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;GENETICS;IMMUNOLOGY;PEDIATRICS;ANESTHESIA;ENDOCRINOLOGY;MECHANICAL ENGINEERING;PATHOLOGY;PHYSICAL THERAPY;CANCER RESEARCH;GASTROENTEROLOGY;PALEONTOLOGY;PSYCHIATRY;INTENSIVE CARE MEDICINE;LAW;OPTICS","74;24;18;14;14;14;11;9;6;6;6;6;6;5;5;5;5;4;4;4","CANCER;POPULATION;DISEASE;GENE;MYOCARDIAL INFARCTION;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;LEUKEMIA;CLINICAL TRIAL;CHEMOTHERAPY;COHORT;CONFIDENCE INTERVAL;REGIMEN;RETROSPECTIVE COHORT STUDY;RHEUMATOLOGY;ARTERY;CONTEXT (ARCHAEOLOGY);HEART FAILURE;INCIDENCE (GEOMETRY);PREGNANCY;RHEUMATOID ARTHRITIS;STROKE (ENGINE)","16;13;10;9;9;8;7;7;6;5;5;5;5;5;5;4;4;4;4;4;4;4","CLINICAL ENDPOINT;BREAST CANCER;CHRONIC LYMPHOCYTIC LEUKEMIA;PERCUTANEOUS CORONARY INTERVENTION;HAZARD RATIO;IMMUNOTHERAPY;IMATINIB;MICRORNA;PARKINSON'S DISEASE;RADIAL ARTERY;ACUTE CORONARY SYNDROME;CHROMOSOME;CLOPIDOGREL;EJECTION FRACTION;OVERWEIGHT;PLACEBO;PROSTATE CANCER;PSORIATIC ARTHRITIS;VIRAL LOAD;WNT SIGNALING PATHWAY","8;7;6;6;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2","ESTROGEN RECEPTOR;METASTATIC BREAST CANCER;NIVOLUMAB;ANTIRETROVIRAL THERAPY;AROMATASE;BONE METASTASIS;CARDIAC RESYNCHRONIZATION THERAPY;CYTOGENETICS;IGHV@;KARYOTYPE;LEVODOPA;TRASTUZUMAB;ABATACEPT;ACE INHIBITOR;ADENOSINE RECEPTOR;ANTHRACYCLINE;ANTISYNTHETASE SYNDROME;AUTOIMMUNE THYROIDITIS;BIORESORBABLE SCAFFOLD;BRAIN METASTASIS;CD38;CHILDLESSNESS;CONCURRENT VALIDITY;CONVERGENT VALIDITY;DEEP BRAIN STIMULATION;DIGITAL POLYMERASE CHAIN REACTION;EXCESS WEIGHT;FOLLICLE-STIMULATING HORMONE;GASTROSCHISIS;GENE EXPRESSION PROFILING;HOX GENE;HYPERTRIGLYCERIDEMIA;IBRUTINIB;IMATINIB MESYLATE;KRAS;MACE;MCL1;MICROARRAY;MICROARRAY ANALYSIS TECHNIQUES;NEOADJUVANT THERAPY;NILOTINIB;P2Y12;PEER VICTIMIZATION;POINT MUTATION;QUALITY MANAGEMENT SYSTEM;REGORAFENIB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RETURN OF SPONTANEOUS CIRCULATION;RYANODINE RECEPTOR 2;SANGER SEQUENCING;SHORT QT SYNDROME;SPECKLE TRACKING ECHOCARDIOGRAPHY;SYSTEMIC THERAPY;TAKAYASU ARTERITIS;TAMOXIFEN;TAXANE;TICAGRELOR;TOTAL THYROIDECTOMY","4;4;4;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;;MALE;MIDDLE AGED;AGED;ADULT;ITALY;STROKE;TREATMENT OUTCOME;AGED, 80 AND OVER;HIV INFECTIONS;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;PERCUTANEOUS CORONARY INTERVENTION;PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;RETROSPECTIVE STUDIES;ADOLESCENT;ARTHRITIS, RHEUMATOID;BIOMARKERS;BRAIN ISCHEMIA","55;47;41;40;38;28;19;19;14;14;12;12;12;11;10;10;9;9;9;9","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;VASCULAR ACCESS FOR CORONARY PROCEDURES AND TRAUMA MANAGEMENT;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;EFFICACY AND RESISTANCE IN CML TREATMENT;INFLAMMATION'S ROLE IN CANCER DEVELOPMENT AND PROGRESSION;RHEUMATOID ARTHRITIS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CANCER IMMUNOTHERAPY;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;MANAGEMENT OF BRAIN METASTASES IN CANCER PATIENTS;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;STANDARDISATION AND MANAGEMENT OF COPD;;ACCURACY OF CLINICAL CODING IN HEALTHCARE DATA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH","5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1","CLINICAL ENDPOINT;BREAST CANCER;REGIMEN;FULVESTRANT;STROKE (ENGINE);TRANSRADIAL APPROACH;CANCER THERAPY;CARDIAC RESYNCHRONIZATION THERAPY;DISCONTINUATION;NEUTROPHIL-TO-LYMPHOCYTE RATIO;RADIAL ACCESS;ALPHA PARTICLE THERAPY;ANTIRETROVIRAL THERAPY;BIOMARKERS FOR IMMUNOTHERAPY;BRAIN METASTASES;CARDIAC CATHETERIZATION;DIAGNOSIS;ETIOLOGY;EXEMESTANE;EXPANDED ACCESS","8;5;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2","BREAST CANCER;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;CLINICAL PRACTICE;RHEUMATOID ARTHRITIS;CHRONIC MYELOID;EXPANDED ACCESS;LEUKEMIA PATIENTS;MYELOID LEUKEMIA;OBSERVATIONAL STUDY;RETROSPECTIVE STUDY;ACCESS PROGRAM;ACUTE CORONARY;ADVANCED BREAST;ADVANCED NON-SQUAMOUS;ARTERY DISEASE;BIORESORBABLE VASCULAR;BRAIN METASTASES;CARDIAC RESYNCHRONIZATION;CELL DISTRIBUTION;CLINICAL EXPERIENCE;CLINICAL TRIALS;COLORECTAL CANCER;CORONARY ARTERY;CORONARY SYNDROMES;CYTOGENETIC CHARACTERIZATION;DISTRIBUTION WIDTH;ELECTROMYOGRAPHIC ACTIVITY;EXTENSIVE MOLECULAR;HIGH-RISK CHRONIC","6;6;6;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","OSPEDALIERO-UNIVERSITARIA ARCISPEDALE;ARCISPEDALE SANTANNA;AZ OSPEDALIERO-UNIVERSITARIA;CONA FERRARA;NEUROLOGY DEPARTMENT;SANTANNA CONA;DEPARTMENT AZ;FEMORAL ACCESS;FERRARA ITALYSEARCH;MEDIAN AGE;HR CI;RADIAL ACCESS;BMI Z-SCORE;CONGENITAL ANOMALY;PATIENTS TREATED;PEER VICTIMIZATION;ADVERSE EVENTS;ANTI PL-;PRIMARY MALIGNANCIES;PTS RECEIVED;STABLE COPD;CLINICAL TRIALS;FERRARA ITALY;AOR CI;BREAST CANCER;PATIENTS PTS;POSITIVE PATIENTS;PRIMARY ENDPOINT;TIP-APEX DISTANCE;CHRONIC MYELOID","17;16;16;16;16;16;14;13;12;11;10;10;9;9;9;9;8;8;8;8;8;7;7;6;6;6;6;6;6;5",34,0.35,4.8,4,1.5,1,1,4.5,1,0,0,4.75,0,1,4,0,1,2,3.5,3,6.75,0,0,72.75,72.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,5,1016.23,11.7,6,0.27,48.14,0,0,2,0,3,0,1,16,0,13,9,0,0,0,0,0,0,21,1,0,22,0,0,0,0,0,0,0,0,0,"United States;Italy;Denmark;Germany;Japan;Turkey","3;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;4012 FLUID MECHANICS AND THERMAL ENGINEERING;4202 EPIDEMIOLOGY","21;14;5;4;3;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CARDIOVASCULAR;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEART DISEASE;PATIENT SAFETY;CANCER;BIOENGINEERING;HEART DISEASE - CORONARY HEART DISEASE;ASSISTIVE TECHNOLOGY;ATHEROSCLEROSIS;RARE DISEASES;BIOMEDICAL IMAGING;LUNG;PREVENTION;ACUTE RESPIRATORY DISTRESS SYNDROME;AGING;BREAST CANCER;DIGESTIVE DISEASES;HEMATOLOGY;BRAIN DISORDERS","20;13;13;12;12;7;6;6;5;5;4;3;3;3;2;2;2;2;2;1","CARDIOVASCULAR;CANCER;RESPIRATORY;INJURIES AND ACCIDENTS;STROKE","12;4;2;1;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;6.3 MEDICAL DEVICES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.3 MEDICAL DEVICES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS;8.4 RESEARCH DESIGN AND METHODOLOGIES (HEALTH SERVICES)","6;6;3;2;2;1;1;1;1","BREAST CANCER;LUNG CANCER;COLON AND RECTAL CANCER;KIDNEY CANCER;LEUKEMIA / LEUKAEMIA;MYELOMA","2;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;3.3 CHEMOPREVENTION;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","4;3;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;SCIELO JOURNALS","11;2;1","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;40 ENGINEERING;3105 GENETICS;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;4006 COMMUNICATIONS ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3103 ECOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;4007 CONTROL ENGINEERING, MECHATRONICS AND ROBOTICS;44 HUMAN SOCIETY;4403 DEMOGRAPHY","11;8;5;4;4;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;COOLEY'S ANEMIA;GENETICS;HEMATOLOGY;PREVENTION;PROSTATE CANCER;RARE DISEASES;REHABILITATION;UROLOGIC DISEASES","2;1;1;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","1;1","7.1 INDIVIDUAL CARE NEEDS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","3;1","CLINICAL;BIOMEDICAL","2;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","5;1","PROSTATE CANCER","1",NA,NA
"AOU_FERRARA",2018,103,16.4757281553398,2.30097087378641,0.233009708737864,0.213592233009709,0.563106796116505,1.71739130434783,1.2,1.29411764705882,1.20833333333333,0.660194174757282,2,51,22,11,9,0.5,0.21,0.11,0.09,23.32,0.764396026666459,4.00216919739696,0.398058252427184,0.970873786407767,0.436,0.307,0.399,0.369,"GIANLUCA CAMPO;ANTONIO CUNEO;ANTONIO FRASSOLDATI;ROBIN FOÀ;FRANCESCO CAVAZZINI;GIAN MATTEO RIGOLIN;ANKE RIßMANN;LIVIO TRENTIN;ESTER GARNE;GIANPIETRO SEMENZATO;ROBERTO FERRARI;AMANDA J. NEVILLE;MATTIA ANDREOTTI;ALESSANDRA IURLO;FRANCESCA ROMANA MAURO;SAVINO SPADARO;RITA PAVASINI;SIMONE BISCAGLIA;ROBERTO DE GIORGIO;GAETANO CARUSO","13;8;7;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4","VINCENZO GASBARRO;LUCIANO FEGGI;GIANLUCA CAMPO;MATTIA ANDREOTTI;GAETANO CARUSO;LEO MASSARI;RICCARDO RAGAZZI;GIUSEPPE MAGGIORE;FEDERICO PICCIONI;PANTALEO GRECO;GENNARO SCUTIERO;MARCO SCIVERES;SILVIA NASTASIO;ANTONIO FRASSOLDATI;SILVIA VERTUANI;STEFANO MANFREDINI;FRANCESCO TONON;RITA PAVASINI;ROBERTO FERRARI;ANTONIO FARINA","1;1;0.94;0.69;0.69;0.69;0.67;0.52;0.5;0.5;0.5;0.48;0.48;0.45;0.42;0.42;0.4;0.38;0.38;0.37","GIANLUCA CAMPO;ANTONIO CUNEO;ANTONIO FRASSOLDATI;FRANCESCO CAVAZZINI;GIAN MATTEO RIGOLIN;ROBERTO FERRARI;AMANDA J. NEVILLE;MATTIA ANDREOTTI;SAVINO SPADARO;RITA PAVASINI;SIMONE BISCAGLIA;ROBERTO DE GIORGIO;GAETANO CARUSO;LEO MASSARI;MATTEO TEBALDI;GIOSAFAT SPITALERI;MARIA RITA GAMBERINI;MARCO CONTOLI;MARIA SESSA;MATTEO BERTINI","13;8;7;6;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3","VINCENZO GASBARRO;LUCIANO FEGGI;GIANLUCA CAMPO;MATTIA ANDREOTTI;GAETANO CARUSO;LEO MASSARI;RICCARDO RAGAZZI;GIUSEPPE MAGGIORE;PANTALEO GRECO;GENNARO SCUTIERO;SILVIA NASTASIO;ANTONIO FRASSOLDATI;SILVIA VERTUANI;STEFANO MANFREDINI;FRANCESCO TONON;RITA PAVASINI;ROBERTO FERRARI;DANILA MORANO;MASSIMO PEDRIALI;ANGELINA PASSARO","1;1;0.94;0.69;0.69;0.69;0.67;0.52;0.5;0.5;0.48;0.45;0.42;0.42;0.4;0.38;0.38;0.37;0.37;0.36","GIANLUCA CAMPO;MATTEO TEBALDI;ANKE RIßMANN;ESTER GARNE;ASHKAN EFTEKHARI;BIRGITTE KROGSGAARD ANDERSEN;CHRISTOPH NABER;DOMENICO DI GIROLAMO;EVALD HØJ CHRISTIANSEN;FEDERICO RONCO;G MERCONE;GIOVANNI ESPOSITO;HANS ERIK BØTKER;HERNÁN MEJÍA‐RENTERÍA;HITOSHI MATSUO;HOLGER NEF;JANUSZ KOCHMAN;JAVIER ESCANED;JELMER WESTRA;LUIGI DI SERAFINO","659;434;329;329;328;328;328;328;328;328;328;328;328;328;328;328;328;328;328;328","GIANLUCA CAMPO;MATTEO TEBALDI;AMANDA J. NEVILLE;ANTONIO FRASSOLDATI;SIMONE BISCAGLIA;MONICA SPROCATI;SILVIA VERTUANI;STEFANO MANFREDINI;ROBERTO FERRARI;FRANCESCO GALLO;VERONICA LODOLINI;GIAN MATTEO RIGOLIN;RICCARDO RAGAZZI;RITA PAVASINI;SAVINO SPADARO;CARLO ALBERTO VOLTA;GIUSEPPE MAGGIORE;ANTONIO CUNEO;AMEDEO ZURLO;ROBERTO DE GIORGIO","633;434;291;171;156;122;120;120;112;103;95;93;89;87;85;81;81;80;76;71","GIANLUCA CAMPO;ANTONIO FRASSOLDATI;FRANCESCO CAVAZZINI;AMANDA J. NEVILLE;GIAN MATTEO RIGOLIN;ANTONIO CUNEO;GAETANO CARUSO;LEO MASSARI;MATTEO TEBALDI;MATTIA ANDREOTTI;RITA PAVASINI;ROBERTO DE GIORGIO;ROBERTO FERRARI;SAVINO SPADARO;SIMONE BISCAGLIA;ELISABETTA TONET;CARLO ALBERTO VOLTA;GIUSEPPE MAGGIORE;MATTEO BERTINI;RICCARDO RAGAZZI","12;7;6;5;5;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3","MEDICINE;BIOLOGY;ENGINEERING;PHYSICS;CHEMISTRY;MATHEMATICS;PSYCHOLOGY;SOCIOLOGY;COMPUTER SCIENCE;ECONOMICS;GEOLOGY;PHILOSOPHY;POLITICAL SCIENCE","99;27;12;11;9;4;4;4;3;3;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;SURGERY;GENETICS;ENVIRONMENTAL HEALTH;ONCOLOGY;PATHOLOGY;IMMUNOLOGY;PEDIATRICS;PHYSICAL THERAPY;BIOCHEMISTRY;MECHANICAL ENGINEERING;RADIOLOGY;ANESTHESIA;GASTROENTEROLOGY;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;CANCER RESEARCH;EMERGENCY MEDICINE;NUCLEAR MEDICINE;OPTICS;PHARMACOLOGY","78;26;21;18;17;17;15;14;14;11;9;9;9;8;8;7;5;4;4;4;4;4","POPULATION;DISEASE;MYOCARDIAL INFARCTION;GENE;COHORT;CANCER;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;LEUKEMIA;OBSERVATIONAL STUDY;PREGNANCY;STROKE (ENGINE);ADVERSE EFFECT;ARTERY;CHEMOTHERAPY;ENZYME;STENT;ULTRASOUND;ANTIBODY;ATRIAL FIBRILLATION;BLOOD PRESSURE;BONE MARROW;CLINICAL TRIAL;COHORT STUDY;COPD;DISCONTINUATION;HEART FAILURE;HEPATITIS;IMMUNOHISTOCHEMISTRY;INCIDENCE (GEOMETRY);INFLAMMATION;LYMPHOMA;MAGNETIC RESONANCE IMAGING;MECHANICAL VENTILATION;NEUROLOGY;PROSPECTIVE COHORT STUDY;RETROSPECTIVE COHORT STUDY;STENOSIS;THALASSEMIA","16;14;14;12;9;8;7;6;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","CLINICAL ENDPOINT;BREAST CANCER;CHRONIC LYMPHOCYTIC LEUKEMIA;PERCUTANEOUS CORONARY INTERVENTION;MUTATION;CHROMOSOME;CORONARY ANGIOGRAPHY;DEFERASIROX;FETUS;FIXATION (POPULATION GENETICS);HAZARD RATIO;MYELOFIBROSIS;PHENOTYPE;RESTENOSIS;THROMBOLYSIS;ACUTE CORONARY SYNDROME;ALLELE;ARTERIAL DISEASE;AUTOANTIBODY;AUTOIMMUNE HEPATITIS;AZATHIOPRINE;DEFERIPRONE;DEMENTIA;EJECTION FRACTION;HEART RATE;IMMUNOTHERAPY;IMPUTATION (STATISTICS);INTERSTITIAL CELL OF CAJAL;INTRACEREBRAL HEMORRHAGE;IONIZING RADIATION;KAWASAKI DISEASE;KYPHOSIS;NEURORADIOLOGY;PRESSURE SUPPORT VENTILATION;REVASCULARIZATION;SYSTEMIC INFLAMMATION;TIDAL VOLUME","7;5;5;5;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","RUXOLITINIB;TRASTUZUMAB;CLAUDICATION;ESTROGEN RECEPTOR;FRACTIONAL FLOW RESERVE;IGHV@;KARYOTYPE;ABLATION OF ATRIAL FIBRILLATION;ADIPOKINE;ANEUPLOIDY;AROMATASE;BARE METAL;BIORESORBABLE SCAFFOLD;BRADYCARDIA;CATHEPSIN G;CORONARY RESTENOSIS;CTGF;DIGITAL POLYMERASE CHAIN REACTION;DRUG-ELUTING STENT;ENOS;ENTEROENDOCRINE CELL;EVANS SYNDROME;EXOME SEQUENCING;FEBRILE NEUTROPENIA;GENETIC HETEROGENEITY;GERMLINE MUTATION;HEME OXYGENASE;HEPATITIS A VACCINE;IBRUTINIB;INTERMITTENT CLAUDICATION;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;LEUKOARAIOSIS;LEVODOPA;LIPOPROTEIN(A);LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2;LONG NON-CODING RNA;MACE;METASTATIC BREAST CANCER;MICROARRAY;MIGRAINE WITH AURA;MITOCHONDRIAL PERMEABILITY TRANSITION PORE;MODIFIED RANKIN SCALE;MPTP;NEOADJUVANT THERAPY;NEOINTIMA;NILOTINIB;NIVOLUMAB;OMPHALOCELE;OSWESTRY DISABILITY INDEX;P2Y12;PAPILLARY THYROID CANCER;POINT MUTATION;PRENATAL DIAGNOSIS;RESPIRATORY RATE;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RIGHT CORONARY ARTERY;RUBELLA;SINGLE-NUCLEOTIDE POLYMORPHISM;SPECKLE TRACKING ECHOCARDIOGRAPHY;SPONTANEOUS INTRACEREBRAL HEMORRHAGE;STAPHYLOCOCCUS;TERIFLUNOMIDE;THORACIC VERTEBRAE;TICAGRELOR;TRIPLE-NEGATIVE BREAST CANCER;TUMOR-INFILTRATING LYMPHOCYTES;VACCINE-PREVENTABLE DISEASES","3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;;MALE;AGED;MIDDLE AGED;ITALY;TREATMENT OUTCOME;PERCUTANEOUS CORONARY INTERVENTION;ADULT;RISK FACTORS;TIME FACTORS;STROKE;AGED, 80 AND OVER;PROSPECTIVE STUDIES;CORONARY STENOSIS;RETROSPECTIVE STUDIES;PERIPHERAL ARTERIAL DISEASE;ARRHYTHMIAS, CARDIAC;BETA-THALASSEMIA","59;45;41;41;30;22;20;18;17;14;13;13;12;11;11;10;10;9;8;8","CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ATRIAL FIBRILLATION;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;DIAGNOSIS AND MANAGEMENT OF KAWASAKI DISEASE;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;ETIOLOGY AND MANAGEMENT OF ABDOMINAL WALL DEFECTS;HEALTH ECONOMICS AND QUALITY OF LIFE ASSESSMENT;MANAGEMENT AND TREATMENT OF PERIPHERAL ARTERIAL DISEASE;PATHOPHYSIOLOGY AND MANAGEMENT OF PREECLAMPSIA;PEDIATRIC URINARY TRACT INFECTIONS;PRENATAL ANEUPLOIDY DIAGNOSIS AND SCREENING TECHNIQUES;RHEUMATOID ARTHRITIS;SPINE SURGERY TECHNIQUES AND TECHNOLOGIES;ACCURACY OF CLINICAL CODING IN HEALTHCARE DATA","6;6;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1","CLINICAL ENDPOINT;STROKE (ENGINE);TREATMENT;CARDIOVASCULAR RISK ASSESSMENT;COPD;DEFERASIROX;DISCONTINUATION;MYELOFIBROSIS;POSITIVE END-EXPIRATORY PRESSURE;RUXOLITINIB;RUXOLITINIB THERAPY;ANTICOAGULANT THERAPY;AORTIC ROOT REPLACEMENT;AUTOIMMUNE HEPATITIS;BREAST CANCER;CARDIAC IMAGING;CLAUDICATION;COST-EFFECTIVENESS ANALYSIS;DEFERIPRONE;DISEASE-MODIFYING ANTIRHEUMATIC DRUGS","7;5;5;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","BREAST CANCER;CHRONIC LYMPHOCYTIC;MYOCARDIAL INFARCTION;LYMPHOCYTIC LEUKEMIA;PATIENTS TREATED;CONGENITAL ANOMALIES;CORONARY ARTERY;LEUKEMIA PATIENTS;ST-SEGMENT ELEVATION;ACUTE CORONARY;ACUTE MYOCARDIAL;ACUTE PYELONEPHRITIS;ADVERSE EVENTS;AORTIC VALVE;ATRIAL FIBRILLATION;BOTULINUM TOXIN;CALCIUM PYROPHOSPHATE;CANCER PATIENTS;CELL-FREE DNA;CORONARY SYNDROME;DECISION SUPPORT;DEPOSITION DISEASE;ELDERLY PATIENTS;ELEVATION MYOCARDIAL;FLOW RESERVE;GENDER DIFFERENCES;HOME-BASED EXERCISE;ITALIAN COHORT;ITALIAN PROJECT;KAWASAKI DISEASE","5;5;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","SPEAKERS BUREAU;ADVISORY COMMITTEES;ENTITYS BOARD;ADVISORY BOARD;HONORARIA MEMBERSHIP;BOARD SPEAKERS;RESEARCH FUNDING;QUARTERLY COST;HR CI;FUNDING SPEAKERS;COMMITTEES RESEARCH;CLL PATIENTS;ELTS SCORE;ITALY UNIT;PATIENTS TREATED;RUX START;MMP- MMP-;SOKAL SCORE;BUREAU JANSSEN;LOW INTERMEDIATE;OVERT PMF;CLINICAL TRIAL;CONFIDENCE INTERVAL;CONGENITAL ANOMALY;ODDS RATIO;PATIENTS AGED;PHYSICAL PERFORMANCE;BONE MARROW;BRAFVE MUTATION;BREAST CANCER","59;46;46;34;34;24;19;16;15;12;11;10;10;10;10;10;9;9;8;8;8;7;7;7;7;7;7;6;6;6",44,0.43,7.25,7.25,1.25,1.75,2,2.5,2,0,1,8,1,0,6.75,0,2.25,1,1.5,5,2,0,0,58.5,58.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,4.4,539.87,11.9,5,0.33,82.93,0,0,1,0,6,0,0,8,0,11,4,0,0,0,0,0,0,14,1,0,15,0,0,0,0,0,0,0,0,0,"Japan;United Kingdom;Italy;Switzerland;United States","2;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;3213 PAEDIATRICS;4203 HEALTH SERVICES AND SYSTEMS;4207 SPORTS SCIENCE AND EXERCISE;47 LANGUAGE, COMMUNICATION AND CULTURE","13;9;5;2;2;2;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BRAIN DISORDERS;NEUROSCIENCES;RARE DISEASES;BREAST CANCER;HEMATOLOGY;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);NEURODEGENERATIVE;PEDIATRIC;AUTOIMMUNE DISEASE;CHILDHOOD LEUKEMIA;MULTIPLE SCLEROSIS;PEDIATRIC CANCER;BIOENGINEERING;CARDIOVASCULAR;CEREBRAL PALSY;DOWN SYNDROME;HEART DISEASE","12;9;9;5;4;4;3;3;3;3;3;2;2;2;2;1;1;1;1;1","CANCER;NEUROLOGICAL;CARDIOVASCULAR;REPRODUCTIVE HEALTH AND CHILDBIRTH","7;2;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES;6.7 PHYSICAL;7.1 INDIVIDUAL CARE NEEDS","8;1;1;1;1;1","BREAST CANCER;LEUKEMIA / LEUKAEMIA;CERVICAL CANCER;COLON AND RECTAL CANCER;LUNG CANCER;OVARIAN CANCER","3;3;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;1.4 CANCER PROGRESSION AND METASTASIS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","6;2;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,"PUBLIC LIBRARY OF SCIENCE;KARGER PUBLISHERS;SPRINGER NATURE","31;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;38 ECONOMICS;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;49 MATHEMATICAL SCIENCES;31 BIOLOGICAL SCIENCES;3801 APPLIED ECONOMICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3207 MEDICAL MICROBIOLOGY;3208 MEDICAL PHYSIOLOGY;52 PSYCHOLOGY;3107 MICROBIOLOGY;3215 REPRODUCTIVE MEDICINE;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;37 EARTH SCIENCES;3701 ATMOSPHERIC SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4904 PURE MATHEMATICS;4905 STATISTICS","32;12;11;5;5;5;3;3;2;2;2;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;AGING;AUTOIMMUNE DISEASE;BIOTECHNOLOGY;BRAIN DISORDERS;CARDIOVASCULAR;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;GENETICS;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HEPATITIS;HEPATITIS - C;HIV/AIDS;INFECTIOUS DISEASES;KIDNEY DISEASE;LIVER DISEASE;MULTIPLE SCLEROSIS","5;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;INFECTION;RESPIRATORY;NEUROLOGICAL;RENAL AND UROGENITAL","2;2;2;1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;7.1 INDIVIDUAL CARE NEEDS;8.2 HEALTH AND WELFARE ECONOMICS","1;1;1;1;1","CLINICAL;POPULATION & SOCIETY","8;1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH;HEALTH SERVICES RESEARCH","14;4;1","LIVER CANCER","1",NA,NA
"AOU_FERRARA",2019,95,19.2105263157895,2.42105263157895,0.2,0.136842105263158,0.2,1.88524590163934,1.11764705882353,1.3,1.05555555555556,0.71578947368421,0,48,23,4,10,0.51,0.24,0.04,0.11,46.84,1.92631995900066,4.49902152641878,0.421052631578947,1,0.368,0.383,0.438,0.409,"GIANLUCA CAMPO;MARCELLO GOVONI;ANTONIO CUNEO;ANTONIO FRASSOLDATI;SIMONE BISCAGLIA;ANDREA DORIA;ROBERTO FERRARI;ROBIN FOÀ;MARTA MOSCA;FEDERICA FURINI;MARIO TIRIBELLI;RITA PAVASINI;ELISA MAIETTI;MASSIMILIANO BONIFACIO;MASSIMO BRECCIA;STEFANO VOLPATO;MATTEO SERENELLI;MONICA CRUGNOLA;ALESSIA TIEGHI;ROSSELLA RUGGIERO","12;11;9;8;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4","GIANLUCA CAMPO;MARCELLO GOVONI;PANTALEO GRECO;TOMMASO MAURI;ELENA SPINELLI;FRANCESCA DALLA CORTE;ROBERTO FERRARI;ANTONIO FRASSOLDATI;FRANCESCO DI VIRGILIO;ANTONIO PESENTI;FEDERICA FURINI;SIMONE BISCAGLIA;ANDREA MOROTTI;ALESSANDRA BORTOLUZZI;ANTONIO CUNEO;ELISA MAIETTI;ENRICO FAINARDI;GIORGIO BUSTO;ANDREA BERNARDONI;SAVINO SPADARO","0.81;0.66;0.58;0.54;0.54;0.54;0.48;0.45;0.44;0.44;0.42;0.4;0.39;0.39;0.39;0.38;0.38;0.37;0.37;0.36","GIANLUCA CAMPO;MARCELLO GOVONI;ANTONIO CUNEO;ANTONIO FRASSOLDATI;SIMONE BISCAGLIA;ROBERTO FERRARI;FEDERICA FURINI;RITA PAVASINI;MATTEO SERENELLI;ROSSELLA RUGGIERO;SAVINO SPADARO;GIAN MATTEO RIGOLIN;ELISABETTA TONET;GIULIA BUGANI;FRANCESCA DALLA CORTE;MATTEO TEBALDI;PAOLO CIMAGLIA;ROSARIA CAPPADONA;ALESSANDRA BORTOLUZZI;FRANCESCO CAVAZZINI","12;11;9;8;6;6;5;5;4;4;4;4;4;4;4;4;4;3;3;3","GIANLUCA CAMPO;MARCELLO GOVONI;PANTALEO GRECO;FRANCESCA DALLA CORTE;ROBERTO FERRARI;ANTONIO FRASSOLDATI;FEDERICA FURINI;SIMONE BISCAGLIA;ALESSANDRA BORTOLUZZI;ANTONIO CUNEO;ANDREA BERNARDONI;SAVINO SPADARO;ROSARIA CAPPADONA;CLAUDIA GUIDUCCI;UGO INDRACCOLO;RITA PAVASINI;RICCARDO RAGAZZI;CARLO ALBERTO VOLTA;GIULIA BUGANI;FRANCESCO GALLO","0.81;0.66;0.58;0.54;0.48;0.45;0.42;0.4;0.39;0.39;0.37;0.36;0.34;0.33;0.33;0.33;0.29;0.29;0.27;0.27","MARCELLO GOVONI;ANDREA DORIA;MARTA MOSCA;ANǴELA TINCANI;ALESSIA ALUNNO;ANNE TROLDBORG;ANNEGRET KUHN;ANTONIS FANOURIAKIS;CAROLINE GORDON;DAVID JAYNE;ELISABET SVENUNGSSON;FRÉDÉRIC HOUSSIAU;GEORGE ΒERTSIAS;INGEBORG M. BAJEMA;J.L. LARSEN;JOERG WENZEL;JOHN BOLETIS;JOSEF S SMOLEN;KIRSTEN LERSTRØM;M. SCHNEIDER","1833;1796;1790;1627;1624;1624;1624;1624;1624;1624;1624;1624;1624;1624;1624;1624;1624;1624;1624;1624","MARCELLO GOVONI;GIANLUCA CAMPO;ANTONIO FRASSOLDATI;ANTONIO CUNEO;MATTEO SERENELLI;SIMONE BISCAGLIA;RITA PAVASINI;MATTEO TEBALDI;FEDERICA FURINI;CARLO ALBERTO SCIRÈ;ROBERTO FERRARI;FRANCESCO VITALI;GIULIA PASSARINI;ROSSELLA RUGGIERO;ELISABETTA TONET;ANDREA ERRIQUEZ;GIULIA BUGANI;CARLO TUMSCITZ;GIAN MATTEO RIGOLIN;FRANCESCO CAVAZZINI","1833;890;333;293;293;281;259;229;195;163;157;153;144;138;132;127;127;125;124;122","MARCELLO GOVONI;GIANLUCA CAMPO;ANTONIO FRASSOLDATI;SIMONE BISCAGLIA;ANTONIO CUNEO;FRANCESCO CAVAZZINI;ROBERTO FERRARI;FEDERICA FURINI;FRANCESCO VITALI;RITA PAVASINI;GIAN MATTEO RIGOLIN;FRANCESCA DALLA CORTE;GIULIA BUGANI;MATTEO SERENELLI;MATTEO TEBALDI;ROSSELLA RUGGIERO;SAVINO SPADARO;ELISABETTA TONET;CARLO ALBERTO VOLTA;RICCARDO RAGAZZI","11;10;8;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;3;3","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;MATHEMATICS;CHEMISTRY;COMPUTER SCIENCE;MATERIALS SCIENCE;POLITICAL SCIENCE;ECONOMICS;PHILOSOPHY;PSYCHOLOGY;SOCIOLOGY;ART;BUSINESS;ENVIRONMENTAL SCIENCE","92;18;13;9;9;6;5;4;4;3;3;2;2;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;SURGERY;ONCOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;GENETICS;INTENSIVE CARE MEDICINE;GASTROENTEROLOGY;PEDIATRICS;RADIOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;MECHANICAL ENGINEERING;PHYSICAL THERAPY;OPTICS;PATHOLOGY;QUANTUM MECHANICS;STATISTICS;ANESTHESIA;EMERGENCY MEDICINE;FAMILY MEDICINE;GYNECOLOGY;LAW;NURSING;OBSTETRICS;PSYCHIATRY","78;28;21;17;15;13;12;12;11;10;9;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4","DISEASE;MYOCARDIAL INFARCTION;POPULATION;CANCER;CONFIDENCE INTERVAL;COHORT;ADVERSE EFFECT;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;CLINICAL TRIAL;LEUKEMIA;CHEMOTHERAPY;GENE;LUNG;MECHANICAL VENTILATION;PREGNANCY;PROSPECTIVE COHORT STUDY;ANTIBODY;BONE MARROW;CONFOUNDING;HEALTH CARE;INCIDENCE (GEOMETRY);MYELOID LEUKEMIA","15;15;12;11;11;10;8;8;7;6;6;5;5;5;5;5;5;4;4;4;4;4;4","CLINICAL ENDPOINT;HAZARD RATIO;ACUTE CORONARY SYNDROME;BREAST CANCER;PERCUTANEOUS CORONARY INTERVENTION;ARDS;CHRONIC LYMPHOCYTIC LEUKEMIA;CONVENTIONAL PCI;EJECTION FRACTION;GENOTYPE;GESTATION;INTRACEREBRAL HEMORRHAGE;MYELOFIBROSIS;THROMBOLYSIS;B CELL;CATHETER ABLATION;CEREBRAL PERFUSION PRESSURE;ELECTRICAL IMPEDANCE TOMOGRAPHY;FRAMINGHAM RISK SCORE;IMATINIB;IMMUNOTHERAPY;INFECTIOUS DISEASE (MEDICAL SPECIALTY);INFLAMMASOME;PERFUSION SCANNING;PERIPHERAL BLOOD MONONUCLEAR CELL;PHASES OF CLINICAL RESEARCH;PROSTATE CANCER;RELATIVE RISK;REVASCULARIZATION;SEROSITIS;SPIROMETRY;SYSTEMIC INFLAMMATION;TOLERABILITY;UNIVARIATE ANALYSIS","9;7;6;6;5;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANDROGEN RECEPTOR;B-CELL ACTIVATING FACTOR;CHEMOIMMUNOTHERAPY;CORONAVIRUS DISEASE 2019 (COVID-19);IGHV@;METASTATIC BREAST CANCER;NIVOLUMAB;ABLATION OF ATRIAL FIBRILLATION;AJCC STAGING SYSTEM;ANCA-ASSOCIATED VASCULITIS;ANDROGEN DEPRIVATION THERAPY;ANTHRACYCLINE;ANTISYNTHETASE SYNDROME;AROMATASE;ASSISTED REPRODUCTIVE TECHNOLOGY;AXIAL SPONDYLOARTHRITIS;BASDAI;BIORESORBABLE SCAFFOLD;BIVALIRUDIN;CARDIAC RESYNCHRONIZATION THERAPY;CHROMOSOME 12;CYANOACRYLATE;DABIGATRAN;DAPAGLIFLOZIN;FAMILY PLANNING;FICOLL;FIRST TRIMESTER;FLUDARABINE;GEFITINIB;GENE EXPRESSION PROFILING;HAPLOTYPE;HERPESVIRIDAE;HORMONAL THERAPY;IBRUTINIB;IMATINIB MESYLATE;LONG ARM;LYMPHOBLASTIC LYMPHOMA;LYMPHOPLASMACYTIC LYMPHOMA;MODIFIED RANKIN SCALE;NILOTINIB;NONALCOHOLIC FATTY LIVER DISEASE;PERTUSSIS VACCINE;PKD1;PLACENTA;PON1;PREMATURE RUPTURE OF MEMBRANES;RATING OF PERCEIVED EXERTION;REVERSE CHOLESTEROL TRANSPORT;RUXOLITINIB;SINGLE-NUCLEOTIDE POLYMORPHISM;SPLENIC MARGINAL ZONE LYMPHOMA;SPONTANEOUS CONCEPTION;SPONTANEOUS INTRACEREBRAL HEMORRHAGE;STEATOHEPATITIS;STREPTOCOCCUS AGALACTIAE;SYSTEMIC THERAPY;TAMOXIFEN;TAXANE;THIRD TRIMESTER;TICAGRELOR;TIMI;TRANSCRIPTOME;TRASTUZUMAB;VEDOLIZUMAB;VITAMIN K ANTAGONIST","2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ITALY;ADULT;STROKE;ACUTE CORONARY SYNDROME;PROSPECTIVE STUDIES;TREATMENT OUTCOME;CORONARY ARTERY DISEASE;PERCUTANEOUS CORONARY INTERVENTION;MYOCARDIAL INFARCTION;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;HEART FAILURE;PLATELET AGGREGATION INHIBITORS;YOUNG ADULT","53;42;41;35;32;28;22;19;18;16;14;14;13;13;11;11;10;10;10;9","MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;ATRIAL FIBRILLATION;ERRORS AND COMMUNICATION IN RADIOLOGY IMAGING;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;MANAGEMENT AND PATHOPHYSIOLOGY OF INTRACEREBRAL HEMORRHAGE;MANAGEMENT OF BRAIN METASTASES IN CANCER PATIENTS;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;ACUTE MYELOID LEUKEMIA;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN LUNG CANCER RESEARCH;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ASTHMA","5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1","CLINICAL ENDPOINT;SYSTEMIC LUPUS ERYTHEMATOSUS;TREATMENT;POSITIVE END-EXPIRATORY PRESSURE;BREAST CANCER;CARDIOVASCULAR RISK ASSESSMENT;DELPHI METHOD;DISCONTINUATION;IGHV@;INTERQUARTILE RANGE;INTRACEREBRAL HEMORRHAGE;REGIMEN;STROKE (ENGINE);TREATMENT OUTCOMES;ANTICOAGULANT THERAPY;AROMATASE INHIBITOR;BELIMUMAB;BRAIN METASTASES;CARDIAC RISK;CARDIAC SUPPORT DEVICE","9;6;6;5;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2","BREAST CANCER;ACUTE CORONARY;CORONARY SYNDROME;LUPUS ERYTHEMATOSUS;SYSTEMIC LUPUS;MYELOID LEUKEMIA;ATRIAL FIBRILLATION;CANCER PATIENTS;CHRONIC LYMPHOCYTIC;EULAR RECOMMENDATIONS;INTRACEREBRAL HEMORRHAGE;RISK FACTORS;ACUTE MYELOID;ACUTE MYOCARDIAL;ADVANCED BREAST;AROMATASE INHIBITORS;ARTERY DISEASE;BODY MASS;BRAIN METASTASES;CARDIOVASCULAR RISK;CHRONIC KIDNEY;CHRONIC MYELOID;CLINICAL SPECTRUM;COMPUTED TOMOGRAPHY;CORONARY ARTERY;DELPHI CONSENSUS;ELECTRICAL IMPEDANCE;FINAL RESULTS;FIRST-LINE CHEMOTHERAPY;GIMEMA CML","6;5;5;5;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ADVISORY CONSULTANCY;ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;BUREAU EXPERT;EXPERT TESTIMONY;SPEAKER BUREAU;CONSULTANCY SPEAKER;ACCOMMODATION EXPENSES;TRAVEL ACCOMMODATION;HONORARIA MEMBERSHIP;NOVARTIS HONORARIA;COMMITTEES SPEAKERS;CONSULTANCY HONORARIA;PFIZER HONORARIA;ADVERSE EVENTS;GRANTRESEARCH SUPPORT;CONSULTANCY TRAVEL;ELI LILLY;HONORARIA NOVARTIS;MEDIAN AGE;MYOCARDIAL INFARCTION;BUREAU ABBVIE;INCYTE HONORARIA;BMS HONORARIA;CELGENE HONORARIA;PHYSICAL ACTIVITY;ROCHE HONORARIA;CLINICAL TRIAL;CONFIDENCE INTERVAL","94;66;66;65;62;62;62;45;34;34;33;30;28;24;19;17;17;14;14;13;13;13;12;12;11;11;11;11;10;10",47,0.49,16.25,13.5,2,1,0,7,4.25,0,1.5,15.5,0,0,13.75,0,1,2,5,9.75,4,0,0,76,76,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,4,1013.5,13.68,3,0.19,37.38,0,0,0,0,4,0,0,12,0,6,10,0,0,0,0,0,0,16,0,0,16,0,0,0,0,0,0,0,0,0,"Italy;United States;Belgium;Denmark","5;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3213 PAEDIATRICS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","15;10;2;2;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;PATIENT SAFETY;LUNG;PEDIATRIC;RARE DISEASES;BIOENGINEERING;BRAIN DISORDERS;CARDIOVASCULAR;HEART DISEASE;INFANT MORTALITY;NEUROSCIENCES;PREVENTION;AGING;ASSISTIVE TECHNOLOGY;ASTHMA;ATHEROSCLEROSIS;AUTOIMMUNE DISEASE","15;11;4;4;4;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1","CARDIOVASCULAR;BLOOD;CANCER;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY;STROKE","3;1;1;1;1;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;7.1 INDIVIDUAL CARE NEEDS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;7.3 MANAGEMENT AND DECISION MAKING","5;2;2;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;LIVER CANCER;LUNG CANCER;PANCREATIC CANCER","1;1;1;1","4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;6.2 SURVEILLANCE","1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE","7;6;2","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;3105 GENETICS;4202 EPIDEMIOLOGY;3202 CLINICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3203 DENTISTRY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;38 ECONOMICS;44 HUMAN SOCIETY;3208 MEDICAL PHYSIOLOGY;3215 REPRODUCTIVE MEDICINE;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3801 APPLIED ECONOMICS;49 MATHEMATICAL SCIENCES;4905 STATISTICS","15;10;7;5;4;3;2;2;2;2;2;2;1;1;1;1;1;1","GENETICS;CLINICAL RESEARCH;AUTOIMMUNE DISEASE;BRAIN DISORDERS;HUMAN GENOME;INFECTIOUS DISEASES;MULTIPLE SCLEROSIS;NEURODEGENERATIVE;NEUROSCIENCES;HIV/AIDS;IMMUNIZATION;KIDNEY DISEASE;RARE DISEASES;VACCINE RELATED;BIOTECHNOLOGY;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEPATITIS;HEPATITIS - C","7;4;3;3;3;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1","INFECTION;NEUROLOGICAL;CONGENITAL","4;3;2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","5","BIOMEDICAL;CLINICAL","5;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;HEALTH SERVICES RESEARCH;PUBLIC HEALTH","11;1;1;1","LIVER CANCER;NON-HODGKIN'S LYMPHOMA","3;2","3 GOOD HEALTH AND WELL BEING","2"
"AOU_FERRARA",2020,125,21.304,2.528,0.264,0.144,0.272,1.85882352941176,1.17857142857143,1.2,1.25925925925926,0.656,1,65,31,2,12,0.52,0.25,0.02,0.1,23.16,0.919099900448616,5.61186440677966,0.384,0.96,0.477,0.474,0.405,0.463,"GIANLUCA CAMPO;SIMONE BISCAGLIA;SAVINO SPADARO;RITA PAVASINI;MATTEO TEBALDI;ANDREA ZINI;ELISABETTA TONET;MAURO MAGONI;ANTONIO CUNEO;CARLO ALBERTO VOLTA;ROSSANA TASSI;ROBERTO FERRARI;GUIDO BIGLIARDI;VALENTINA SAIA;ROBERTO GASPAROTTI;MANUEL CAPPELLARI;MARINA MANNINO;LUCIO CASTELLAN;MAURO BERGUI;PANTALEO GRECO","22;9;8;8;8;7;7;7;7;7;7;7;6;6;6;6;6;6;6;6","GIANLUCA CAMPO;CLAUDIO CAMPA;SIMONE BISCAGLIA;ELISABETTA TONET;RITA PAVASINI;FRANCESCO VITALI;ANDREA ERRIQUEZ;ALFREDO DE GIORGI;FABIO FABBIAN;SAVINO SPADARO;ANGELINA PASSARO;MATTEO TEBALDI;GIOVANNI ZULIANI;ROBERTO FERRARI;PANTALEO GRECO;ALESSANDRO BRIEDA;FRANCESCO VITALI;CARLO ALBERTO VOLTA;EMANUELE DI SIMONE;ROBERTO MANFREDINI","2.23;1.17;1.13;0.87;0.82;0.76;0.7;0.66;0.66;0.65;0.59;0.55;0.52;0.51;0.5;0.5;0.5;0.48;0.41;0.41","GIANLUCA CAMPO;SIMONE BISCAGLIA;SAVINO SPADARO;RITA PAVASINI;MATTEO TEBALDI;ELISABETTA TONET;ANTONIO CUNEO;CARLO ALBERTO VOLTA;ROBERTO FERRARI;PANTALEO GRECO;MATTEO SERENELLI;ALFREDO DE GIORGI;ANDREA SALETTI;MARCELLO GOVONI;FABIO FABBIAN;RICCARDO RAGAZZI;GIOVANNI ZULIANI;ANTONIO FRASSOLDATI;FRANCESCO VITALI;ANDREA ERRIQUEZ","22;9;8;8;8;7;7;7;7;6;5;5;5;5;5;5;5;5;5;5","GIANLUCA CAMPO;CLAUDIO CAMPA;SIMONE BISCAGLIA;ELISABETTA TONET;RITA PAVASINI;FRANCESCO VITALI;ANDREA ERRIQUEZ;ALFREDO DE GIORGI;FABIO FABBIAN;SAVINO SPADARO;MATTEO TEBALDI;GIOVANNI ZULIANI;ROBERTO FERRARI;PANTALEO GRECO;ALESSANDRO BRIEDA;CARLO ALBERTO VOLTA;EMANUELE DI SIMONE;ROBERTO MANFREDINI;SILVIA VERTUANI;RICCARDO RAGAZZI","2.23;1.17;1.13;0.87;0.82;0.76;0.7;0.66;0.66;0.65;0.55;0.52;0.51;0.5;0.5;0.48;0.41;0.41;0.41;0.35","ANNA CANDONI;FELICETTO FERRARA;PATRIZIA ZAPPASODI;ANTONIO CUNEO;FABRIZIO PANE;MAURO KRAMPERA;MICHÈLE CAVO;ROBERTO M. LEMOLI;ADRIANO VENDITTI;AGOSTINO TAFURI;ALESSANDRA ROMANO;ALESSANDRO BUSCA;ALESSANDRO CORSO;ALESSANDRO MOROTTI;ALFREDO MOLTENI;ANNA MARIA SCATTOLIN;ANNARITA CONCONI;ANNAROSA CUCCARO;ANTONIO PINTO;ATTILIO GUARINI","552;552;552;521;502;502;502;502;501;501;501;501;501;501;501;501;501;501;501;501","ANTONIO CUNEO;CARLO ALBERTO VOLTA;GIANLUCA CAMPO;MATTEO TEBALDI;SAVINO SPADARO;SIMONE BISCAGLIA;RITA PAVASINI;MATTEO SERENELLI;PANTALEO GRECO;MATTEO BERTINI;BEATRICE BIANCHI;DANILA MORANO;MARIA GIULIA MARINO;ELISABETTA TONET;ALBERTO FOGAGNOLO;RICCARDO RAGAZZI;ALESSANDRO DE VITO;ANDREA SALETTI;MARCELLO GOVONI;MARIA RITA GAMBERINI","520;285;219;208;193;192;165;162;158;144;143;143;143;142;137;136;125;125;108;98","GIANLUCA CAMPO;MATTEO TEBALDI;RITA PAVASINI;SIMONE BISCAGLIA;ELISABETTA TONET;CARLO ALBERTO VOLTA;ALFREDO DE GIORGI;MATTEO SERENELLI;ANDREA ERRIQUEZ;ANDREA SALETTI;ANTONIO FRASSOLDATI;FRANCESCO CAVAZZINI;RICCARDO RAGAZZI;SAVINO SPADARO;PANTALEO GRECO;ALESSANDRO DE VITO;ANTONIO CUNEO;ELEONORA CAPATTI;FABIO FABBIAN;FRANCESCA DI VECE","17;8;8;8;7;6;5;5;5;5;5;5;5;5;4;4;3;3;3;3","MEDICINE;BIOLOGY;ENGINEERING;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;PSYCHOLOGY;POLITICAL SCIENCE;MATHEMATICS;SOCIOLOGY;ECONOMICS;MATERIALS SCIENCE;PHILOSOPHY;BUSINESS;ENVIRONMENTAL SCIENCE;GEOLOGY","116;24;15;12;8;7;7;6;5;5;4;2;2;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;SURGERY;ONCOLOGY;PATHOLOGY;RADIOLOGY;INTENSIVE CARE MEDICINE;GENETICS;GASTROENTEROLOGY;MECHANICAL ENGINEERING;PHYSICAL THERAPY;PEDIATRICS;PSYCHIATRY;ANESTHESIA;IMMUNOLOGY;NURSING;BIOCHEMISTRY;EMERGENCY MEDICINE;NUCLEAR MEDICINE;GENERAL SURGERY;LAW;PALEONTOLOGY","97;31;31;18;17;17;15;13;12;12;11;10;10;9;8;8;7;7;7;6;6;6","DISEASE;MYOCARDIAL INFARCTION;COHORT;RANDOMIZED CONTROLLED TRIAL;CANCER;GENE;CONFIDENCE INTERVAL;STROKE (ENGINE);ODDS RATIO;LUNG;OUTBREAK;QUALITY OF LIFE (HEALTHCARE);RETROSPECTIVE COHORT STUDY;ALTERNATIVE MEDICINE;BLOOD PRESSURE;CLINICAL TRIAL;CORONARY ARTERY DISEASE;ISCHEMIA;MAGNETIC RESONANCE IMAGING;OBSERVATIONAL STUDY;POPULATION;PROSPECTIVE COHORT STUDY","23;23;17;12;11;10;9;8;7;6;6;6;6;5;5;5;5;5;5;5;5;5","ACUTE CORONARY SYNDROME;INFECTIOUS DISEASE (MEDICAL SPECIALTY);PERCUTANEOUS CORONARY INTERVENTION;2019-20 CORONAVIRUS OUTBREAK;AUTOIMMUNE DISEASE;CONVENTIONAL PCI;EJECTION FRACTION;HAZARD RATIO;ISCHEMIC STROKE;BREAST CANCER;CLINICAL ENDPOINT;CLOPIDOGREL;CORONARY ANGIOGRAPHY;CULPRIT;INTRACEREBRAL HEMORRHAGE;MULTICENTER STUDY;MUTATION;THROMBOLYSIS;ADENOCARCINOMA;ARDS;CARDIAC MAGNETIC RESONANCE IMAGING;CHRONIC LYMPHOCYTIC LEUKEMIA;DIASTOLE;ELECTRICAL IMPEDANCE TOMOGRAPHY;EMOTIONAL EXHAUSTION;EXON;GESTATIONAL AGE;INCLUSION AND EXCLUSION CRITERIA;KAWASAKI DISEASE;METHYLATION;MYELOFIBROSIS;NEURORADIOLOGY;POSITIVE END-EXPIRATORY PRESSURE;REPOLARIZATION;RESTENOSIS;SPIROMETRY;SYSTEMIC LUPUS ERYTHEMATOSUS;THYROID CANCER","8;8;8;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);CONNECTIVE TISSUE DISEASE;MODIFIED RANKIN SCALE;TICAGRELOR;DEPERSONALIZATION;FRACTIONAL FLOW RESERVE;IGHV@;METASTATIC BREAST CANCER;P2Y12;PRASUGREL;TIROFIBAN;ABTS;ANDROGEN RECEPTOR;APOLIPOPROTEIN A1;BARE METAL;BMPR2;BONE MORPHOGENETIC PROTEIN 7;BONE MORPHOGENETIC PROTEIN RECEPTOR;BRCA MUTATION;CANADIAN CARDIOVASCULAR SOCIETY;CATH LAB;CD38;CDH1;COPY-NUMBER VARIATION;DAPAGLIFLOZIN;DASATINIB;DNA METHYLATION;DRUG-ELUTING STENT;DYSKINESIA;ENTHESITIS;ESTROGEN RECEPTOR;EXOME SEQUENCING;FUNDUS FLUORESCEIN ANGIOGRAPHY;GENE MUTATION;GENOTYPING;HUNTINGTIN;IBRUTINIB;IMATINIB MESYLATE;KRAS;LEVODOPA;LYMPHOBLASTIC LYMPHOMA;MOLECULAR MEDICINE;MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION;NILOTINIB;OFATUMUMAB;ONCOGENE;OSWESTRY DISABILITY INDEX;PENETRANCE;PROMOTER;ROS1;RUXOLITINIB;STAPHYLOCOCCUS EPIDERMIDIS;STROKE VOLUME;THIENOPYRIDINE;TIMI;TRANSPULMONARY PRESSURE;TRASTUZUMAB;TRINUCLEOTIDE REPEAT EXPANSION;TUMOR-INFILTRATING LYMPHOCYTES;VO2 MAX;WILD TYPE","8;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;ITALY;MIDDLE AGED;AGED;ADULT;LUPUS ERYTHEMATOSUS, SYSTEMIC;STROKE;AGED, 80 AND OVER;TREATMENT OUTCOME;BRAIN ISCHEMIA;COVID-19;CORONARY ARTERY DISEASE;RETROSPECTIVE STUDIES;BETA-THALASSEMIA;BIOMARKERS;CORONARY ANGIOGRAPHY;CORONARY VESSELS","66;57;44;40;34;31;27;20;14;13;12;12;11;11;10;10;9;8;8;8","ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT;CORONAVIRUS DISEASE 2019;DIAGNOSIS AND MANAGEMENT OF KAWASAKI DISEASE;EXERCISE PHYSIOLOGY AND CARDIOVASCULAR HEALTH;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MANAGEMENT OF VALVULAR HEART DISEASE;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ANTIOXIDANTS AND FREE RADICALS IN HEALTH AND DISEASE","5;5;5;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;1;1","STROKE (ENGINE);CARDIAC IMAGING;INFARCTION TREATMENT;2019-20 CORONAVIRUS OUTBREAK;CARDIOVASCULAR RISK ASSESSMENT;CLINICAL ENDPOINT;EXERCISE CAPACITY;REFRACTORY (PLANETARY SCIENCE);AEROBIC EXERCISE;CARDIAC ULTRASOUND;CARDIOPULMONARY EXERCISE TESTING;COMPUTED TOMOGRAPHY ANGIOGRAPHY;CULPRIT;ENDURANCE TRAINING;GROIN;HIGH-INTENSITY INTERVAL TRAINING;INTERQUARTILE RANGE;INTERVAL TRAINING;INTRAVASCULAR ULTRASOUND;MYOCARDIAL REVASCULARIZATION","8;6;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","MYOCARDIAL INFARCTION;ACUTE CORONARY;COHORT STUDY;ELDERLY PATIENTS;LUPUS ERYTHEMATOSUS;OBSERVATIONAL STUDY;RISK FACTORS;SYSTEMIC LUPUS;ACUTE ISCHEMIC;CANCER PATIENTS;CONTROLLED TRIAL;CORONARY ARTERY;CORONARY SYNDROMES;CORONAVIRUS DISEASE;COVID- PATIENTS;ENDURANCE TRAINING;INTERVAL TRAINING;ISCHEMIC STROKE;MULTICENTER OBSERVATIONAL;RANDOMIZED CONTROLLED;ACUTE KIDNEY;ARTERY DISEASE;BURNOUT SYNDROME;CHRONIC LYMPHOCYTIC;CLINICAL OUTCOMES;CLINICAL TRIAL;COMPARATIVE STUDY;CONNECTIVE TISSUE;CORONARY SYNDROME;COVID- PANDEMIC","6;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;ADVISORY COMMITTEES;ENTITYS BOARD;CROSSREF PUBMED;SPEAKERS BUREAU;COMMITTEES SPEAKERS;CONSULTANCY HONORARIA;SIGNIFICANT DIFFERENCES;DIFFERENCES EXIST;PATIENTS TREATED;RESEARCH FUNDING;STATISTICALLY SIGNIFICANT;TRAVEL EXPENSES;GA VERSUS;AOR CI;FERRARA FERRARA;IGG SUBCLASS;MYOCARDIAL INFARCTION;PDN MGDAY;PGA LT;PRIMARY OUTCOME;A-V ODIFF;MECHANICAL VENTILATION;ANTI-GLIADIN IGG;CLASSIFICATION CRITERIA;DISEASES UNIVERSITY;FERRARA ITALYSEARCH;HONORARIA NOVARTIS;INFECTIOUS DISEASES;MEDICAL SCIENCES","40;27;27;26;25;17;17;16;12;12;12;12;12;11;10;10;10;10;10;10;10;9;9;8;8;8;8;8;8;8",68,0.54,11.45,14.25,1,1,0,11,2,0,0,16.75,0,1,12.5,1,1,2,3.5,10,3,0,0,56,54.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,3.38,1083.46,16.78,15,0.6,66.68,0,0,4,1,4,0,0,16,0,13,11,1,0,0,0,0,0,23,2,0,22,0,0,2,0,0,0,0,0,1,"Italy;Canada;United States;Japan","7;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;3215 REPRODUCTIVE MEDICINE;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;4205 NURSING;4207 SPORTS SCIENCE AND EXERCISE;46 INFORMATION AND COMPUTING SCIENCES","24;16;6;5;3;3;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;CANCER;PREVENTION;RARE DISEASES;INFECTIOUS DISEASES;CARDIOVASCULAR;PATIENT SAFETY;PNEUMONIA;PNEUMONIA & INFLUENZA;EMERGING INFECTIOUS DISEASES;HEMATOLOGY;BIOENGINEERING;HEART DISEASE;LUNG CANCER;VACCINE RELATED;ACUTE RESPIRATORY DISTRESS SYNDROME;BEHAVIORAL AND SOCIAL SCIENCE;BIODEFENSE","22;12;12;8;7;7;6;5;5;5;5;4;4;3;3;3;3;2;2;2","CANCER;RESPIRATORY;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;MENTAL HEALTH;RENAL AND UROGENITAL;STROKE","7;3;2;2;1;1;1;1","6.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.7 PHYSICAL;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.6 PSYCHOLOGICAL AND BEHAVIOURAL","12;3;2;2;2;2;1;1;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;BREAST CANCER;COLON AND RECTAL CANCER;KIDNEY CANCER;NON-HODGKIN'S LYMPHOMA","3;3;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","8",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;AMERICAN ASSOCIATION FOR CANCER RESEARCH;KARGER PUBLISHERS;MENDELEY DATA","10;5;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;49 MATHEMATICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;4905 STATISTICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;40 ENGINEERING;42 HEALTH SCIENCES;52 PSYCHOLOGY;4003 BIOMEDICAL ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;5205 SOCIAL AND PERSONALITY PSYCHOLOGY","17;6;4;3;3;2;2;2;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;NEUROSCIENCES;PATIENT SAFETY;INFECTIOUS DISEASES;BREAST CANCER;CANCER;GENETICS;PREVENTION;REGENERATIVE MEDICINE;STEM CELL RESEARCH","6;6;5;4;4;2;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE;MUSCULOSKELETAL","3;1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS","1;1;1;1","CLINICAL;BIOMEDICAL","4;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","9;1","BREAST CANCER;NOT SITE-SPECIFIC CANCER","2;1","3 GOOD HEALTH AND WELL BEING","4"
"AOU_FERRARA",2021,137,19.7810218978102,2.46715328467153,0.226277372262774,0.233576642335766,0.35036496350365,2,1.03333333333333,1.77777777777778,1.2972972972973,0.708029197080292,0,71,21,18,8,0.52,0.15,0.13,0.06,16.95,1.09910007399853,6.51411589895989,0.335766423357664,0.941605839416058,0.448,0.53,0.549,0.522,"GIANLUCA CAMPO;ANGELINA PASSARO;RITA PAVASINI;SIMONE BISCAGLIA;ANTONIO CUNEO;SAVINO SPADARO;MATTEO TEBALDI;ROBIN FOÀ;CARLO ALBERTO VOLTA;MASSIMILIANO BONIFACIO;ROBERTO FERRARI;DARIA BORTOLOTTI;MONICA CRUGNOLA;MARCO CONTOLI;CLAUDIO RAPEZZI;MARIO TIRIBELLI;GIAN MATTEO RIGOLIN;ELISABETTA TONET;ROBERTA GAFÀ;ALFONSO IELASI","28;11;10;10;10;9;9;7;7;7;7;6;6;6;6;6;6;6;6;6","GIANLUCA CAMPO;ANGELINA PASSARO;RITA PAVASINI;SIMONE BISCAGLIA;PANTALEO GRECO;ROBERTA GAFÀ;MATTEO TEBALDI;DARIA BORTOLOTTI;ROBERTA RIZZO;UGO INDRACCOLO;ROBERTO FERRARI;PAOLO ZAMBONI;SALVATORE GRECO;SAVINO SPADARO;MARIA CHIARA ZATELLI;CLAUDIO RAPEZZI;MARCO CONTOLI;ANDREA ERRIQUEZ;LUCA TRAINA;ELISABETTA TONET","1.85;1.16;0.75;0.74;0.71;0.61;0.6;0.59;0.59;0.58;0.58;0.57;0.52;0.52;0.5;0.49;0.49;0.48;0.48;0.44","GIANLUCA CAMPO;ANGELINA PASSARO;RITA PAVASINI;SIMONE BISCAGLIA;ANTONIO CUNEO;SAVINO SPADARO;MATTEO TEBALDI;CARLO ALBERTO VOLTA;ROBERTO FERRARI;MARCO CONTOLI;CLAUDIO RAPEZZI;GIAN MATTEO RIGOLIN;ELISABETTA TONET;ROBERTA GAFÀ;ROBERTA RIZZO;OTTAVIO ZUCCHETTI;MATTEO SERENELLI;FRANCESCO CAVAZZINI;ALBERTO PAPI;ANTONIO FRASSOLDATI","28;11;10;10;10;9;9;7;7;6;6;6;6;6;6;6;5;5;5;5","GIANLUCA CAMPO;ANGELINA PASSARO;RITA PAVASINI;SIMONE BISCAGLIA;PANTALEO GRECO;ROBERTA GAFÀ;MATTEO TEBALDI;ROBERTA RIZZO;UGO INDRACCOLO;ROBERTO FERRARI;PAOLO ZAMBONI;SALVATORE GRECO;SAVINO SPADARO;MARIA CHIARA ZATELLI;CLAUDIO RAPEZZI;MARCO CONTOLI;ANDREA ERRIQUEZ;LUCA TRAINA;ELISABETTA TONET;ELEONORA CAPATTI","1.85;1.16;0.75;0.74;0.71;0.61;0.6;0.59;0.58;0.58;0.57;0.52;0.52;0.5;0.49;0.49;0.48;0.48;0.44;0.42","GIANLUCA CAMPO;SAVINO SPADARO;CARLO ALBERTO VOLTA;ANTONELLA POTALIVO;TOMMASO TONETTI;V. MARCO RANIERI;GIULIA FALÒ;ALESSANDRO MELE;ALESSIO MACCAGLIA;ANGELA SCAVONE;ANTONIO GULLÌ;ANTONIO MARIA DELL’ANNA;CARLOTTA RUBINO;CARMELINA ZACCONE;CECILIA BERARDI;DANIELE NATALINI;DOMENICO LUCA GRIECO;DONATELLA SETTANNI;EDOARDO PIERVINCENZI;ELOISA SOFIA TANZARELLA","855;749;725;463;463;463;402;350;350;350;350;350;350;350;350;350;350;350;350;350","GIANLUCA CAMPO;SAVINO SPADARO;CARLO ALBERTO VOLTA;GIULIA FALÒ;OTTAVIO ZUCCHETTI;RITA PAVASINI;MARCO CONTOLI;ALBERTO PAPI;ANTONIO CUNEO;MATTEO TEBALDI;GAETANO SCARAMUZZO;IRENE OTTAVIANI;ANGELINA PASSARO;SIMONE BISCAGLIA;GIAN MATTEO RIGOLIN;ALESSANDRA BORTOLUZZI;ROBERTO FERRARI;FRANCESCA TORSANI;LUCA MORANDI;LUCA RONZONI","764;544;541;350;252;234;168;166;164;115;113;113;97;94;83;80;76;70;70;70","GIANLUCA CAMPO;ANTONIO CUNEO;RITA PAVASINI;ANGELINA PASSARO;MATTEO TEBALDI;SIMONE BISCAGLIA;FRANCESCO CAVAZZINI;GIAN MATTEO RIGOLIN;SAVINO SPADARO;ANTONIO FRASSOLDATI;CARLO ALBERTO VOLTA;ELISABETTA TONET;ANDREA ERRIQUEZ;ANDREA SALETTI;ELEONORA CAPATTI;GRAZIELLA POMPEI;MARCO CONTOLI;MATTEO SERENELLI;OTTAVIO ZUCCHETTI;ROBERTA GAFÀ","26;9;9;8;8;7;6;6;6;5;5;5;4;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;ENGINEERING;PHYSICS;MATHEMATICS;COMPUTER SCIENCE;SOCIOLOGY;CHEMISTRY;GEOLOGY;PHILOSOPHY;POLITICAL SCIENCE;PSYCHOLOGY","133;27;10;10;7;6;5;4;1;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;IMMUNOLOGY;PATHOLOGY;ONCOLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;PEDIATRICS;GASTROENTEROLOGY;GENETICS;INTENSIVE CARE MEDICINE;MECHANICAL ENGINEERING;EMERGENCY MEDICINE;NUCLEAR MEDICINE;PHYSICAL THERAPY;PSYCHIATRY;NURSING;OPTICS;VIROLOGY","122;33;26;23;21;18;18;16;15;14;12;12;10;9;9;9;9;7;7;7","DISEASE;COHORT;MYOCARDIAL INFARCTION;CANCER;POPULATION;PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;OBSERVATIONAL STUDY;RETROSPECTIVE COHORT STUDY;LEUKEMIA;STROKE (ENGINE);ALTERNATIVE MEDICINE;BLOOD PRESSURE;GENE;QUALITY OF LIFE (HEALTHCARE);ANTIBODY;CLINICAL TRIAL;INCIDENCE (GEOMETRY);ISCHEMIA;OUTBREAK","32;27;20;15;14;12;12;10;10;9;8;8;7;7;7;7;6;6;6;6;6","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;PERCUTANEOUS CORONARY INTERVENTION;BREAST CANCER;CHRONIC LYMPHOCYTIC LEUKEMIA;CONVENTIONAL PCI;2019-20 CORONAVIRUS OUTBREAK;ACUTE CORONARY SYNDROME;HAZARD RATIO;AUTOANTIBODY;ISCHEMIC STROKE;UNIVARIATE ANALYSIS;AORTIC VALVE STENOSIS;CORONARY ANGIOGRAPHY;CULPRIT;MIDDLE CEREBRAL ARTERY;THROMBOLYSIS;AORTIC VALVE REPLACEMENT;BICUSPID AORTIC VALVE;COLORECTAL CANCER;CUMULATIVE INCIDENCE;DEEP VEIN;ENDOVASCULAR TREATMENT;GENE EXPRESSION;GESTATIONAL AGE;HEART RATE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HOME HEMODIALYSIS;IMATINIB;IMMUNOTHERAPY;INTERSTITIAL LUNG DISEASE;INTRACEREBRAL HEMORRHAGE;METASTATIC MELANOMA;MUTATION;MYELOFIBROSIS;NECK PAIN;NEURORADIOLOGY;OBSTETRICS AND GYNAECOLOGY;PERFUSION SCANNING;PLACEBO;PROGRAMMED CELL DEATH;REVASCULARIZATION;SPIROMETRY;SYSTEMIC LUPUS ERYTHEMATOSUS;TYROSINE-KINASE INHIBITOR;WEIGHT LOSS","20;9;7;6;6;6;5;5;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);IBRUTINIB;IGHV@;MODIFIED RANKIN SCALE;FRACTIONAL FLOW RESERVE;ANTI-NUCLEAR ANTIBODY;DASATINIB;IMATINIB MESYLATE;MACE;NILOTINIB;NIVOLUMAB;RUXOLITINIB;VENETOCLAX;ACINETOBACTER BAUMANNII;ANTERIOR CEREBRAL ARTERY;AORTIC VALVULOPLASTY;AORTOENTERIC FISTULA;AROMATASE;AXIAL SPONDYLOARTHRITIS;BASDAI;BICUSPID VALVE;BISHOP SCORE;BIVALIRUDIN;BRACHIOCEPHALIC ARTERY;BRONCHOPULMONARY DYSPLASIA;BRUTON'S TYROSINE KINASE;CANADIAN CARDIOVASCULAR SOCIETY;CATH LAB;CD3;CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS;COLONOSCOPY;COLPOSCOPY;CRITICAL LIMB ISCHEMIA;CROSSOVER STUDY;DEEP BRAIN STIMULATION;DISKECTOMY;DNA METHYLATION;DRUG-ELUTING STENT;E-SELECTIN;ELECTROCHEMOTHERAPY;GENE SIGNATURE;GERMLINE MUTATION;HORMONE THERAPY;IDIOPATHIC INTERSTITIAL PNEUMONIA;INTRAVENTRICULAR HEMORRHAGE;KARYOTYPE;LIMBIC ENCEPHALITIS;MAMMOGRAPHY;MITOCHONDRIAL PERMEABILITY TRANSITION PORE;MITOPHAGY;NEOADJUVANT THERAPY;OFATUMUMAB;PARANEOPLASTIC CEREBELLAR DEGENERATION;PERIVENTRICULAR LEUKOMALACIA;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SECONDARY HYPERPARATHYROIDISM;STREPTOCOCCUS AGALACTIAE;SULFASALAZINE;SYSTEMIC THERAPY;TAMOXIFEN;TARGET LESION;TRAMETINIB;TRASTUZUMAB;UNIPORTER;VAGUS NERVE STIMULATION;VATS LOBECTOMY;VEMURAFENIB;VIRAL ENCEPHALITIS;VO2 MAX","20;4;4;4;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;COVID-19;FEMALE;MALE;AGED;MIDDLE AGED;ITALY;RETROSPECTIVE STUDIES;ADULT;SARS-COV-2;TREATMENT OUTCOME;PROSPECTIVE STUDIES;AGED, 80 AND OVER;STROKE;PROGNOSIS;ACUTE CORONARY SYNDROME;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;PERCUTANEOUS CORONARY INTERVENTION;ST ELEVATION MYOCARDIAL INFARCTION","75;62;37;33;31;27;25;21;20;17;16;16;14;12;12;11;10;9;8;8","CORONAVIRUS DISEASE 2019;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;EFFICACY AND RESISTANCE IN CML TREATMENT;MANAGEMENT OF VALVULAR HEART DISEASE;MANAGEMENT OF DELIRIUM IN CRITICAL CARE PATIENTS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;INFLUENZA-ASSOCIATED ENCEPHALOPATHY AND ENCEPHALITIS;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;ACUTE MYELOID LEUKEMIA","10;6;6;5;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;1","CLINICAL ENDPOINT;PANDEMIC;STROKE (ENGINE);INFARCTION TREATMENT;2019-20 CORONAVIRUS OUTBREAK;CARDIAC IMAGING;CARDIOVASCULAR RISK ASSESSMENT;IGHV@;TRANSCATHETER AORTIC-VALVE REPLACEMENT;TREATMENT;UNIVARIATE ANALYSIS;CLINICAL CHARACTERISTICS;CORONA VIRUS;CULPRIT;ECHOCARDIOGRAPHY;ENDOVASCULAR THERAPY;FRACTIONAL FLOW RESERVE;HEMATOLOGY;ISCHEMIC STROKE;PROSTHETIC VALVES EVALUATION","9;9;9;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3","ACUTE CORONARY;COHORT STUDY;CORONARY SYNDROME;MYOCARDIAL INFARCTION;OBSERVATIONAL STUDY;AORTIC VALVE;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;CHRONIC MYELOID;COVID- PANDEMIC;COVID- PATIENTS;ACUTE ISCHEMIC;CAMPUS CML;CASE-CONTROL STUDY;CONTROLLED TRIAL;CRITICALLY ILL;DIFFERENTIAL DIAGNOSIS;ELEVATION MYOCARDIAL;ISCHEMIC STROKE;MYELOID LEUKEMIA;PROSPECTIVE STUDY;RANDOMIZED CONTROLLED;STUDY PROTOCOL;VALVE STENOSIS;ACUTE KIDNEY;ARTERY DISEASE;ASYMPTOMATIC PATIENTS;BICUSPID AORTIC;BREAST CANCER;BRONCHIAL CARCINOIDS","7;6;6;6;6;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2","ADVISORY COMMITTEES;ENTITYS BOARD;CONSULTANCY HONORARIA;SPEAKERS BUREAU;HONORARIA MEMBERSHIP;RESEARCH FUNDING;HR CI;NOVARTIS HONORARIA;BRISTOL MYERS;PB- PB-;PFIZER HONORARIA;HONORARIA PFIZER;HONORARIA RESEARCH;MEDIAN AGE;SARS-COV- INFECTION;ANTIBIOTIC THERAPY;COVID- PANDEMIC;COVID- PATIENTS;DAY MORTALITY;MYOCARDIAL INFARCTION;PUBMED SCOPUS;COMMITTEES SPEAKERS;INTERSTITIAL PNEUMONIA;MYERS SQUIBB;PRIMARY OUTCOME;ABBVIE CONSULTANCY;ACS PATIENTS;HONORARIA NOVARTIS;JANSSEN CONSULTANCY;RISK FACTORS","64;64;55;39;32;28;23;16;15;15;15;13;13;13;13;12;12;12;12;12;12;11;11;11;11;10;10;10;10;10",75,0.55,11.77,13.5,1,1,0,1.75,1.75,0,2.5,15.5,2,1,14.5,2,0,3,4.75,10.75,4,0,0,44.5,43,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,3.44,1712.04,16.34,12,0.48,84.48,0,0,2,1,9,0,0,13,0,18,7,0,0,0,0,0,0,25,0,0,25,0,0,0,0,0,0,0,0,0,"United States;Italy;Japan;Switzerland;United Kingdom","2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;3207 MEDICAL MICROBIOLOGY;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","24;15;4;4;3;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;HEART DISEASE;CANCER;HEMATOLOGY;PATIENT SAFETY;PREVENTION;HEART DISEASE - CORONARY HEART DISEASE;RARE DISEASES;ATHEROSCLEROSIS;BIOENGINEERING;INFECTIOUS DISEASES;LYMPHOMA;ASSISTIVE TECHNOLOGY;BIOMEDICAL IMAGING;LUNG;NEUROSCIENCES;PAIN RESEARCH;REHABILITATION","22;14;11;9;6;5;5;5;4;4;3;3;3;3;2;2;2;2;2;2","CARDIOVASCULAR;CANCER;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;MUSCULOSKELETAL;NEUROLOGICAL;RESPIRATORY","12;3;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;6.7 PHYSICAL;7.1 INDIVIDUAL CARE NEEDS;7.3 MANAGEMENT AND DECISION MAKING","12;2;2;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;GALLBLADDER CANCER;LIVER CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER","2;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","6",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;ZENODO","10;4;2","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;4202 EPIDEMIOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3107 MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","11;7;3;3;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;RARE DISEASES;AUTOIMMUNE DISEASE;BRAIN DISORDERS;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;MULTIPLE SCLEROSIS;NEURODEGENERATIVE;NEUROSCIENCES;AGING;BIODEFENSE;BREAST CANCER;DENTAL/ORAL AND CRANIOFACIAL DISEASE;DIABETES;EMERGING INFECTIOUS DISEASES;GENETICS;INFECTIOUS DISEASES;LUNG CANCER;MENTAL HEALTH","4;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE;INFECTION","1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;5.1 PHARMACEUTICALS","3;3;1","BIOMEDICAL;CLINICAL;HEALTH SERVICES & SYSTEMS;POPULATION & SOCIETY","2;1;1;1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","3;3","BREAST CANCER;LUNG CANCER","1;1","3 GOOD HEALTH AND WELL BEING","3"
"AOU_FERRARA",2022,172,20.6744186046512,3.04651162790698,0.267441860465116,0.27906976744186,0.325581395348837,2.26406926406926,1.17948717948718,1.6,1.24444444444444,0.796511627906977,0,53,31,30,15,0.31,0.18,0.17,0.09,5.73,0.642173309961524,6.19440745672438,0.296511627906977,0.866279069767442,0.494,0.412,0.464,0.447,"GIANLUCA CAMPO;SIMONE BISCAGLIA;GABRIELE GUARDIGLI;GRAZIELLA POMPEI;MATTEO BERTINI;ELISABETTA TONET;RITA PAVASINI;MARIA RITA GAMBERINI;SALVATORE BRUGALETTA;SAVINO SPADARO;ANTONELLA SCALA;FEDERICO MARCHINI;ALFONSO IELASI;ANGELINA PASSARO;MATTEO TEBALDI;MASSIMO BRECCIA;SERENA CAGLIONI;ILARIA CASETTA;ROSSELLA RUGGIERO;MANEL SABATÉ","39;12;11;11;10;10;9;8;8;7;7;7;7;7;7;7;7;6;6;6","GIANLUCA CAMPO;GABRIELE GUARDIGLI;FEDERICO GIBIINO;RITA PAVASINI;FRANCESCO VITALI;MATTEO BERTINI;ALBERTO BOCCADORO;MICHELE MALAGÙ;GRAZIELLA POMPEI;SIMONE BISCAGLIA;ELISABETTA TONET;FAUSTO SALAFFI;ANTONELLA SCALA;MARIA RITA GAMBERINI;FRANCESCO VITALI;FEDERICO MARCHINI;FRANCESCA GUALANDI;STEFANO VOLPATO;ROBERTO FERRARI;ALDO CARNEVALE","2.78;1.27;1.26;1.17;1.08;1.08;1;1;0.92;0.9;0.89;0.83;0.75;0.69;0.67;0.66;0.61;0.57;0.56;0.55","GIANLUCA CAMPO;SIMONE BISCAGLIA;GABRIELE GUARDIGLI;GRAZIELLA POMPEI;MATTEO BERTINI;ELISABETTA TONET;RITA PAVASINI;MARIA RITA GAMBERINI;SAVINO SPADARO;ANTONELLA SCALA;FEDERICO MARCHINI;ANGELINA PASSARO;MATTEO TEBALDI;SERENA CAGLIONI;ILARIA CASETTA;ROSSELLA RUGGIERO;MICHELE MALAGÙ;FEDERICO GIBIINO;ALBERTO BOCCADORO;MARCELLO GOVONI","39;12;11;11;10;10;9;8;7;7;7;7;7;7;6;6;6;6;6;6","GIANLUCA CAMPO;GABRIELE GUARDIGLI;FEDERICO GIBIINO;RITA PAVASINI;FRANCESCO VITALI;MATTEO BERTINI;ALBERTO BOCCADORO;MICHELE MALAGÙ;GRAZIELLA POMPEI;SIMONE BISCAGLIA;ELISABETTA TONET;ANTONELLA SCALA;MARIA RITA GAMBERINI;FEDERICO MARCHINI;FRANCESCA GUALANDI;STEFANO VOLPATO;ROBERTO FERRARI;ALDO CARNEVALE;ANGELINA PASSARO;SAVINO SPADARO","2.78;1.27;1.26;1.17;1.08;1.08;1;1;0.92;0.9;0.89;0.75;0.69;0.66;0.61;0.57;0.56;0.55;0.53;0.53","GIANLUCA CAMPO;BÉLA MERKELY;TARO SHIBASAKI;LEONARDO CALÒ;BERNHARD REIMERS;LUCIANO FATTORE;GIORGIO QUADRI;LUC JANSSENS;ALESSANDRO SCIAHBASI;ANDREA PICCHI;ANDREAS SCHOBER;ANDRZEJ BUDAJ;ANDRÁS VOROBCSUK;ATSUSHI YAMAMURO;BODO KIRSCH;BURKHARD SIEVERS;BÉLA HERCZEG;CHRISTIAN HENGSTENBERG;CHRISTOPHE BEAULOYE;CLAUDIO BRUNELLI","387;200;200;133;110;110;108;104;100;100;100;100;100;100;100;100;100;100;100;100","GIANLUCA CAMPO;RITA PAVASINI;CLAUDIO RAPEZZI;MATTEO BERTINI;LUCA DI IENNO;SAVINO SPADARO;LUCA CECCARELLI;CARLO ALBERTO VOLTA;MARIA RITA GAMBERINI;SIMONE BISCAGLIA;ANDREA SALETTI;ANGELINA PASSARO;ANDREA ERRIQUEZ;CECILIA TURRINI;MONICA FORTINI;GRAZIELLA POMPEI;MATTEO TEBALDI;ANTONELLA SCALA;MATTEO SERENELLI;ELEONORA CAPATTI","149;89;75;75;68;65;62;55;53;51;49;45;43;39;33;32;32;30;29;28","GIANLUCA CAMPO;GRAZIELLA POMPEI;GABRIELE GUARDIGLI;SIMONE BISCAGLIA;ELISABETTA TONET;MATTEO BERTINI;RITA PAVASINI;FRANCESCO CAVAZZINI;MATTEO TEBALDI;SERENA CAGLIONI;FEDERICO MARCHINI;SAVINO SPADARO;ANTONELLA SCALA;ANGELINA PASSARO;MICHELE MALAGÙ;ALBERTO BOCCADORO;FEDERICO GIBIINO;FRANCESCO VITALI;MATTEO SERENELLI;MICHELE TRICHILO","32;11;11;11;10;10;10;7;7;7;7;7;7;6;6;6;6;6;6;6","MEDICINE;PHYSICS;BIOLOGY;ENGINEERING;COMPUTER SCIENCE;MATHEMATICS;CHEMISTRY;MATERIALS SCIENCE;SOCIOLOGY;ECONOMICS;POLITICAL SCIENCE;PSYCHOLOGY;BUSINESS;ENVIRONMENTAL SCIENCE;PHILOSOPHY;HISTORY","167;25;24;18;8;5;4;4;4;3;3;3;2;2;2;1","INTERNAL MEDICINE;CARDIOLOGY;SURGERY;RADIOLOGY;PEDIATRICS;ENVIRONMENTAL HEALTH;OPTICS;MECHANICAL ENGINEERING;ONCOLOGY;ENDOCRINOLOGY;PATHOLOGY;INTENSIVE CARE MEDICINE;GASTROENTEROLOGY;PHYSICAL THERAPY;GENETICS;IMMUNOLOGY;PSYCHIATRY;VIROLOGY;NUCLEAR MEDICINE;PALEONTOLOGY","146;62;46;27;21;20;19;16;16;14;13;12;11;11;9;9;9;8;7;7","MYOCARDIAL INFARCTION;DISEASE;COHORT;POPULATION;HEART FAILURE;INCIDENCE (GEOMETRY);CONFIDENCE INTERVAL;ATRIAL FIBRILLATION;RANDOMIZED CONTROLLED TRIAL;STROKE (ENGINE);CANCER;DISCONTINUATION;RHEUMATOID ARTHRITIS;STENT;THALASSEMIA;CLINICAL TRIAL;RETROSPECTIVE COHORT STUDY;STENOSIS;ADVERSE EFFECT;OUTBREAK","38;31;23;20;17;15;13;11;11;11;10;10;10;10;10;9;9;9;8;8","INFECTIOUS DISEASE (MEDICAL SPECIALTY);ACUTE CORONARY SYNDROME;CORONARY ANGIOGRAPHY;REVASCULARIZATION;CLINICAL ENDPOINT;BREAST CANCER;EJECTION FRACTION;PERCUTANEOUS CORONARY INTERVENTION;2019-20 CORONAVIRUS OUTBREAK;CONVENTIONAL PCI;CARDIOMYOPATHY;HAZARD RATIO;CUMULATIVE INCIDENCE;CATHETER ABLATION;MYELOFIBROSIS;THROMBOLYSIS;ARDS;BETA THALASSEMIA;CARDIOGENIC SHOCK;CHELATION THERAPY;CHRONIC LYMPHOCYTIC LEUKEMIA;ENDOCRINE SYSTEM;IMATINIB;INTRACEREBRAL HEMORRHAGE;SUPRAVENTRICULAR ARRHYTHMIA;SYNOVITIS;TOLERABILITY","23;12;12;12;10;8;8;8;7;7;6;6;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3","CORONAVIRUS DISEASE 2019 (COVID-19);FRACTIONAL FLOW RESERVE;RUXOLITINIB;METASTATIC BREAST CANCER;NILOTINIB;RIGHT CORONARY ARTERY;ABATACEPT;CRITICAL LIMB ISCHEMIA;DIFFUSING CAPACITY;ESTROGEN RECEPTOR;IBRUTINIB;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;MODIFIED RANKIN SCALE;TARGET LESION;TICAGRELOR;VENETOCLAX;ABLATION OF ATRIAL FIBRILLATION;ACROMEGALY;ADENOSINE RECEPTOR;ANTERIOR CEREBRAL ARTERY;ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA;ATHERECTOMY;B-CELL ACTIVATING FACTOR;BASDAI;BRADYCARDIA;BRENTUXIMAB VEDOTIN;CARBOPLATIN;CARDIAC ALLOGRAFT VASCULOPATHY;CARDIAC RESYNCHRONIZATION THERAPY;CAROTID STENTING;CENTRAL SENSITIZATION;CHLORAMBUCIL;CLASSICAL HODGKIN LYMPHOMA;CORONARY STENT;DASATINIB;EXHALED NITRIC OXIDE;FLUDARABINE;FNDC5;GENE MUTATION;HERPESVIRIDAE;HORMONE RECEPTOR;IGHV@;IMATINIB MESYLATE;IMPAIRED GLUCOSE TOLERANCE;INEFFECTIVE ERYTHROPOIESIS;INTRAUTERINE GROWTH RESTRICTION;KOUNIS SYNDROME;LDL RECEPTOR;MACE;MICROSCOPIC COLITIS;MONTREAL COGNITIVE ASSESSMENT;MYELOPROLIFERATIVE NEOPLASM;MYH7;NATIONAL CHOLESTEROL EDUCATION PROGRAM;NIVOLUMAB;NUMBER NEEDED TO TREAT;OBINUTUZUMAB;OFF-PUMP CORONARY ARTERY BYPASS;P2 RECEPTOR;P2Y RECEPTOR;PERILIPIN;PHOTODEGRADATION;PLATEAU PRESSURE;PUSTULOSIS;QUANTITATIVE COMPUTED TOMOGRAPHY;ROTAVIRUS VACCINE;RUBELLA;SACUBITRIL;SACUBITRIL, VALSARTAN;SENTINEL LYMPH NODE;SENTINEL NODE;SEVERE SEPSIS;STROKE VOLUME;TAMOXIFEN;TERIPARATIDE;TIMI;TNF INHIBITOR;TRANSCRIPTOME;TRASTUZUMAB;TRINUCLEOTIDE REPEAT EXPANSION;UNDERWEIGHT;UNDIFFERENTIATED PLEOMORPHIC SARCOMA;VACCINE SAFETY","23;7;4;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;COVID-19;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;FEMALE;PERCUTANEOUS CORONARY INTERVENTION;MALE;ACUTE CORONARY SYNDROME;AGED;STROKE;BETA-THALASSEMIA;CORONARY ARTERY DISEASE;MYOCARDIAL INFARCTION;MIDDLE AGED;ARTHRITIS, RHEUMATOID;ST ELEVATION MYOCARDIAL INFARCTION;HEART FAILURE;BRAIN ISCHEMIA;SARS-COV-2","86;86;24;23;23;21;19;17;16;16;16;15;13;13;12;11;10;9;8;8","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;RHEUMATOID ARTHRITIS;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MANAGEMENT OF VALVULAR HEART DISEASE;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;DIAGNOSIS AND MANAGEMENT OF CARDIAC TUMORS;EFFICACY AND RESISTANCE IN CML TREATMENT;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MANAGEMENT AND TREATMENT OF PERIPHERAL ARTERIAL DISEASE;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;;ACUTE MYELOID LEUKEMIA;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE","12;10;7;6;5;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2","CARDIAC IMAGING;CLINICAL ENDPOINT;DISCONTINUATION;STROKE (ENGINE);PANDEMIC;ECHOCARDIOGRAPHY;FRACTIONAL FLOW RESERVE;TRANSFUSION THERAPY;2019-20 CORONAVIRUS OUTBREAK;MYOCARDIAL REVASCULARIZATION;CARDIOVASCULAR RISK ASSESSMENT;CUMULATIVE INCIDENCE;EXERCISE;THALASSEMIA;TREATMENT;COMPUTED TOMOGRAPHY ANGIOGRAPHY;INFARCTION TREATMENT;PROSTHETIC VALVES EVALUATION;RUXOLITINIB;RUXOLITINIB THERAPY","11;10;10;10;9;8;8;8;7;7;5;5;5;5;5;4;4;4;4;4","ACUTE CORONARY;CORONARY SYNDROME;BREAST CANCER;MYOCARDIAL INFARCTION;RHEUMATOID ARTHRITIS;OBSERVATIONAL STUDY;COMPUTED TOMOGRAPHY;ENDOVASCULAR TREATMENT;ISCHEMIC STROKE;PATIENTS TREATED;ACUTE ISCHEMIC;ACUTE RESPIRATORY;ADVERSE EVENTS;ATRIAL FIBRILLATION;CHRONIC LYMPHOCYTIC;CHRONIC MYELOID;CONGENITAL ANOMALIES;COVID- PANDEMIC;HEART FAILURE;ITALIAN REGISTRY;JAK INHIBITORS;LEUKEMIA PATIENTS;LUPUS ERYTHEMATOSUS;LYMPHOCYTIC LEUKEMIA;MYELOID LEUKEMIA;PILOT STUDY;PROSPECTIVE OBSERVATIONAL;SYSTEMIC LUPUS;ACTIVE RHEUMATOID;ACUTE MYOCARDIAL","8;7;6;6;6;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2","MYOCARDIAL INFARCTION;HR CI;PUBMED GOOGLE;SITE PUBMED;DISEASE ACTIVITY;MOD SAMIS;SCHOLARCROSSREFSEARCH ADS;ADS PUBMED;AORTIC VALVE;CORONARY ARTERY;LEFT VENTRICLE;LEFT VENTRICULAR;MECHANICAL VENTILATION;COVID- PANDEMIC;GOOGLE SCHOLARCROSSREFSEARCH;ITALY SEARCH;PRIMARY ENDPOINT;CLINICAL TRIALS;CORONARY ANGIOGRAPHY;EJECTION FRACTION;MYOCARDIAL DAMAGE;ADVERSE EVENTS;ALL-CAUSE DEATH;BREAST CANCER;HEART FAILURE;MEDIAN AGE;PATIENTS TREATED;PRIMARY OUTCOME;RISK FACTORS;ACUTE CORONARY","30;23;23;23;21;18;16;15;15;15;14;14;14;13;13;13;13;12;12;12;12;11;11;11;11;11;11;11;11;10",68,0.4,8.95,11,1,1,0,3,0,1,0,12.25,0,0,11,1,1.75,1.25,4,7,4,0,0,16.25,16.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,3.27,5010.6,7.21,4,0.27,160.73,0,0,0,0,5,0,0,10,0,9,6,0,0,0,0,0,0,15,0,0,14,0,0,1,0,0,0,0,0,0,"Italy;United States;Switzerland;United Kingdom","5;4;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3208 MEDICAL PHYSIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","14;9;4;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;HEART DISEASE;RARE DISEASES;ATHEROSCLEROSIS;LUNG;BIOENGINEERING;HEART DISEASE - CORONARY HEART DISEASE;PATIENT SAFETY;BIOMEDICAL IMAGING;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;INFECTIOUS DISEASES;NUTRITION;OBESITY;ACUTE RESPIRATORY DISTRESS SYNDROME;AGING;AUTOIMMUNE DISEASE;BIOTECHNOLOGY;CANCER","15;7;6;5;5;4;4;3;3;3;2;2;2;2;2;1;1;1;1;1","CARDIOVASCULAR;RESPIRATORY;ORAL AND GASTROINTESTINAL;CANCER","4;3;2;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.4 SURVEILLANCE AND DISTRIBUTION;5.1 PHARMACEUTICALS;7.3 MANAGEMENT AND DECISION MAKING","6;2;1;1;1","LIVER CANCER;MYELOMA","1;1","4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;KARGER PUBLISHERS;TAYLOR & FRANCIS GROUP","5;3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;52 PSYCHOLOGY;3204 IMMUNOLOGY;3210 NUTRITION AND DIETETICS;3211 ONCOLOGY AND CARCINOGENESIS;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4607 GRAPHICS, AUGMENTED REALITY AND GAMES;5202 BIOLOGICAL PSYCHOLOGY","10;3;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN DISORDERS;CANCER;NEUROSCIENCES;AGING;ASSISTIVE TECHNOLOGY;AUTOIMMUNE DISEASE;BIOENGINEERING;BIOMEDICAL IMAGING;BIOTECHNOLOGY;BRAIN CANCER;BREAST CANCER;CARDIOVASCULAR;DEPRESSION;DIABETES;HEALTH SERVICES;HEART DISEASE;MENTAL HEALTH;NETWORKING AND INFORMATION TECHNOLOGY R&D (NITRD)","5;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","NEUROLOGICAL;CANCER;CARDIOVASCULAR;STROKE","2;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;7.3 MANAGEMENT AND DECISION MAKING","1;1","CLINICAL;HEALTH SERVICES & SYSTEMS;BIOMEDICAL","3;2;1","CLINICAL MEDICINE AND SCIENCE","2","BRAIN TUMOR;BREAST CANCER","1;1","4 QUALITY EDUCATION","1"
"AOU_FERRARA",2023,122,23.3688524590164,2.71311475409836,0.237704918032787,0.229508196721311,0.30327868852459,2.01829268292683,1.16,1.75,1.23333333333333,0.704918032786885,0,52,17,10,13,0.43,0.14,0.08,0.11,4.21,0.96122034937325,5.85915492957746,0.426229508196721,0.926229508196721,0.473,0.354,0.443,0.45,"GIANLUCA CAMPO;RITA PAVASINI;SAVINO SPADARO;GABRIELE GUARDIGLI;MANUEL CAPPELLARI;ILARIA CASETTA;ANDREA ZINI;VALENTINA SAIA;ELISABETTA TONET;DANILO TONI;ANGELINA PASSARO;ROSSANA TASSI;SIMONE BISCAGLIA;ENRICO FAINARDI;FABRIZIO SALLUSTIO;GIOVANNI PRACUCCI;ANDREA SALETTI;GUIDO BIGLIARDI;FEDERICO MARCHINI;ANDREA NALDI","22;11;9;9;9;8;8;8;8;8;8;8;7;7;7;7;6;6;6;6","GIANLUCA CAMPO;RITA PAVASINI;GABRIELE GUARDIGLI;ELISABETTA TONET;ASSUNTA DI DOMENICO;ANGELINA PASSARO;MICHELE TRICHILO;FEDERICO MARCHINI;FILOMENA LONGO;MATTEO BERTINI;SAVINO SPADARO;GRAZIELLA POMPEI;FEDERICA FRASCARO;FEDERICO SANGUETTOLI;MICHELE MALAGÙ;STEFANO CLÓ;PAOLO SIRUGO;A CAPANNI;MARIA RITA GAMBERINI;SILVIA ZAGNONI","1.82;1.28;1.23;0.87;0.74;0.73;0.7;0.49;0.48;0.47;0.47;0.43;0.42;0.42;0.4;0.4;0.4;0.4;0.39;0.38","GIANLUCA CAMPO;RITA PAVASINI;SAVINO SPADARO;GABRIELE GUARDIGLI;ILARIA CASETTA;ELISABETTA TONET;ANGELINA PASSARO;SIMONE BISCAGLIA;ANDREA SALETTI;FEDERICO MARCHINI;GRAZIELLA POMPEI;FILOMENA LONGO;ANTONIO FRASSOLDATI;MARIA RITA GAMBERINI;MATTEO BERTINI;ANTONELLA SCALA;GAETANO SCARAMUZZO;CARLO ALBERTO VOLTA;ALESSANDRO DE VITO;MATTEO SERENELLI","22;11;9;9;8;8;8;7;6;6;5;5;5;4;4;4;4;4;4;3","GIANLUCA CAMPO;RITA PAVASINI;GABRIELE GUARDIGLI;ELISABETTA TONET;ASSUNTA DI DOMENICO;ANGELINA PASSARO;MICHELE TRICHILO;FEDERICO MARCHINI;FILOMENA LONGO;MATTEO BERTINI;SAVINO SPADARO;GRAZIELLA POMPEI;FEDERICA FRASCARO;FEDERICO SANGUETTOLI;MICHELE MALAGÙ;STEFANO CLÓ;PAOLO SIRUGO;A CAPANNI;MARIA RITA GAMBERINI;SIMONE BISCAGLIA","1.82;1.28;1.23;0.87;0.74;0.73;0.7;0.49;0.48;0.47;0.47;0.43;0.42;0.42;0.4;0.4;0.4;0.4;0.39;0.37","SIMONE BISCAGLIA;STUART WATKINS;ANDREAS TORP KRISTENSEN;ANDREW MCNEICE;ASHKAN EFTEKHARI;CHRISTIAN EEK;DARREN MYLOTTE;EVALD HØJ CHRISTIANSEN;FRANCESCO BURZOTTA;FREDRIK CALAIS;INDULIS KUMSĀRS;IRENE SANTOS‐PARDO;J.P. VAN KUIJK;JACOB LØNBORG;JACOB ODENSTEDT;JAMES C. SPRATT;JAMES COCKBURN;JO DENS;JOHAN BENNETT;LENE NYHUS ANDREASEN","143;124;122;122;122;122;122;122;122;122;122;122;122;122;122;122;122;122;122;122","SIMONE BISCAGLIA;GIANLUCA CAMPO;MATTEO SERENELLI;ANDREA ERRIQUEZ;SAVINO SPADARO;ALESSANDRA BORTOLUZZI;RITA PAVASINI;GAETANO SCARAMUZZO;ILARIA CASETTA;ETTORE SILVAGNI;ANDREA SALETTI;CRISTINA BALLA;SERENA CAGLIONI;ANGELINA PASSARO;FEDERICO MARCHINI;ELISABETTA TONET;ALESSANDRO DE VITO;MARIACHIARA SENSI;ANTONELLA SCALA;CARLO ALBERTO VOLTA","141;60;49;37;33;29;27;25;22;21;19;19;17;16;15;14;13;13;12;11","GIANLUCA CAMPO;RITA PAVASINI;GABRIELE GUARDIGLI;ELISABETTA TONET;ANGELINA PASSARO;SAVINO SPADARO;ANDREA SALETTI;FEDERICO MARCHINI;ILARIA CASETTA;SIMONE BISCAGLIA;ANTONIO FRASSOLDATI;GRAZIELLA POMPEI;FILOMENA LONGO;ALESSANDRO DE VITO;ANTONELLA SCALA;GAETANO SCARAMUZZO;MARIA RITA GAMBERINI;MICHELE TRICHILO;ALBERTO BOCCADORO;ANDREA ERRIQUEZ","22;11;9;8;7;7;6;6;6;6;5;5;5;4;4;4;4;4;3;3","MEDICINE;BIOLOGY;ENGINEERING;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS;PSYCHOLOGY;ECONOMICS;GEOGRAPHY;GEOLOGY;HISTORY;ENVIRONMENTAL SCIENCE;MATERIALS SCIENCE;PHILOSOPHY;SOCIOLOGY","116;21;15;13;10;9;4;3;2;2;2;2;1;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;SURGERY;IMMUNOLOGY;GENETICS;MECHANICAL ENGINEERING;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;ONCOLOGY;PATHOLOGY;PSYCHIATRY;PEDIATRICS;RADIOLOGY;OPTICS;PHYSICAL THERAPY;ANESTHESIA;ENDOCRINOLOGY;NURSING;VIROLOGY","105;42;34;14;13;13;12;12;11;11;11;11;10;10;8;8;7;7;6;6","MYOCARDIAL INFARCTION;DISEASE;HEART FAILURE;CANCER;POPULATION;RANDOMIZED CONTROLLED TRIAL;STROKE (ENGINE);ATRIAL FIBRILLATION;COHORT;GENE;THALASSEMIA;CLINICAL TRIAL;INCIDENCE (GEOMETRY);CONFIDENCE INTERVAL;ISCHEMIA;LUNG;OBSERVATIONAL STUDY;PREGNANCY;QUALITY OF LIFE (HEALTHCARE);ADVERSE EFFECT;ANTIBODY;IMMUNE SYSTEM;LEUKEMIA;PROSPECTIVE COHORT STUDY;RETROSPECTIVE COHORT STUDY;THROMBOSIS","23;19;15;12;12;11;11;10;10;10;9;8;8;6;6;6;6;6;6;5;5;5;5;5;5;5","EJECTION FRACTION;PERCUTANEOUS CORONARY INTERVENTION;INFECTIOUS DISEASE (MEDICAL SPECIALTY);REVASCULARIZATION;CONVENTIONAL PCI;BETA THALASSEMIA;BREAST CANCER;ISCHEMIC STROKE;CLINICAL ENDPOINT;HAZARD RATIO;THROMBOLYSIS;CHRONIC LYMPHOCYTIC LEUKEMIA;CORONARY ANGIOGRAPHY;FETUS;IMMUNOTHERAPY;NEURORADIOLOGY;PARKINSON'S DISEASE;PLACEBO;VALVE REPLACEMENT;WARFARIN","12;10;9;9;6;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3","CORONAVIRUS DISEASE 2019 (COVID-19);MODIFIED RANKIN SCALE;IGHV@;MACE;VITAMIN K ANTAGONIST;CARBOPLATIN;DABIGATRAN;DRUG-ELUTING STENT;FRACTIONAL FLOW RESERVE;HYDROXYTYROSOL;IBRUTINIB;PLACENTA;RIVAROXABAN;TARGET LESION;TRASTUZUMAB;VENETOCLAX;ABCA1;ACUTE PROMYELOCYTIC LEUKEMIA;AUTONOMIC NERVOUS SYSTEM;B-CELL ACTIVATING FACTOR;BIORESORBABLE SCAFFOLD;BLINATUMOMAB;BRADYCARDIA;BRONCHOPULMONARY DYSPLASIA;CAPECITABINE;CARDIAC RESYNCHRONIZATION THERAPY;CYSTATIN;DASATINIB;DIFFUSING CAPACITY;DISEASE MANAGEMENT;DOCOSAHEXAENOIC ACID;EICOSAPENTAENOIC ACID;FEMALE INFERTILITY;FETAL HEMOGLOBIN;GANCICLOVIR;GENE SIGNATURE;GIANT CELL ARTERITIS;HEART FAILURE WITH PRESERVED EJECTION FRACTION;HEART RATE VARIABILITY;HERPESVIRIDAE;HLA-G;IMATINIB MESYLATE;INEFFECTIVE ERYTHROPOIESIS;IPILIMUMAB;KRAS;LEVODOPA;MICROSATELLITE;N100;NEOADJUVANT THERAPY;NILOTINIB;NIVOLUMAB;NON-CODING RNA;ODDBALL PARADIGM;OLIGOMYCIN;PEMBROLIZUMAB;PLEURAL DISEASE;PON1;RASAGILINE;SINGLE-NUCLEOTIDE POLYMORPHISM;STROKE VOLUME;TAMOXIFEN;TRANSCRIPTOME","9;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;STROKE;TREATMENT OUTCOME;BRAIN ISCHEMIA;RETROSPECTIVE STUDIES;PERCUTANEOUS CORONARY INTERVENTION;THROMBECTOMY;CORONARY ARTERY DISEASE;HEART FAILURE;MYOCARDIAL INFARCTION;PROSPECTIVE STUDIES;FEMALE;ADULT;ENDOVASCULAR PROCEDURES;ISCHEMIC STROKE;REGISTRIES;AGED;COVID-19;MALE","65;57;27;22;20;17;14;14;13;13;13;10;9;8;8;8;8;7;7;7","CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;ATRIAL FIBRILLATION;DIAGNOSIS AND TREATMENT OF HEART FAILURE;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;IMPACT OF COVID-19 INFECTION ON PREGNANCY OUTCOMES;MANAGEMENT AND EPIDEMIOLOGY OF INFECTIVE ENDOCARDITIS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;;CANCER IMMUNOTHERAPY;CARDIAC REHABILITATION AND CARDIOVASCULAR HEALTH INTERVENTIONS;CHOLESTEROL-LOWERING TREATMENT;CORONAVIRUS DISEASE 2019;CORONAVIRUS DISEASE 2019 RESEARCH;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;MANAGEMENT OF VALVULAR HEART DISEASE;MOLECULAR MECHANISMS OF AMYLOIDOSIS;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS","13;9;7;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","STROKE (ENGINE);INFARCTION TREATMENT;TREATMENT;CLINICAL ENDPOINT;BETA THALASSEMIA;CARDIAC IMAGING;DRUG-ELUTING STENTS;TRANSFUSION THERAPY;CORONARY STENTS;GROIN;INTERQUARTILE RANGE;ANTICOAGULANT THERAPY;BREAST CANCER;CARDIOVASCULAR RISK ASSESSMENT;DISCONTINUATION;ENDOCARDITIS GUIDELINES;FRACTIONAL FLOW RESERVE;IGHV@;INFECTIVE ENDOCARDITIS;MACE","12;7;7;6;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3","HEART FAILURE;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;IV THROMBOLYSIS;MYOCARDIAL INFARCTION;PATIENTS TREATED;ACUTE STROKE;BREAST CANCER;CHRONIC TOTAL;COVID- PATIENTS;ENDOVASCULAR TREATMENT;ITALIAN REGISTRY;MECHANICAL THROMBECTOMY;MYELOID LEUKEMIA;PHASE II;SARS-COV- INFECTION;ABSTRACT P--;ACUTE CORONARY;ACUTE MYELOID;ANTAGONIST ORAL;AORTIC STENOSIS;ATRIAL FIBRILLATION;BIFURCATION LESIONS;CARBOPLATIN ETOPOSIDE;CASECONTROL STUDY;CLINICAL PRACTICE;CLINICAL TRIAL;COHORT STUDY;COMPLETE RECANALIZATION;CORONARY CHRONIC","7;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GLOBAL HEART;IRON OVERLOAD;MYOCARDIAL INFARCTION;PATIENTS TREATED;TDT PATIENTS;WIREBASED ADR;ISCHEMIC STROKE;PHYSICAL PERFORMANCE;RISK FACTORS;SERUM FERRITIN;Β Β;ICD PATIENTS;MEDIAN TIME;PATIENTS UNDERGOING;AML SURVIVORS;ATRIAL FIBRILLATION;CMV INFECTION;CPPD DISEASE;FIBRILLATION AF;HEART FAILURE;INFECTIVE ENDOCARDITIS;INTENSIVE CARE;LUNG-PROTECTIVE VENTILATION;MEDIAN AGE;MYELOID LEUKEMIA;OSBORN WAVE;PHYSICALLY ACTIVE;SARS-COV- INFECTION;SIGNIFICANTLY LOWER;STATISTICALLY SIGNIFICANT","11;11;9;9;9;9;8;8;8;8;8;7;7;7;6;6;6;6;6;6;6;6;6;6;6;6;6;6;6;6",49,0.4,9.15,12,1,1,0,7,0,1,0,12,0,0,12,0,1,2,3.5,10,4.75,0,0,7,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,2.6,521,6.25,3,0.3,29.5,0,0,2,0,1,0,1,6,0,7,3,0,0,0,0,0,0,10,0,0,10,0,0,0,0,0,0,0,0,0,"Italy;United States","3;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;46 INFORMATION AND COMPUTING SCIENCES;4608 HUMAN-CENTRED COMPUTING","9;5;4;2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;HEART DISEASE;CANCER;HEMATOLOGY;RARE DISEASES;ATHEROSCLEROSIS;BIOENGINEERING;HEART DISEASE - CORONARY HEART DISEASE;ASSISTIVE TECHNOLOGY;BASIC BEHAVIORAL AND SOCIAL SCIENCE;BEHAVIORAL AND SOCIAL SCIENCE;BIOMEDICAL IMAGING;COLO-RECTAL CANCER;DIGESTIVE DISEASES;GENETICS;INFECTIOUS DISEASES;LUNG;LYMPHOMA","10;5;4;4;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;CANCER;RESPIRATORY","4;3;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.3 MEDICAL DEVICES;6.4 SURGERY","4;1;1;1;1","BLADDER CANCER;COLON AND RECTAL CANCER;KIDNEY CANCER;MELANOMA;NON-HODGKIN'S LYMPHOMA","1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","3",1,1565275,223610.71,5,7,7,1,0,44722.1428571429,2.72795515165067,"AALTO UNIVERSITY;ARCISPEDALE SANT'ANNA;OTTOBOCK (GERMANY);TECNALIA SERBIA (SERBIA);UNIVERSITY COLLEGE DUBLIN;UNIVERSITY OF MICHIGAN–ANN ARBOR;VRIJE UNIVERSITEIT BRUSSEL","1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","HORIZON-MSCA-2022-DN-01 (CALL FOR PROPOSAL);HORIZON-TMA-MSCA-DN-ID - HORIZON TMA MSCA DOCTORAL NETWORKS - INDUSTRIAL DOCTORATES (FUNDING SCHEME);HORIZON.1.2 - MARIE SKŁODOWSKA-CURIE ACTIONS (MSCA) (PROGRAMME)","1;1;1","42 HEALTH SCIENCES;4207 SPORTS SCIENCE AND EXERCISE","1;1","BIOENGINEERING;CLINICAL RESEARCH","1;1",NA,NA,NA,NA,NA,NA,NA,NA,"A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1",NA,NA,1,"FRONTIERS","1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;52 PSYCHOLOGY;3202 CLINICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;5203 CLINICAL AND HEALTH PSYCHOLOGY","2;2;2;1;1;1;1","BEHAVIORAL AND SOCIAL SCIENCE;BRAIN DISORDERS;CLINICAL RESEARCH;HEALTH SERVICES;KIDNEY DISEASE;MENTAL HEALTH","1;1;1;1;1;1","MENTAL HEALTH","1","6.6 PSYCHOLOGICAL AND BEHAVIOURAL","1","CLINICAL","1","HEALTH SERVICES RESEARCH","1",NA,NA,NA,NA
"AOU_FERRARA",2024,108,22.0833333333333,2.61111111111111,0.324074074074074,0.240740740740741,0.314814814814815,1.67857142857143,1.16666666666667,1.44444444444444,1.13333333333333,0.518518518518518,1,46,17,12,14,0.43,0.16,0.11,0.13,0.9,0.939775966473888,4.7088772845953,0.425925925925926,0.944444444444444,0.497,0.479,0.503,0.472,"GIANLUCA CAMPO;SIMONE BISCAGLIA;GIANNI CASELLA;SAVINO SPADARO;ELISABETTA TONET;ROBERTO SCARSINI;JAVIER ESCANED;ANDREA ERRIQUEZ;FEDERICO MARCHINI;VINCENZO GUIDUCCI;CATERINA CAVAZZA;RITA PAVASINI;MATTEO BERTINI;IGNACIO J. AMAT‐SANTOS;CARLO ALBERTO VOLTA;FRANCESCO VITALI;RAÚL MORENO;STEFANO VOLPATO;IGINIO COLAIORI;ANDREA MARRONE","20;11;9;7;7;7;7;7;6;6;5;5;5;5;5;5;5;4;4;4","GIANLUCA CAMPO;GLADIOL ZENUNAJ;SIMONE BISCAGLIA;ELISABETTA TONET;ANDREA ERRIQUEZ;FRANCESCO VITALI;GIANNI CASELLA;VERONICA AMANTEA;SAVINO SPADARO;LEONARDO DE LUCA;MICHELE MALAGÙ;MARTA HELENA COCCO;GAETANO SCARAMUZZO;MATTEO BERTINI;MICHELE TRICHILO;MARCO MICILLO;FEDERICO MARCHINI;MATTEO ARZENTON;GRAZIELLA POMPEI;ALESSANDRO CAPECCHI","2.21;1.14;0.96;0.77;0.63;0.61;0.54;0.54;0.5;0.5;0.5;0.49;0.49;0.47;0.46;0.44;0.43;0.42;0.41;0.41","GIANLUCA CAMPO;SIMONE BISCAGLIA;GIANNI CASELLA;SAVINO SPADARO;ELISABETTA TONET;ANDREA ERRIQUEZ;FEDERICO MARCHINI;RITA PAVASINI;MATTEO BERTINI;CARLO ALBERTO VOLTA;FRANCESCO VITALI;STEFANO VOLPATO;ANDREA MARRONE;MARTA HELENA COCCO;CRISTIANO AZZINI;MICHELE MALAGÙ;GRAZIELLA POMPEI;GAETANO SCARAMUZZO;CRISTINA BALLA;FILOMENA LONGO","20;11;9;7;7;7;6;5;5;5;5;4;4;4;4;4;4;4;4;4","GIANLUCA CAMPO;GLADIOL ZENUNAJ;SIMONE BISCAGLIA;ELISABETTA TONET;ANDREA ERRIQUEZ;FRANCESCO VITALI;GIANNI CASELLA;VERONICA AMANTEA;SAVINO SPADARO;MICHELE MALAGÙ;MARTA HELENA COCCO;GAETANO SCARAMUZZO;MATTEO BERTINI;MICHELE TRICHILO;MARCO MICILLO;FEDERICO MARCHINI;MATTEO ARZENTON;GRAZIELLA POMPEI;CARLO ALBERTO VOLTA;STEFANO VOLPATO","2.21;1.14;0.96;0.77;0.63;0.61;0.54;0.54;0.5;0.5;0.49;0.49;0.47;0.46;0.44;0.43;0.42;0.41;0.39;0.36","GIANLUCA CAMPO;SIMONE BISCAGLIA;JAVIER ESCANED;ANDREA MARRONE;ANDREA ERRIQUEZ;GIANNI CASELLA;ROBERTO SCARSINI;VINCENZO GUIDUCCI;RAÚL MORENO;IGNACIO J. AMAT‐SANTOS;EMANUELE BARBATO;GIORGIO SACCHETTA;IGINIO COLAIORI;JOSÉ LUIS DÍEZ GIL;ENRICO CERRATO;CATERINA CAVAZZA;MATTEO TEBALDI;RITA PAVASINI;ALEXANDRA STRODA;ENRIQUE GUTIÉRREZ","34;30;23;21;20;20;20;20;19;18;17;17;17;17;15;14;13;13;12;12","GIANLUCA CAMPO;SIMONE BISCAGLIA;ANDREA ERRIQUEZ;ANDREA MARRONE;RITA PAVASINI;STANA LOREDANA;SAVINO SPADARO;MARTA COCCO;DANILA MORANO;ALESSANDRA LUMACA;ELISABETTA TONET;MARTA HELENA COCCO;FILIPPO MARIA VERARDI;GRAZIELLA POMPEI;MATTEO SERENELLI;STEFANO ZUCCHINI;VERONICA VENTURELLI;FEDERICA SGANGA;FILOMENA LONGO;IRENE MATTIOLI","25;24;20;16;13;11;9;8;7;6;6;6;5;5;5;5;4;3;3;3","GIANLUCA CAMPO;SIMONE BISCAGLIA;ELISABETTA TONET;ANDREA ERRIQUEZ;SAVINO SPADARO;RITA PAVASINI;FEDERICO MARCHINI;MATTEO BERTINI;ANDREA MARRONE;CARLO ALBERTO VOLTA;CRISTINA BALLA;FILOMENA LONGO;FRANCESCO VITALI;GRAZIELLA POMPEI;MARTA HELENA COCCO;MICHELE MALAGÙ;MARTA COCCO;FEDERICO SANGUETTOLI;ILARIA CASETTA;ALBERTO FOGAGNOLO","19;10;7;7;7;6;5;5;4;4;4;4;4;4;4;4;3;3;3;2","MEDICINE;ENGINEERING;BIOLOGY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;CHEMISTRY;ECONOMICS;POLITICAL SCIENCE;BUSINESS;MATERIALS SCIENCE;PSYCHOLOGY;SOCIOLOGY","107;16;15;9;8;5;4;4;2;1;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;SURGERY;PEDIATRICS;PATHOLOGY;RADIOLOGY;MECHANICAL ENGINEERING;ANESTHESIA;PSYCHIATRY;GENETICS;INTENSIVE CARE MEDICINE;EMERGENCY MEDICINE;ENVIRONMENTAL HEALTH;ENDOCRINOLOGY;GASTROENTEROLOGY;ONCOLOGY;PHYSICAL THERAPY;FAMILY MEDICINE;IMMUNOLOGY;OPTICS;PHARMACOLOGY","88;48;17;16;12;12;11;10;10;9;9;6;6;5;5;5;5;4;4;4;4","MYOCARDIAL INFARCTION;DISEASE;COHORT;HEART FAILURE;CORONARY ARTERY DISEASE;RANDOMIZED CONTROLLED TRIAL;COHORT STUDY;CONFIDENCE INTERVAL;STROKE (ENGINE);POPULATION;RETROSPECTIVE COHORT STUDY;CLINICAL TRIAL;GENE;MECHANICAL VENTILATION;CANCER;ELECTROCARDIOGRAPHY;PROSPECTIVE COHORT STUDY;SUDDEN CARDIAC DEATH;THALASSEMIA;VENTILATION (ARCHITECTURE)","23;20;14;11;8;8;7;7;7;6;6;5;5;5;4;4;4;4;4;4","CORONARY ANGIOGRAPHY;REVASCULARIZATION;PERCUTANEOUS CORONARY INTERVENTION;CULPRIT;HAZARD RATIO;ACUTE CORONARY SYNDROME;CARDIOMYOPATHY;CLINICAL ENDPOINT;EJECTION FRACTION;INFECTIOUS DISEASE (MEDICAL SPECIALTY);ANGINA;BREAST CANCER;BUNDLE BRANCH BLOCK;INTRACEREBRAL HEMORRHAGE;RESTENOSIS;RIGHT BUNDLE BRANCH BLOCK;TYPE 2 DIABETES;AGONIST;AORTIC VALVE REPLACEMENT;ARTERIAL DISEASE;CARDIAC MAGNETIC RESONANCE;CONVENTIONAL PCI;CORONARY ATHEROSCLEROSIS;CORONARY FLOW RESERVE;ISCHEMIC STROKE;LEFT BUNDLE BRANCH BLOCK;NEURORADIOLOGY;POSITIVE END-EXPIRATORY PRESSURE;ST SEGMENT;TYPE 1 DIABETES","8;8;7;5;5;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","FRACTIONAL FLOW RESERVE;CORONAVIRUS DISEASE 2019 (COVID-19);DRUG-ELUTING STENT;MACE;OBETICHOLIC ACID;ARTERY DISSECTION;ATYPICAL ANTIPSYCHOTIC;B-CELL ACTIVATING FACTOR;BONE METASTASIS;CANADIAN CARDIOVASCULAR SOCIETY;CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME;CENTRAL VENOUS PRESSURE;CORONARY RESTENOSIS;CORONARY STENT;CORONARY STENTING;DEATH CERTIFICATE;DNA METHYLATION;EXOME SEQUENCING;GENETICALLY MODIFIED MOUSE;HMGA2;LMNA;MISSENSE MUTATION;MODIFIED RANKIN SCALE;MOOD STABILIZER;NEOINTIMAL HYPERPLASIA;SERTRALINE;STROKE VOLUME;TRANSPULMONARY PRESSURE;TRASTUZUMAB;TRIPLE NEGATIVE;TRIPLE-NEGATIVE BREAST CANCER;VANCOMYCIN","6;4;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;MALE;FEMALE;AGED;MIDDLE AGED;AGED, 80 AND OVER;PROSPECTIVE STUDIES;TREATMENT OUTCOME;ADULT;ITALY;RETROSPECTIVE STUDIES;RISK FACTORS;CHILD;PERCUTANEOUS CORONARY INTERVENTION;CORONARY ARTERY DISEASE;TIME FACTORS;ADOLESCENT;BIOMARKERS;COHORT STUDIES","55;53;36;35;24;21;13;12;12;11;11;10;9;8;8;7;7;6;5;5","ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;DIAGNOSIS AND MANAGEMENT OF ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;MANAGEMENT OF VALVULAR HEART DISEASE;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT;;ACUTE MYELOID LEUKEMIA;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CORONAVIRUS DISEASE 2019 RESEARCH;DETECTION AND MANAGEMENT OF RETINAL DISEASES;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;MANAGEMENT AND PATHOPHYSIOLOGY OF INTRACEREBRAL HEMORRHAGE;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;ANESTHESIA AND SEDATION MANAGEMENT;ANORECTAL SURGICAL PROCEDURES","7;7;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1","CARDIAC IMAGING;CARDIOVASCULAR RISK ASSESSMENT;MYOCARDIAL REVASCULARIZATION;STROKE (ENGINE);FRACTIONAL FLOW RESERVE;MYOCARDIAL PERFUSION;CULPRIT;MICROVASCULAR DYSFUNCTION;POSITIVE END-EXPIRATORY PRESSURE;;CLINICAL ENDPOINT;INTRAVASCULAR ULTRASOUND;PROSTHETIC VALVES EVALUATION;REVASCULARIZATION;TRANSCATHETER AORTIC-VALVE REPLACEMENT;BUNDLE BRANCH BLOCK;CARDIAC SURGERY RISK MODELS;CONTINUOUS GLUCOSE MONITORING;CORONARY FLOW RESERVE;DIABETES","13;10;8;7;6;6;5;5;5;4;4;4;4;4;4;3;3;3;3;3","MYOCARDIAL INFARCTION;CORONARY ARTERY;ACUTE CORONARY;ARTERY DISEASE;CLINICAL TRIAL;COHORT STUDY;OBSERVATIONAL STUDY;TRANSFUSION-DEPENDENT Β-THALASSEMIA;ACUTE MYELOID;AGE-RELATED MACULAR;AORTIC VALVE;ARTERIAL DISEASE;ARTIFICIAL INTELLIGENCE;BILIARY CHOLANGITIS;BLEEDING RISK;BREAST CANCER;COMPLETE REVASCULARIZATION;CORONARY INTERVENTION;CORONARY MICROVASCULAR;CORONARY SYNDROMES;CULPRIT-ONLY REVASCULARIZATION;DISEASE MANAGEMENT;ELEVATION ACUTE;FAILURE INSIGHTS;HEART FAILURE;INTENSIVE CARE;INTRACEREBRAL HAEMORRHAGE;ISCHEMIC STROKE;LEUKEMIA TREATED;MACULAR DEGENERATION","6;5;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","POSTOPERATIVE PULMONARY;PULMONARY COMPLICATIONS;HR CI;NONCULPRIT VESSELS;FAMILY HISTORY;IN-HOSPITAL MORTALITY;INTENSIVE CARE;IRON OVERLOAD;MYOCARDIAL INFARCTION;RAD REPAIR;VENTRICULAR ARRHYTHMIAS;ACUTE RESPIRATORY;AD PATIENTS;ARTERY DISEASE;CLINICAL TRIAL;CORONARY ARTERY;ENROLLED PATIENTS;FUNCTIONAL ASSESSMENT;MACHINE LEARNING;MAGNETIC RESONANCE;MI PATIENTS;MLA MM;PACEMAKER IMPLANTATION;PATIENTS UNDERGOING;RISK FACTORS;SCA PATIENTS;AORTIC VALVE;ATRIOVENTRICULAR BLOCK;CARDIAC SURGERY;CRITICALLY ILL","16;15;10;9;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4",2,0.02,1.19,2,0,0,0,0,0,0,0,2.75,0,0,2,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
